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Summary 
Epilepsy is a common and serious but treatable neurological disorder. Current treatment 
is limited by high rates of adverse drug effects and lack of complete seizure control in a 
significant proportion of patients. Epilepsy is suitable for pharmacogenetic exploration 
because response to antiepileptic drug (AED) treatment can be quantified and adverse 
effects can be assessed by several measures. Furthermore, there is substantial 
knowledge of the pharmacodynamics and pharmacokinetics of AEDs and some 
candidate genes implicated in the disorder have been identified. However, recent studies 
examining the association of particular genes and their genetic variants with seizure 
control and adverse drug effects have not provided definitive conclusions. 
Commonly, pharmacogenetic studies focus primarily on single nucleotide 
polymorphisms, which are single base variations in the sequence of genes. This form of 
genetic variant has the potential to influence the structure and/or function of the proteins 
those genes encode. Candidate genes for pharmacogenetic studies in epilepsy are those 
that encode proteins directly involved in the pharmacokinetics (drug metabolizing 
enzymes (DMEs), drug transporters (DTPs) and pharmacodynamics (voltage-gated 
sodium channels, y-aminobutyric acid receptors (GABA) of AED action. These 
principals have been applied to this research programme, investigating the influence of 
genetic variability on the clinical pharmacology of carbamazepine (CBZ) and 
lamotrigine (LTG). 
Although many genes could influence response to these drugs, obvious candidates are 
known. CBZ and LTG target the a-subunit of the voltage-gated sodium channels. CBZ 
metabolism involves several DMEs such as CYP3A4, CYP3A5, CYPIA2, microsomal 
epoxide hydrolase (mEH) and UGT2B7, and LTG is a probable substrate of P- 
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glycoprotein (P-gp). Common polymorphisms in genes encoding these proteins were 
examined as initial genetic factors that may influence the response to CBZ and LTG 
monotherapy. These polymorphisms include CYP3A4 g. -392A>G, CYP3A5 
g. 6986A>G, CYP1A2 g. 5734C>A, EPHX1 c. 337T>C, EPHX1 c. 416A>G, UGT2B7 
c. 802C>T, ABCBI c. 1236C>T, ABCBI c. 2677G>T/A, ABCBI c. 3435C>T and 
SCN2A c. 56G>A. 
The prevalence of these common polymorphisms was evaluated in a 400-strong study 
population from a single research unit. The polymorphisms were identified by 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), with 
the exception of EPHX1 c. 337 >C, which was identified by direct sequencing assay. 
Genotype distribution of each polymorphism was examined for Hardy-Weinberg 
equilibrium (HWE). Minor allele frequency ranged between 3.5% (CYP3A4 -392G) 
and 48.0% (ABCB 1 1236T). Allele and genotype distributions were comparable to 
published data for other Caucasian populations. All genotype distributions were 
consistent with HWE. As such, no apparent systematic error in the genotyping assay 
was identified. 
The influence of common polymorphisms in DME and sodium channel genes on the 
optimal dose of CBZ was assessed in a cohort of 70 patients. Optimal dose in this study 
was defined as the final dose given to a patient that successfully maintained optimal 
seizure control without intolerable side effects. Several basic clinical factors such as age 
and gender were also examined as potential predictors. The effect of predictors on the 
optimal dose of CBZ was investigated using linear regression analysis. This study 
revealed that age and common polymorphisms in the EPHX 1 gene (c. 337T>C and 
c. 416A>G) are potential predictors for optimal dose of CBZ. The significant effects of 
EPHX 1 variants may be explained by their significant contribution to the inactivation of 
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CBZ. These potential predictors explain approximately 15% of the inter-individual 
variation in CBZ dose requirements. 
The prevalence of common polymorphisms in genes that encode CBZ-related DMEs 
was examined in an effort to identify a unique adverse effect profile. A total of 14 out of 
104 patients receiving CBZ monotherapy experienced at least one intolerable adverse 
effect which led to withdrawal of treatment. Of these, 9 patients experienced central 
nervous system (CNS)-related effects and 5 patients experienced idiosyncratic 
reactions. The variant allele distributions were compared between patients who 
experienced the adverse effects and those who did not by an appropriate contingency 
table test. There was no significant difference in allele distributions between these 
groups, either for CNS-related effects or idiosyncratic reactions. These preliminary 
findings suggest that common polymorphisms in DME genes do not form a unique 
profile which increases the risk of developing intolerable CBZ adverse effects. 
The prevalence of common polymorphisms in ABCB 1 and SCN2A genes was 
investigated between seizure free and non-seizure free patients who received LTG 
monotherapy as the first AED treatment. A total of 79 patients were involved in this 
study cohort. Of these, 39 patients had reached seizure free status within the first year of 
treatment. Differences in the distribution of gene variants were examined by logistic 
regression analysis. No difference was observed in the distribution of these 
polymorphisms between the two groups, whether analysed by allele, genotype, 
haplotype or diplotype frequency. It is unlikely that common polymorphisms in ABCB1 
and SCN2A genes influence the expression and/or activity of their respective proteins to 
the level at which they can dictate response to LTG therapy. 
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The influence of common polymorphisms in ABCB 1 and SCN2A genes on the optimal 
dose of LTG was assessed in a cohort of 94 patients. Optimal dose in this study was 
defined as the final dose given to the patients that successfully maintained seizure 
freedom for at least 1 year with LTG monotherapy. Several basic clinical factors such as 
age and gender were also examined as potential predictors. The effect of predictors on 
the optimal dose of LTG was investigated using linear regression analysis. This study 
revealed that gender and common polymorphisms in the ABCB 1 gene (c. 1236C>T and 
c. 3435C>T) are potential predictors for optimal dose of LTG. These predictors explain 
approximately 17% of the inter-individual variation in LTG dose requirement. These 
findings further highlight the potential role of P-gp in the management of epilepsy 
The final study investigated the influence of ABCB 1 c. 1236C>T and ABCB 1 
c. 3435C>T polymorphisms on the pharmacokinetics of LTG. A total of 156 blood 
samples from 50 patients receiving LTG monotherapy were available for analysis. The 
influence of ABCB1 variants was evaluated by population pharmacokinetics. This 
approach successfully estimated the oral clearance of LTG monotherapy at steady-state. 
However, the absorption rate constant (Ka) and volume of distribution (Vd) of LTG 
were poorly estimated. The inclusion of common polymorphisms in the ABCB 1 gene in 
the pharmacokinetic model did not improve the estimation of oral clearance. This may 
indicate that common variants of ABCB I do not influence clearance of LTG. 
In conclusion, these results suggest that optimal doses of CBZ and LTG are associated 
with polymorphisms in genes involved in their respective pharmacokinetics. Common 
genetic polymorphisms of other DMEs that are responsible for CBZ metabolism did not 
significantly associate with CBZ dose and none were associated with CBZ adverse 
effects. Polymorphisms in the ABCB 1 gene may not be useful in predicting response to 
LTG treatment and did not influence the oral clearance of LTG. The present study is 
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preliminary but provides encouragement for future investigation, particularly, large 
scale studies of multiple polymorphisms and combinations thereof which attempt to 
identify a panel of genotypes that can be used as predictors of an individual patient's 
response to AED treatment. 
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CHAPTER I 
GENERAL INTRODUCTION 
Chapter 1: General Introduction 
1.1 Epilepsy 
1.1.1 History of epilepsy 
The word `epilepsy' originates from a Greek word, epilambanein, which means 'to 
seize' or `to attack' (World Health Organization, 2001), and the term'epilepsia' is used 
to denote a seizure. In ancient times, epilepsy or an epileptic attack was depicted as an 
abrupt suspension or seizing of a person's senses (Gastaut & Broughton, 1972). The 
basic concepts of epilepsy in ancient Indian medicine were identified during the Vedic 
period in 4500-1500 BC. The complete Ayurvedic medical system, Charaka Samhit, 
described epilepsy as'apasmara' which means `loss of consciousness'. A description of 
epilepsy was also found in a Babylonian textbook of medicine dating as far back as 
1067 BC, and which emphasized the supernatural nature of epilepsy (Pierce, 2002). A 
later description of epilepsy appeared in the Hippocratic text entitled "On the Sacred 
Disease". In describing epilepsy, Hippocrates wrote the following statement: 
"It is thus with regard to the disease called Sacred: it appears to me 
to be nowise more divine nor more sacred than other diseases, but 
has a natural cause from the originates like other affections 
(Hippocrates, 400 B. C. E. )" 
Hippocrates has highlighted the fact that epilepsy is just one kind of brain disorder. This 
notion has countered the superstitious thought that epilepsy is a curse or a prophetic 
power. Galen (AD 130-200) described three types of fits, and suggested that epilepsy 
was a brain disorder related to an accumulation of "thick humours" (Pierce, 2002). 
Later, in the 19th-century, John Hughlings Jackson deduced the basic pathophysiology 
of epileptic seizures through his clinical observation (Hogan & Kaiboriboon, 2003). 
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Jackson's contributions to the field of epilepsy continue to be recognised in modern 
medical sciences. 
1.1.2 Epilepsy and its syndromes 
Epilepsy is one of the most important clinical syndromes, with a prevalence range of 3 
to 7.3 per 1000 population (Wright et al., 2000; Al Rajeh et al., 2001; Oun et al., 2003; 
Hui & Kwan, 2004). It is a difficult disorder to control (Spear, 2001) and may even 
cause sudden unexplained death (Pedley & Hauser, 2002). The term epilepsy refers to 
the recurrence of seizures from all types of pathological states or diseases (Janz, 1985). 
The International League Against Epilepsy (ILAE) and the International Bureau for 
Epilepsy (IBE) consensus defined an epileptic seizure and epilepsy as follows: 
"An epileptic seizure is a transient occurrence of signs and/or 
symptoms due to abnormal excessive or synchronous neuronal 
activity in the brain (Fisher et al., 2005)" 
"Epilepsy is a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures and by the 
neurobiologic, cognitive, psychological, and social consequences of 
this condition. The definition of epilepsy requires the occurrence of 
at least one epileptic seizure (Fisher et al., 2005)" 
Seizures occur due to a sudden, excessive, rapid discharge in the grey matter of some 
part of the brain; this might spread further all over the brain, to produce generalised 
syndromes. The brain's electrical discharge may result in an almost instantaneous loss 
of consciousness, alteration of perception or impairment of psychic function, convulsive 
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movement, disturbance of sensation, or some combination thereof (Victor & Ropper, 
2001). 
Epilepsy syndromes are commonly characterised by their clinical presentation such as 
seizure type, age at onset, brain electrical pattern, causal factors and trend of genetic 
inheritance (Brodie & French, 2000). Generally, epilepsy syndromes are widely 
grouped into idiopathic, cryptogenic and symptomatic (Commission, 1989; Brodie & 
French, 2000). Idiopathic or primary epilepsies are epileptic syndromes with an 
unknown cause except perhaps a genetic one; cryptogenic epilepsies are epileptic 
syndromes with uncertain nature of origin and the seizures may be the only sign of brain 
abnormalities; meanwhile symptomatic or secondary epilepsies are epileptic syndromes 
with clearly known causes (Victor & Ropper, 2001; Brodie et al., 2005). Epilepsy 
treatment decisions are based principally on the type of epilepsy syndrome and the 
kinds of seizures that occur. 
1.1.3 Classification of seizures 
The present commonly used classification was proposed by the ILAE more than twenty 
years ago (TABLE 1.1; Commission, 1981) using clinical description and 
electroencephalogram (EEG) characteristics. The limitations of this classification are 
becoming increasingly apparent with advances in imaging technology and 
neurophysiology. Nevertheless, the present system has gained widespread acceptance 
and provides an effective means of communication among clinicians. 
The current classification divides seizures broadly into partial and generalised. Partial 
seizures, also called focal, are those seizures that begin in a focal region of the cortex in 
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one hemisphere. Based on the symptoms of the seizures, partial seizures can be 
subdivided into simple partial seizures and complex partial seizures. 
TABLE 1.1. International classification of epileptic seizure. Adapted from 
Commission (1981). 
Partial (focal) seizures (seizures beginning locally) 
A Simple (consciousness not impaired) 
i With motor symptoms 
ii With somatosensory or special sensory symptoms 
iii With autonomic symptoms or signs 
iv With psychic symptoms 
B Complex (with impaired consciousness) 
i Simple partial onset followed by impairment of 
consciousness 
ii Impaired consciousness at onset 
C Partial seizures evolving into secondary generalised seizures 
II Generalised seizures (convulsive or non-convulsive) 
A Absence seizures 
i Typical (petit mal) 
ii Atypical 
B Myoclonic seizures 
C Clonic seizures 
D Tonic seizures 
E Tonic-clonic seizures 
F Atonic seizures 
III Unclassified seizures 
Simple partial seizures have no impact on the level of consciousness. Depending on the 
area of the brain affected, these seizures could be expressed as shaking of a small part of 
the body, an unusual tingling or numbness of a localised body part, or even an unusual 
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smell, visual hallucination, or ill-defined feeling. Complex partial seizures occur when 
the abnormal electrical activity involves parts of the brain that affect level of 
consciousness. Thus, the critical feature of a complex partial seizure is that the person 
has altered consciousness, so that he may be confused or staring unresponsively. There 
may also be subtle, repetitive and stereotypical movements of the face or extremities. 
Sometimes a complex partial seizure can start in just one area and spread throughout the 
entire brain, resulting in a generalised tonic-clonic seizure. This seizure type is known 
as complex partial with secondary generalisation. 
Generalised seizures are caused by abnormal electrical activity that occurs over the 
entire brain simultaneously. This group of seizures affect the level of awareness and 
muscle movement of all extremities. Absence seizures are also known as "petit mal". 
They are described as staring spells. These seizures typically start in childhood and are 
often outgrown by adolescence, although adults can occasionally have absence seizures. 
Myoclonic seizures are characterized by sudden brief jerks of a single muscle or muscle 
group. It may appear as if sufferers have been startled and you may also see the head or 
body suddenly bend forward or backward. Atonic seizures are also very sudden brief 
seizures, but they involve loss of all muscle tone. The patient will suddenly go limp and 
fall to the ground. There is a significant risk of head injury during the fall. Tonic 
seizures involve stiffening of parts of the body or the entire body. Unlike tonic-clonic 
seizures, there is no progression to a clonic phase. Tonic-clonic seizures are also known 
as "grand mal". They generally start with a tonic phase with stiffening of the entire 
body. The eyes may roll back in the head, the back arches, and arms and legs stiffen. 
The clonic part is described as rhythmic jerking of the entire body. Once the seizure is 
over, the patient may feel worn out and may even sleep for a period of time. They may 
also experience some confusion. 
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1.1.4 Diagnosis of epilepsy 
The diagnosis procedure aims to determine whether the patient has epilepsy, and if so, 
the syndromic classification and underlying aetiology. Epilepsy may be difficult to 
diagnose in the early stages especially in the absence of a witnessed account. It is 
imperative that the physician obtains a complete patient history, including details of 
birth, childhood, family history, and medication regimen; a thorough medical history, 
including illnesses of the nervous system; and a thorough history of drug and alcohol 
use. A detailed description of the seizures is important to distinguish seizure types. 
The primary tool in the diagnosis of epilepsy is the EEG (King et al., 1998), which 
measures electrical activity in the brain. Seizure disorders produce characteristic 
patterns in an EEG test. In patients with partial epilepsy, the EEG may also help to 
localise the area of seizure onset. Inpatient video-EEG monitoring is used to localise 
seizure onset in patients undergoing evaluation for epilepsy surgery. It is also used to 
confirm epilepsy when the diagnosis is uncertain. Neuroimaging approaches are another 
means to identify any underlying epileptogenic structural abnormalities and are 
indicated in patients suspected to have localisation-related epilepsy. Magnetic resonance 
imaging (MRI) is undoubtedly the investigation of choice (Duncan, 1997). However, 
computer tomography should be used in preference to MRI in patients with cardiac pace 
makers, metal aneurysm clips, or severe claustrophobia, or when MRI is not available. 
Imaging techniques that show cerebral function play a growing role in the evaluation of 
epilepsy. These techniques include functional MRI, magnetoencephalography, magnetic 
resonance spectroscopy, single photon emission computed tomography, and positron 
emission tomography (Duncan 1997). Making an accurate diagnosis of an epileptic 
syndrome may allow the clinician to define the likely prognosis, provide appropriate 
counselling and choose the most appropriate treatment (Brodie & French, 2000). 
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1.2 Treatment of Epilepsy 
Treatment approaches for the epilepsies can include pharmacotherapy using AEDs, 
neurosurgical procedures, removal of causative and precipitating factors, and regulation 
of physical and mental activities (Victor & Ropper, 2001). AED treatment is the 
commonest initial approach to treat epilepsy. AEDs can reduce or stop seizures 
altogether. Some patients with epilepsy do not respond to several AEDs and in this 
situation those with partial epilepsy might be considered for surgery. Another option for 
patient who are resistant to AEDs is vagal nerve stimulation (Brodie et al., 2005). 
1.2.1 History of antiepileptic drug development 
The first effective agent in the treament of epilepsy was bromide (Pearce, 2002). 
However, the usage of bromide was limited due to an association with frequent side 
effects. In 1912, phenobarbital (PB) was introduced as a better-tolerated antiepileptic 
agent. In subsequent years, Merritt and Putnam introduced a new non-sedating AED, 
phenytoin (PHT; Merritt & Putnam, 1938). Since its introduction, PHT has been a first- 
line medication for the prevention of partial and tonic-clonic seizures, and the acute 
treatment of seizures and status epilepticus. In 1953, CBZ was synthesised at the Geigy 
laboratory by Schindler and Blattner (Schmutz, 1985). It was originally developed as an 
antipsychotic and its antiepileptic properties were not observed clinically until 1963 
(Brodie & Dichter, 1997). Sodium valproate (VPA) was serendipitously discovered in 
1963 by Pierre Eymard, when it was used as a solvent in testing other potential AEDs 
(Brodie & Dichter, 1997). Since the introduction of VPA, many new AEDs have been 
developed and marketed (FIGURE 1.1). Generally, AEDs can be divided into two 
generations, the established AEDs and the modem AEDs. The modern AEDs are 
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believed to possess better efficacy and tolerability profiles than their established 
counterparts. 
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FIGURE 1.1. Year of introduction of antiepileptic drugs to the clinical 
management of epilepsy in the United Kingdom. 
1.2.2 Indications of antiepileptic drugs 
Starting treatment with an AED is a major event for the patient and should not be 
undertaken without careful evaluation. AED therapy is long term, usually for at least 
three years and, depending on circumstances, sometimes for life. The modem AEDs 
complement established AEDs that are well known to most clinicians. In addition to 
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providing more options for the adjunctive treatment of seizures, some of these new 
compounds have been approved for monotherapy (TABLE 1.2). 
TABLE 1.2. Approved indications for antiepileptic drugs. 
Partial Broad Infantile Absence 
Drug seizure" spectrumb spasms only 
Established AEDs 
Carbamazepine + 
Ethosuximide 
Phenobarbitone ++ 
Phenytoin + 
Valproic acid +++ 
New AEDs 
Gabapentin + 
Lamotrigine ++ 
Levetiracetam ++ 
Oxcarbazepine + 
Pregabalin` + 
Tiagabine` + 
Topiramate ++ 
Vigabatrin° ++ 
Zonisamide° +++ 
+ 
a Including secondarily generalised 
b Most seizure types, including partial, absence, myoclonic, tonic and both 
primary and secondarily generalised tonic-clonic 
Licensed as adjunctive treatment/add-on therapy only 
(Kwan et al., 2001; Perucca, 2001; Bazil & Pedley, 2003) 
One of the advantages of using established AEDs is that their spectrum of efficacy, 
adverse-effect profiles, drug-drug interactions, and idiosyncrasies are relatively well 
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known. Although some side effects of the established AEDs may be undesirable, they 
are usually predictable. AEDs are generally chosen according to seizure type. LTG, 
controlled-release CBZ, topiramate or VPA are first-line monotherapy options for 
partial seizures. For generalised seizures, LTG, topiramate or VPA are the options and, 
as these drugs are broad spectrum, they may also be used when there is doubt about the 
classification (Kwan et al., 2001; Perucca, 2001; Bazil & Pedley, 2003). Broad 
spectrum AEDs usually cover partial, absence, myoclonic, tonic and both primary and 
secondarily generalised tonic-clonic seizures. Although as effective as other established 
AEDs, PHT is no longer considered as a first-line treatment because of its side effect 
profile when employed on a chronic basis and its saturation kinetics, which require 
routine monitoring of its plasma concentrations. 
1.2.3 Mechanisms of action of antiepileptic drugs 
Experimental studies (both in vitro and in vivo) together with clinical observations have 
contributed to understanding of the mechanisms of action of AEDs. However, current 
knowledge on mechanisms of action is of limited application in the initiation of therapy 
for individual patients. This is because of a poor understanding of seizure 
pathophysiology. Therefore, most first line drugs are usually chosen on the basis of 
available clinical evidence (Perucca, 2001). Knowledge of mechanisms of action can 
have an important role in determining which AEDs to add-on in those patients who fail 
to respond to the first drug (Deckers et al., 2000). Combining AEDs with different 
mechanisms of action can improve the percentage of patients with controlled seizures, 
possibly up to 20 percent (Stephen & Brodie, 2002). The recent influx of newer AEDs 
into clinical practice may elevate knowledge of mechanisms of action amongst other 
potentially important drug selection criteria, particularly in the absence of sufficient 
clinical evidence or experience (Brodie, 1999; Kwan et al., 2001). 
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The mechanisms of action of AEDs are presented in TABLE 1.3. Three mechanisms 
have been proposed to explain the effects of AEDs: modulation of voltage-dependent 
ion channel (sodium, calcium, potassium), potentiation of GABA-mediated inhibitory 
neurotransmission and inhibition of glutamate-mediated excitatory neurotransmission 
(Meldrum, 2001). The opening of voltage-gated sodium channels is responsible for the 
upstroke of the neuronal action potential and these proteins essentially control the 
intrinsic excitability of the nervous system (Clare et al., 2000). Sodium channels cycle 
between functional states (open, closed, inactivated) within a matter of milliseconds. 
This character is important in producing the rapid burst of action potentials during 
normal neuronal transmission, and particularly in the production of epileptic discharges 
(Kwan et al., 2001). Many AEDs such as PHT, CBZ and LTG block the neuronal 
voltage-gated sodium channels as their principal antiseizure action (Tunnicliff, 1996; 
White, 1999). 
The key structure and sequence homology of voltage-dependent calcium channels are 
shared with sodium channels (Anderson & Greenberg, 2001). Low and high activation 
thresholds are used to widely categorise calcium channels. L-type calcium channels are 
expressed in muscle, brain and endocrine cells. N-, P/Q- and R- type calcium channels 
are found mainly in neurones. All of these channels require a strong depolarization (i. e. 
high threshold) to be activated. T-type calcium channels are low threshold channels and 
are found in various cell types (Ertel et al., 2000). The rhythmic 3-Hz spike-and-wave 
discharge that is present in generalised absence seizures is believed to be a product of 
activation of these low-threshold T-type calcium channels (Sohal & Huguenard, 2001). 
Blockade of the voltage-dependent calcium channels in a subtype-specific manner 
explains the effects of several AEDs. For example, LTG reduces N- and P-type calcium 
currents, diminishing repetitive neuronal firing, and consequently controlling seizure, 
without affecting L-type calcium currents (Pisani et al., 2004). 
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TABLE 1.3. Proposed mechanisms of antiepileptic drugs. 
13 
I Na+ 1 Ca T K+ T inhibitory j excitatory 
Drug channels channels channels transmission transmission 
Established AEDs 
Carbamazepine +++ 
Ethosuximide +++ 
Phenobarbital + +++ + 
Phenytoin +++ 
Valproic acid ++ ++ + 
New AEDs 
Felbamate ++ ++ ++ ++ 
Gabapentin + +++ + 
Lamotrigine +++ + 
Levetiracetam +++ ++ 
Oxcarbazepine +++ ++ 
Tiagabine +++ 
Topiramate ++ ++ ++ ++ 
Vigabatrin +++ 
Zonisamide ++ ++ 
+++ = primary action, ++ = probable action and += possible action (Kwan et al., 
2001; Madeja et al., 2003). 
The tetrameric structure of neuronal voltage-gated potassium channels is derived from 
the association of large protein complexes. Their monomers are related to sodium and 
calcium channel subunits (Anderson & Greenberg, 2001). Activation of potassium 
channels suppresses the generation of action potentials (Spitzer et al., 2002). Studies 
have reported levetiracetam (Madeja et al., 2003) and retigabine (Rundfeldt, 1999) 
activate potassium channel conductance as one of their mechanisms of antiseizure 
action. 
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GABA is the principal inhibitory neurotransmitter in mammalian brain and is released 
at up to 40% of all synapses (Olsen & Avoli, 1997). Insufficiency of GABAergic 
neurones has been proposed as a mechanism of seizure generation (Loscher & Schmidt, 
2002). GABA-related mechanisms, such as the promotion of GABA synthesis, increase 
in GABA release, facilitation of GABA receptors and a decrease in GABA inactivation 
are associated with AEDs such as VPA, gabapentin, vigabatrin and tiagabine (Errante et 
al., 2002). 
The complementary neurotransmitter to GABA is glutamate, which is the principal 
excitatory neurotransmitter in the mammalian CNS (Meldrum et al., 1999). Seizures 
have been associated with glutamatergic system abnormalities, including over- 
activation of glutamatergic transmission and defective ionotropic and metabotropic 
glutamate receptor properties (Meldrum et al., 1999). None of the licensed AEDs act 
solely on the glutamatergic neurones, but glutamate receptor blockade is associated with 
some AEDs (Meldrum, 2001). For example, felbamate and topiramate are believed to 
act on the NMDA- and AMPA-subtypes of glutamate receptors, respectively (Harty & 
Rogawski, 2000; Kaminski et al., 2004). 
1.2.4 Clinical pharmacokinetics of antiepileptic drugs 
Evidence supporting the relationship between plasma drug concentration and clinical 
response to established AEDs is available to aid dosage individualization (Perucca, 
1999; Affolter et al., 2003). Drug therapeutic ranges were derived from population 
pharmacokinetic studies using statistical concepts in which most of the patients 
demonstrated an acceptable clinical response with no intolerable side effects (Patsalos, 
2001). Nevertheless, some patients may demonstrate good seizure control below the 
minimum limit of the therapeutic range, and intoxication may also be present in some 
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patients with plasma drug concentrations within the therapeutic range (Browne, 1998). 
Hence, the therapeutic range is regarded as a guide to AED dosage, and an individual 
patient's clinical conditions should always be considered in cases of poor response or 
intolerable side effects. 
To achieve optimal control of seizures, AEDs must be well absorbed from the 
gastrointestinal tract, distributed into body tissues, and reach sufficient concentration in 
the brain. Almost all AEDs have more than 90 percent oral bioavailability, with the 
exception of gabapentin and vigabatrin (TABLE 1.4). Interestingly, some AEDs such as 
PHT are not only well absorbed in the small intestine but absorption also extends up to 
the colonic region (Stevenson et al., 1997). After the absorption phase, AEDs are 
distributed into body compartments depending on their physicochemical properties. In 
the blood, AEDs such as PHT, VPA and tiagabine are highly bound to plasma proteins. 
AEDs with this characteristic have a higher risk for drug interactions through 
competitive depletion from the site of protein binding. This is clearly observed in 
polytherapy regimens comprising PHT and VPA. One should aim for a lower plasma 
concentration of PHT when used concomitantly with VPA, because of plasma protein 
binding displacement (Perucca et al., 1980b; Patsalos & Perucca, 2003). Reduced 
binding to plasma proteins may shorten the AED half-life, requiring a more frequent 
dosing schedule as noted with the newer AED, gabapentin (Perucca, 2001). 
The magnitude and duration of the antiepileptic actions of AEDs are predominantly 
determined by dose and pharmacokinetic profile (Perucca, 1999). The AED dose and 
pharmacokinetic profile are in turn influenced by enzymatic biotransformation and drug 
transporters (Browne, 1998; Kim, 2002a; Ramachandran & Shorvon, 2003). Most 
AEDs undergo enzymatic biotransformation to form a more water-soluble compound 
before being excreted by the kidney. Nevertheless, some AEDs can be excreted in an 
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unchanged form or with only minor enzymatic action, for example gabapentin, 
topiramate and vigabatrin (Patsalos, 1999). 
TABLE 1.4. The pharmacokinetics of antiepileptic drugs. 
Usual 
Plasma effective 
protein plasma 
Bioavailability binding t% concentration T,,,,,, 
Drug (%) (%) (h) (µmoVl) (h) Route of elimination 
Established AEDs 
Carbamazepine 89' 75 8-22 Up to 50 4-8 >90% hepatic 
Ethosuximide <5 60 Up to 700 3-7 65% hepatic 
Phenobarbital >_ 90 45 100 Up to 170 2-8 >90% hepatic 
Phenytoin 90 90-95 22 Up to 80 3-8 >90% hepatic 
Valproic acid >_ 90 80-90 15-20 Up to 700 3-8 >95% hepatic 
New AEDs 
Felbamate >_ 80 20-25 14-23 125-250 2-6 60% hepatic (oxidation), renal excretion 
Gabapentin <60 <5 5-7 70-120 2-3 >95% renal excretion 
Lamotrigine 98 55 15-30b 10-60 2-5 >90% hepatic (glucuronide conjugation) 
Levetiracetam >_ 90 <10 6-8 35-120 1 >65% renal excretion 
Oxcarbazepine 40 8-15 50-140 3-13 >90% hepatic (glucuronide conjugation) 
Tiagabine >_ 90 96 4-13 50-250 I >90% hepatic (oxidation) 
Topiramate >_ 80 13 20-30 15-60 4-10 Renal excretion, 30% hepatic (oxidation) 
Vigabatrin >_ 60 0 5-8 6-278 1 Renal excretion 
Zonisamide 2: 90 50 50-70 45-180 2-6 70% hepatic (glucuronide conjugation, 
acetylation, oxidation) 
aextended release formulation; bcomedication with VPA and enzyme inducers. 
(Patsalos, 1999; Perucca, 1999; Perucca, 2001; Ramsay & Wilder, 2002; Bazil & 
Pedley, 2003) 
Biotransformation occurs mainly through an oxidation process and takes place primarily 
in the liver with the involvement of DMEs such as cytochrome P450 (CYP450) 
isoenzymes, hydrolases and conjugating enzymes. More than 12 isoenzymes of CYP450 
are involved in drug metabolism. Metabolism of AEDs is predominantly driven by a 
variety of CYP450 subfamilies, including CYP1A, CYP2A, CYP2B, CYP2C, CYP2D, 
CYP2E and CYP3A (Ramachandran & Shorvon, 2003), mEll and conjugating enzymes 
such as UDP-glucuronosyltransferases (UGTs; TABLE 1.5). The reaction catalysed by 
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CYP450s involves the oxidation of AEDs where there is a heterocyclic ring, an 
aromatic ring, an alkane, or an alkene substituent. CYP450 metabolism converts AEDs 
into more water-soluble compounds, which are more easily conjugated and excreted 
from the body. CYP450 metabolism also converts some AEDs, such as CBZ, PB and 
PHT, to intermediate epoxide metabolites. Many of these epoxide metabolites are 
reactive and can covalently bind to cell macromolecules, resulting in cytotoxicity 
(Madden et al., 1996). Detoxification of these reactive epoxide metabolites is mediated 
by mEH. mEH converts epoxides to trans-dihydrodiols which can be conjugated and 
excreted from the body. Conjugation of AEDs or AED metabolites is predominantly 
mediated by UGT isoenzymes in a process known as glucuronidation. Glucuronidation 
involves chemical binding of a substance to glucuronic acid via a glycosidic bond. The 
resulting glucuronide metabolite is typically much more water soluble than the original 
substance. Examples of AEDs that are mainly metabolised through glucuronidation are 
VPA and LTG (Staines et al., 2004). 
In order to understand drug disposition, DMEs cannot be studied in isolation, 
particularly where the roles of DTPs have been reported to be significant (Kim, 2002a; 
Kim, 2002b). Drug movement across tissue compartments habitually occurs in two 
directions; influx and efflux. Specific DTPs are responsible for carrying out both of 
these functions in a concentration-dependent manner (Roden, 2001). The most 
commonly recognised efflux transporter is P-gp. Several AEDs, such as PHT and LTG, 
have been shown to be transported by P-gp (Potschka & Loscher, 2001; Potschka et al., 
2002). P-gp can be found in various body tissues such as the intestinal lining, liver and 
brain. Variation in P-gp activities may be present and can potentially affect drug 
pharmacokinetics. It has been demonstrated that variation in the expression of duodenal 
P-gp correlates with the variation in plasma digoxin concentrations (Hoffmeyer et al., 
2000). Interestingly, DMEs and DTPs that are present at the level of the blood-brain 
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barrier (BBB), blood-cerebrospinal fluid barrier and various parts of the brain could also 
alter the elimination process of AEDs (Mcfadyen et al., 1998; de Lange & Danhof, 
2002). Therefore, variation in the expression and function of DMEs and DTPs may 
consequently influence the response to AED treatment. 
TABLE 1.5. Antiepileptic drugs and their related hepatic drug metabolizing 
enzymes. 
Drug 
Metabolizing 
Enzyme 
Antiepileptic Drug 
CBZ ESM PB PHT VPA TGB TPM LTG ZNS 
CYP 1 A2 ++ 
CYP2C9 ++ ++ + 
CYP2C 19 ++ ++++ 
CYP2D6 ++ 
CYP3A4 ++ ++ + ++ ++ 
CYP3A5 + +? ++ 
mEH + +? +? 
UGT 1 A4 ++ 
UGT1A6 & 1A9 ++ 
UGT2B7 + ++ 
CYP, cytochrome P450; mEH, microsomal epoxide hydrolase; UGT, UDP- 
glucuronosyltransferase; CBZ, carbamazepine; ESM, ethosuximide; PB, 
phenobarbital; PHT, phenytoin; VPA, valproic acid; TGB, tiagabine; TPM, 
topiramate; LTG, lamotrigine; ZNS, zonisamide; ++, major involvement; 
significant involvement; +7, potential involvement. (Adapted from Ramachandran 
& Shorvon, 2003). 
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1.2.5 Variability in the response to antiepileptic drug treatment 
The majority of epilepsy patients receive AEDs as the main treatment modality. 
However, response to AED therapy remains poor, despite the ever-expanding list of 
modern AEDs, introduced in the last decade and designed to possess improved efficacy 
and fewer side effects. Poor responders to AED treatment account for about 30 percent 
of epilepsy patients (Kwan & Brodie, 2000), and only small numbers of them have 
shown clinically significant improvement with the introduction of additional AEDs 
(Ramachandran & Shorvon, 2003). Patients with uncontrolled epilepsy not only suffer 
from health implications but also psychosocial and socioeconomic consequences. 
Despite the relative importance of uncontrolled seizures in a large fraction of epilepsy 
patients, the cellular basis of pharmacoresistance has so far remained elusive. Two 
major hypotheses have been proposed to explain poor responsiveness to AED therapy; 
(1) alteration in AED targets such as decreased sensitivity of ion channels and 
neurotransmitter receptors, and (2) modification in AED-related DMEs and DTPs 
resulting in decreased absorption, increased metabolism or decreased uptake into the 
brain (Bazil & Pedley, 2003; Ramachandran & Shorvon, 2003; Remy & Beck, 2006). 
Any one of these alterations may be the result of variation in genes that express the 
corresponding proteins (Roden, 2001; Spear, 2001; Ramachandran & Shorvon, 2003; 
Remy & Beck, 2006). 
1.3 Pharmacogenetics 
Interindividual variation in the response to drugs is an important clinical issue. Such 
variation ranges from resistance to treatment to adverse drug reactions and drug-drug 
interactions. It is now clear that much of the individuality in drug response is inherited 
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(Hartl & Orel, 1992). This genetically determined variability in drug response defines 
the research area known as pharmacogenetics (Vogel, 1959). Pharmacogenetic studies 
create an opportunity to explore individualisation in drug therapy, a concept of tailored 
drug type and dosage to individuals based not only on traditional clinical factors but 
also on their genetic profiles (Kruglyak, 1999). 
1.3.1 Human genetics 
The genome of an organism is its whole hereditary information. The human genome is 
stored in 23 pairs of chromosomes. A chromosome is a single large macromolecule of 
deoxyribonucleic acid (DNA), and is the basic 'unit' of DNA in a cell. DNA consists of 
two associated polynucleotide strands that wind together in a helical fashion. It is often 
described as a double helix. The DNA is a long chain of nucleotides which consist of 
deoxyribose (a pentose sugar), phosphoric acid and 4 organic nitrogenous bases (purines 
- Adenine (A) and Guanine (G), or pyrimidines - Cytosine (C) and Thymidine (T)). The 
human genome contains approximately 3.2 billion base pairs that are specifically 
arranged according to the function of a gene and genetic ancestry. A gene is a relatively 
small segment of DNA that codes for the synthesis of a specific protein. Genes consist 
of a long strand of DNA that contains a promoter, which controls the activity of a gene, 
and exons, coding sequences which determine what the gene produces. Genes also 
contain introns, non-coding regions that do not code for the gene products, but 
sometimes regulate gene expression. Exons and introns are arranged alternate to each 
other. 
Protein synthesis is a 2-part process that involves a second type of nucleic acid known 
as ribonucleic acid (RNA). The first process in protein synthesis is called transcription. 
In this step, the double DNA strands unzip from each other and a single strand of 
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messenger RNA (mRNA) is then made by pairing up mRNA bases with the exposed 
DNA nucleotide bases. Splicing is a modification of genetic information after 
transcription, in which introns are removed and exons are joined. Splicing prepares 
precursor mRNA in eukaryotes to produce mature mRNA. The second process in 
protein synthesis is translation. After the mature mRNA is manufactured, it leaves the 
cell nucleus and travels to a cellular organelle called the ribosome. In the ribosome, the 
mRNA code is translated into a transfer RNA (tRNA) code which, in turn, is transfered 
into a protein sequence. In this process, each set of 3 mRNA bases, known as a codon, 
will pair with a complimentary tRNA base triplet called an anticodon. Each tRNA is 
specific to an amino acid and as tRNA's are added to the sequence, amino acids are 
linked together by peptide bonds, eventually forming a protein that is later released by 
the ribosome. 
1.3.2 Glossary of genetics 
The commonly used terms in pharmacogenetics include allele, genotype, haplotype, 
diplotype and phenotype (Guttmacher & Collins, 2002). Alleles are alternative forms of 
a gene at a particular locus, or location, on a chromosome. Different alleles produce 
variation in inherited characteristics such as hair colour or blood type. In an individual, 
one form of the allele (dominant) may be expressed more than another form (recessive). 
A single allele for each gene locus is inherited from each parent. A pair of alleles forms 
the genotype. Genotype is the genetic constitution of an organism or cell at a particular 
locus. Usually, in a pair of alleles, each individual can be assigned to one of 3 possible 
genotypes. 
Haplotype may refer to only one locus or to an entire genome. Haplotype represents a 
set of closely linked genetic markers present on one chromosome which tend to be 
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inherited together. A diploid is a full set of genetic material consisting of paired 
chromosomes. The diploid human genome has 46 chromosomes. Phenotype is an 
observable characteristic of an organism produced by the organism's genotype 
interacting with the environment. This contrasts with genotype, which is an organism's 
genetic composition. 
1.3.3 Genetic variations among humans 
Even though the DNA sequence between humans is 99.9% identical, millions of base 
pair differences are still present (Kruglyak & Nickerson, 2001). Genetic variations 
occur as a result of insertions, deletions, simple tandem repeats (STRs) and single 
nucleotide polymorphisms (SNPs) of the DNA sequence. In insertion variations, a few 
base pairs are inserted into a genetic sequence. This can happen due to slipping of DNA 
polymerase. Insertions in the coding region of a gene may alter splicing of the mRNA or 
cause a frameshift, both of which may significantly alter the gene product. A sequence 
deletion is a variation in which a part of a chromosome or a sequence of DNA is 
missing. Any number of nucleotides can be deleted, from a single base to an entire piece 
of chromosome. Deletion of a number of base pairs that is not evenly divisible by three 
will lead to a frameshift mutation, causing all of the codons occurring after the deletion 
to be read incorrectly during translation, producing a severely altered and potentially 
non-functional protein. A STR in DNA is a class of polymorphism that occurs when a 
pattern of two or more nucleotides are repeated and the repeated sequences are directly 
adjacent to each other. 
The most common type of genetic variation is the SNP, of which there are an estimated 
1.4 million candidates in the human genome (Kruglyak & Nickerson, 2001). A SNP is a 
DNA sequence variation which occurs when a single nucleotide in the sequence differs 
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between members of a species. For a variation to be considered a SNP, it must occur in 
at least 1% of the population. The estimated frequency of SNPs in the human genome is 
1 per 1000 bases (Wang & Moult, 2001). Commonly, each SNP is represented by two 
alleles. However, SNPs with more than 2 alleles are also present. SNPs may fall within 
promoter regions, coding sequences, noncoding regions, or in the intergenic regions 
between genes. SNPs within a coding sequence may change the amino acid sequence of 
the protein that is produced. A SNP that does not change the polypeptide sequence is 
termed a synonymous SNP. If a different polypeptide sequence is produced they are 
termed as non-synonymous SNPs (Guttmacher & Collins, 2002). SNPs in coding and 
regulatory regions are the most likely to affect gene function (Chakravarti, 1998). 
Approximately 50% of coding SNPs are non-synonymous, and about 80% of these non- 
synonymous SNPs have been associated with disease through alteration in protein 
stability (Wang & Moult, 2001). Nevertheless, SNPs that are not in coding regions may 
still have consequences for gene splicing and transcription factor binding. Interestingly, 
some SNPs may simply serve as markers for the unidentified susceptible 
polymorphisms rather than ascribing a causative role (Chakravarti, 1998; Carlson et al., 
2003). In many pharmacogenetic studies, SNPs are commonly used as phenotype 
markers (Davidson, 2000). SNPs can be identified using several analytical assays such 
as polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) 
and direct sequencing. 
1.3.4 Nomenclature of genetic sequence variations 
A nomenclature system has been suggested to standardise the description of 
polymorphisms in DNA and protein sequences (den Dunnen & Antonarakis, 2001). 
Variations are described at the most basic level using either a genomic or a 
complemetary DNA reference sequence. A genomic reference sequence is preferred 
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because it includes multiple transcription initiation sites (promoters), alternative 
splicing, and multiple translation initiation sites (ATG-codons). A complementary DNA 
reference sequence is used when the entire genomic sequence is not known. 
To avoid confusion in the description of a sequence change, a letter indicating the type 
of reference sequence is used, for example; 'g. ' for a genomic sequence (e. g. g. 54A>T), 
'c. ' for a complemetary DNA sequence (e. g. c. 54A>T) and 'p. ' for a protein sequence 
(e. g. p. R54K). At the DNA level, nucleotides are designated by the bases; A (adenine), 
C (cytosine), G (guanine) and T (thymidine). Nucleotide changes are indicated by a 
number which denotes the position of the substitution in the DNA sequence counted 
from the first coding nucleotide. Substitutions are designated by a `>' character. For 
example, 65A>C denotes that at nucleotide 65 an A residue changed to C. Two 
polymorphisms in one variant are described as "first change + second change", for 
example, 69A>C+102G>C denotes an A to C transition at nucleotide 69 and aG to C 
transition at nucleotide 102 in the same variant. For the purposes of standardisation, 
alleles of a SNP are represented by the position of the SNP and base of the allele, for 
example, alleles of the c. 89A>G substitution are denoted as 89A and 89G. Genotypes of 
a SNP are represented by the position of the SNP and the pair of allele bases, for 
example, genotypes of c. 89A>G substitution are denoted as 89A/A, 89A/G and 89G/G. 
1.3.5 History of pharmacogenetics 
Inherited characteristics that were first observed by Mendel (Hartl & Orel, 1992), have 
now evolved to a more complex and applied discipline known as pharmacogenetics. 
The earliest documented evidence of individual differences in drug metabolism can be 
traced back to the ancient Greeks (Pirmohamed, 2001). Sir Archibald Garrod, an 
English physician brought forward the knowledge of biochemical genetics in his 
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description of "an inborn error of metabolism" (Garrod, 1902). An incident that 
occurred during World War II further highlighted the diversity of pharmacogenetic 
disorders. Service personnel deployed in regions with high malarial risk were given a 
prophylactic antimalarial drug, primaquine. After the drug was taken, approximately 
10% of the African-American servicemen were diagnosed with acute anemia. The 
affected individuals were found to harbour some mutations in the gene expressing 
glucose 6-phosphate dehydrogenase (Carson et al., 1956). At the end of World War II, 
medicine entered the antibiotic era, and isoniazid was introduced to treat tuberculosis. It 
was noted that some individuals who took isoniazid rapidly developed a peripheral 
neuropathy. This was later proven to be associated with genetically polymorphic N- 
acetyltransferase, an enzyme responsible for the metabolism of isoniazid (Kalow & 
Staron, 1957). In the post-war years, Motulsky and Kalow, who were interested in 
genetically determined differences in drug metabolism, wrote extensive reviews on 
heredity and response to drugs (Motulsky, 1957; Kalow, 1962). This laid the 
foundations for `pharmacogenetics', a term coined by Friedrich Vogel of Heidelberg in 
1959 (Vogel, 1959). 
The discovery of polymorphic hydroxylation of debrisoquine in man has strengthened 
the promising future of pharmacogenetics for medicine and science (Mahgoub et al., 
1977). Further polymorphisms relating to other cytochrome enzymes were discovered in 
subsequent decades. Now, the Human Genome Project and other research endeavors are 
providing information that allows a better understanding of the underlying causes of 
pharmacogenetic anomalies. 
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1.4 Pharmacogenetics of antiepileptic drugs 
Epilepsy itself has been linked to at least 33 chromosome regions (Prasad et al., 1999). 
On the basis of prior knowledge of AED pharmacodynamics and pharmacokinetics, 
candidate genes and SNPs for AED pharmacogenetic study can be identified. 
Accordingly, genes that have a potential pharmacogenetic impact in epilepsy are 
divided into four groups; (i) genes that characterize a subclass of the epilepsy, (ii) genes 
for ion channel and AED receptors, (iii) genes that encode pharmacokinetic-related 
proteins associated with AED efficacy, and (iv) genes which are associated with AED 
toxicity (Spear, 2001). Interindividual variations in genes located on or related to 
regions that express drug receptors, ion channels, DMEs and DTPs may influence the 
response to AED treatment (Spear, 2001; Holmes, 2002; Clancy & Kass, 2003; 
Ramachandran & Shorvon, 2003; Ma et al., 2004). 
1.4.1 Pharmacogenetics of antiepileptic drugs: The influence of 
pharmacodynamic genes 
Most forms of human idiopathic epilepsy have been associated with genetic variation in 
ion channels. These include generalised epilepsy with febrile seizure plus (GEFS+) and 
severe myoclonic epilepsy of infancy (SMEI) that were linked to sodium channel 
subunit (SCNIA and SCN2A, respectively) variation (Ceulemans et al., 2004; Kamiya 
et ah, 2004) and some idiopathic generalised epilepsy syndromes that have been 
associated with voltage-gated potassium channel (Chioza et al., 2002) and calcium 
channel gene polymorphisms (Chioza et al., 2001). Most AEDs are believed to act on 
ion channels to modulate the excitability of neurones. Therefore, it is possible that there 
are associations between channel abnormalities and drug responsiveness in epilepsy. 
AED targets may be altered by the changes in the genetic transcription of ion channel 
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subunits. These transcriptional changes most probably affect both the density of ion 
channels in the neuronal membrane, as well as the shape of multi-subunit channel 
complexes. Other post-transcriptional modifications of ion channel proteins that are 
induced by seizures may also affect AED sensitivity (Remy & Beck, 2006). 
Reversal of excessive neuronal hyperexcitability can be achieved by AED binding to its 
recognition site in the domain IV, segment 6 region of the voltage-gated sodium channel 
(Ramachandran & Shorvon, 2003). Alteration of this important binding site could 
potentially result in drug non-responsiveness. This postulated mechanism is supported 
by the phenotypic difference between SMEI and GEFS+. Most patients with SMEI 
carry a truncating mutation which leads to a short Na1.1 sodium channel a-subunit 
protein and most likely causes a loss of function (Ceulemans et al., 2004). In these 
patients, protein truncation might result in destruction of the drug binding site and 
thereby explain resistance to AEDs acting on the sodium channel. On the other hand, 
GEFS+ is a more benign phenotype which results from a few SNPs in sodium channel 
genes, but a nonetheless fully expressed protein (Ceulemans et al., 2004). Compared to 
SMEI, GEFS+ is associated with a better response to AEDs. 
Other than treatment response, variability in the function of ion channels may also 
influence the amount of AED required to achieve optimal seizure control. It has been 
demonstrated that an intronic polymorphism IVS5 -91G>A in the SCNIA gene is 
associated with maximum doses of CBZ and PHT (Tate et al., 2005). Maximum doses 
of CBZ averaged 1313,1225, and 1083 mg for individuals with IVS5 -91A/A, A/G, and 
GIG genotype, respectively; maximum doses of PHT averaged 373,340, and 326 mg, 
for individuals with IVS5 -91A/A, A/G, and GIG genotype, respectively, suggesting a 
trend towards reduction in maximum dose according to genotype. This polymorphism 
affects alternative splicing of exon 5 of the SCNIA gene. The major IVS5 -91A allele 
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disrupts the consensus sequence of fetal exon 5N, possibly reducing the expression of 
this exon relative to the adult exon 5A. Analysis of SCNIA c. DNA from adult human 
brain tissue of individuals with epilepsy showed some degree of association between the 
IVS5 -91G>A genotypes and the SCNIA expression (Tate et al., 2005). Therefore, 
genetic variability in ion channels not only explains epileptogenesis but may also 
influence drug responsiveness and dosing requirements due to subtle alteration of the 
channel structure. 
1.4.2 Pharmacogenetics of antiepileptic drugs: The influence of 
pharmacokinetic genes 
Investigation of AED pharmacogenetic-pharmacokinetic association can be approached 
from two directions; (1) genes encoding DTPs and (2) genes encoding DMEs. Although 
pharmacogenetic studies examining the influence of DTP polymorphisms directly on 
AED pharmacokinetics are limited, some studies have explored the association between 
DTP gene polymorphisms and the response to AED treatment (Siddiqui et al., 2003; 
Tan et al., 2004a; Hung et al., 2005; Sills et al., 2005; Kim et al., 2006; Seo et al., 
2006a). The most studied DTP gene is ABCB 1, a gene responsible for encoding the 
efflux transporter, P-gp. P-gp is believed to be a contributor to pharmacoresistance in 
epilepsy, as several AEDs have been demonstrated to be transported by P-gp (Potschka 
et al., 2002) and over-expression of P-gp has been identified in medically intractable 
epileptic brain tissue (Marchi et al., 2004). Variability in P-gp expression may be the 
result of polymorphisms in the ABCB 1 gene and has been postulated to result in 
interindividual variation in the response to AED treatment. One study has demonstrated 
that patients with drug-resistant epilepsy are more likely to carry the ABCBI 3435C/C 
genotype than the 3435T/T genotype (Siddiqui et al., 2003). Further studies examining 
multiple polymorphic sites have concluded that haplotypes of common polymorphisms 
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in the ABCB 1 gene may be more useful in predicting response to AED treatment (Hung 
et al., 2005; Seo et al., 2006a). However, other investigations have failed to confirm the 
original association between the ABCB 1 c. 3435C>T polymorphisms and drug-resistant 
epilepsy (Tan et al., 2004a; Sills et al., 2005; Kim et al., 2006). As such, the functional 
significance of ABCB 1 gene polymorphisms in the response to AED treatment remains 
elusive. 
The second dimension of AED pharmacogenetic-pharmacokinetic association studies is 
that related to DMEs. Among the DMEs that mediate metabolism of AEDs, only 
isoforms of CYP2C have been studied in depth. (Prasad et al., 1999; Clancy & Kass, 
2003; Ramachandran & Shorvon, 2003). CYP2C9 has two functionally important 
polymorphisms, the c. 430C>T and c. 1075A>C substitutions (Scordo et al. 2004). 
Lower CYP2C9 activity is associated with the 430T+1075C variant. In a single dose 
study using 300 mg PHT, there was a significant difference in trough PHT 
concentrations between the variants of CYP2C9 (Aynacioglu et al., 1999). Compared 
with the CYP2C9 430C/C+1075A/A variant, the greatest difference in trough PHT 
concentrations was demonstrated in individuals carrying the CYP2C9 430T/T+1075A/C 
variant (95% Cl: 0.78 - 2.20; Aynacioglu et al., 1999). In a different study, the PHT 0- 
96 hour AUC after a single dose was also significantly higher in patients carrying the 
430T+1075C variant than in individuals homozygous for the 430C and 1075A alleles. 
Overall, carriers of the 430T+1075C variant have 1.8 to 2.7-fold higher PHT AUC than 
other genetic variants (Caraco et al., 2001). 
In addition, the maximal elimination rate of PHT was shown to be lower in individuals 
with the 1075C allele compared to those with the 1075A allele (Odani et al., 1997), and 
this may explain the association between higher plasma PHT concentrations and the 
CYP2C9 1075C allele (Brandolese et al., 2001; Soga et al., 2004). Carriers of the 
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430T+1075C variant have also been shown to have a higher plasma PHT concentration 
(Caraco et al., 2001), which corresponded with a mean PHT dose that was 30% lower in 
a group of patients with the 430T+1075C variant compared to those with the 
430C+1075A variant (199 ±38.6 mg versus 287 ±80.7 mg, respectively). This 
difference in PHT dose between variant groups was most evident in patients with PHT 
steady-state plasma concentrations within the therapeutic range (10 - 20 mg/l; van der 
Weide et al., 2001). A trend confirming that the PHT dose is associated with CYP2C9 
variants was also demonstrated in the prevalence profile of the variants; CYP2C9 
430T+1075C alleles were present in 62.5% of the low-dose group, 32.4% of the 
standard-dose group and 0% of the high-dose group (van der Weide et al., 2001). A 
study on maximum dose of AEDs has also demonstrated that carriers of CYP2C9 
430T+1075C variant received significantly lower PHT and CBZ doses (Tate et al., 
2005). 
1.4.3 Antiepileptic drugs as drugs of pharmacogenetic interest 
A drug with pharmacogenetic interest is one that is likely to demonstrate significant 
inter-individual variability in mortality, morbidity, quality of life impact and the risk of 
severe adverse effects. In addition to these criteria, the frequency of drug prescription 
and the number of exposed patients should also be considered (Kim et a!., 2007). Drugs 
that are frequently prescribed may also be drugs of pharmacogenetic interest because a 
larger population of patients is at risk of suffering therapeutic failure or severe adverse 
effects. 
The exciting pharmacogenetic findings in relation to PITT metabolism have a limited 
clinical application since this drug is no longer employed as a first line agent in most 
European countries, especially for the chronic treatment of epilepsy (National Institute 
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for Health and Clinical Excellence, 2004). However, a number of other AEDs is 
available for further exploration. VPA, CBZ and LTG are the three most commonly 
prescribed AEDs by clinicians in the UK (Morgan et al., 2004). The Standard and New 
Antiepileptic Drug (SANAD) study has demonstrated that the best AED for newly 
diagnosed idiopathic generalised epilepsy is VPA, whereas CBZ and LTG are the drugs 
of choice for patients with partial epilepsy (Marson et al., 2007a; Marson et al., 2007b). 
The Epilepsy Unit at the Western Infirmary is a tertiary referral centre for adults with 
new-onset and pre-existing seizure disorders and, as such, has a population which is 
predominated with partial or localisation-related epilepsy. Given that these patients are 
most commonly treated with CBZ and LTG, that these drugs have a common 
pharmacodynamic target, and that their pharmacokinetic and metabolic profiles are well 
established, it is reasonable to focus on these two important AEDS. 
1.5 Carbamazepine 
1.5.1 History and indications 
CBZ was first synthesised in the laboratories of J. R. Geigy A. G. by Schindler and 
Blattner in 1957 (Schmutz, 1985). Theoblad and Kunz reported its initial spectrum of 
anticonvulsant activity six years after CBZ had been discovered (Schmutz, 1985). CBZ 
or 5H-dibenz-[b, f]azepine-5-carboxamide (Himes et al., 1981) has been used as an AED 
for many decades. It is effective in the treatment of simple partial, complex partial and 
generalised tonic-clonic seizures. It is ineffective and may even be deleterious in 
generalised absence seizures (Liporace et al., 1994; Kochen et ah, 2002). Other 
indications for CBZ include the treatment of neuropathic pain, such as trigeminal 
neuralgia, and psychiatric disorders, such as manic-depressive illness and aggression 
due to dementia. 
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1.5.2 Mechanisms of action 
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Several mechanisms have been proposed to explain the anticonvulsant activity of CBZ. 
Its principal mechanism is on neuronal ion channels to prevent the generation of high- 
frequency repetitive firing. CBZ blocks voltage-gated sodium channels and L-type 
calcium channels (Ambrosio et al., 1999), and potentiates potassium channel 
conductance (Schmidt & Eiger, 2004), which consequently suppresses the generation of 
high frequency action potentials. CBZ binds to the inactivated state of the voltage-gated 
sodium channel and changes the gating conformation in a voltage-, frequency- and 
time-dependent manner (Courtney, 1975; Kuo, 1998; Kwan et al., 2001). It binds to a 
common receptor site located on the extracellular portion of the sodium channel. The 
common binding site contains two phenyl groups, which are probably part of the side 
chain groups of aromatic amino acids constituting the channel. The two phenyl rings in 
CBZ bind to corresponding phenyl groups in the receptor. Other mechanisms of action 
reported for CBZ include modulation of synaptic transmission and neurotransmitter 
receptors such as the purine, monoamine, acetylcholine and N-methyl-D-aspartate 
(NMDA) receptors (Brodie & Dichter, 1997; Kwan et al., 2001; Bazil & Pedley, 2003; 
Schmidt & Eiger, 2004). However, these mechanisms are not as clear as the first 
mechanism. 
1.5.3 Clinical pharmacokinetics 
CBZ is absorbed relatively slowly from the gastrointestinal tract; however, its oral 
bioavailability is high (>70%). The irregular and delayed absorption is due to its poor 
dissolution in gastrointestinal fluid, and also alteration of gastrointestinal motility by its 
weak anticholinergic properties. After a single oral dose, peak plasma CBZ 
concentrations are achieved within 4 to 8 hours (Spina, 2002). In the blood, CBZ is 75% 
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bound to albumin, and to a lesser degree to a, -acid glycoprotein. In terms of 
physicochemistry, CBZ is neutral and highly lipophilic, making it easy to cross cell 
membranes. CBZ rapidly distributes to various organs and body tissues. In single-dose 
studies employing healthy volunteers and patients, the Vd for CBZ has been estimated at 
between 0.79 and 1.86 1/kg (Spina, 2002). The biotransformation of CBZ occurs mainly 
in the liver, involving multiple DMEs such as the CYP450s, hydrolases and conjugating 
enzymes. CBZ does not undergo significant enterohepatic metabolism (Spina, 2002). In 
humans, less than 2% of CBZ is eliminated unchanged in the urine and approximately 
70% of its oral dose is renally excreted (Bertilsson et al., 1997). 
1.5.4 Metabolism of carbamazepinc 
Multiple isoforms of CYP450 enzymes may be involved in the metabolism of a single 
AED. CYP450-related metabolism has a significant influence on the plasma 
concentrations of CBZ. CBZ metabolism is mediated by CYPIA2, CYP2B6, CYP2C8, 
CYP2C9 and CYP3A4, with the latter being identified as the primary isoenzyme 
(Pearce et al., 2002; Tredger & Stoll, 2002). The phase 1 metabolism of CBZ produces 
four major metabolites; CBZ-10,11-epoxide (CBZ-E); 2-hydroxy-CBZ; 3-hydroxy- 
CBZ; and CBZ-acridan (Bernus et al., 1996). Thereafter, mEH converts CBZ-E to 
CBZ- 10,11 -diol, prior to conjugation and excretion from the body. A significant amount 
of CBZ (15%) is subject to direct N-glucuronidation, with UGT2B7 identified as the 
key enzyme (Staines et al., 2004). Most other products of phase 1 metabolism are also 
conjugated with glucuronides (Maggs et al., 1997; FIGURE 1.2). 
The intermediate metabolite, CBZ-E is known to be pharmacologically active. It is often 
associated with rash and other side effects of CBZ (Ramsay & Wilder, 2002). The rate 
of CBZ epoxidation is believed to correlate with the content of microsomal CYP3A4 in 
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human liver (Kerr et al., 1994), while inhibition of CYP3A4 by drug such as 
ketoconazole can suppress CBZ-E formation by up to 94% (Pelkonen et al., 2001). 
These findings suggest that CYP3A4 is the principal catalyst of CBZ-E formation in 
human liver. A minor role of CYP2C8 in CBZ epoxidation has also been demonstrated 
(Kerr et al., 1994; Pelkonen et al., 2001). A study using cultures of COS-7 cells has 
shown that the activity of CYP3A5 is approximately one third that of CYP3A4 with 
regard to the formation of CBZ-E (Ohmori et al., 1998). Another investigation using 
baculovirus-infected insect cells and human liver microsomes has shown similar levels 
of activity, with the CYP3A5/CYP3A4 ratio of intrinsic clearance in the convertion of 
CBZ to CBZ-E approaching 1.0 (Huang et al., 2004). These investigators also reported 
that the CYP3A4 and CYP3A5 Michaelis-Menten constant values were 248 and 338 
µM, and the maximum rate of metabolism values were 4.87 and 5.98 nmollmin/nmol, 
respectively. These observations indicate a potentially important role of CYP3A5 
enzyme in the in vivo metabolism of CBZ. 
The conversion of CBZ to hydroxy-CBZ metabolites is the second most important 
metabolic pathway after epoxidation. The hydroxylation process is mediated by 
multiple CYP450s, including CYP3A4/5 and CYPIA2 (Pelkonen et al., 2001; Pearce et 
al., 2002; Spina, 2002). Each of these CYP450s has a specific site of action on the CBZ 
molecule, corresponding to the 1-, 2-, 3-, or 4- positions of the aromatic ring (FIGURE 
1.3; Spina, 2002), however, the most common metabolites are 2-hydroxy-CBZ and 3- 
hydroxy-CBZ (Pearce et al., 2002). 
CBZ induces the CYP450 isoenzymes that are involved in its own metabolism. CBZ 
may increase the amount of CYP3A4 protein and its corresponding activity up to 3- to 
4-fold (Wolbold et al., 2003). CBZ induces CYP3A4 activity to a greater extent than 
other CYP450 isoenzymes such as CYP2CI9 (Bertilsson et al., 1997). As CBZ is 
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primarily metabolised by CYP3A4, this effect will automatically accelerate its own 
metabolism in a process known as autoinduction (Tredger & Stoll, 2002), and give a 
unique time-dependent character to the pharmacokinetics of CBZ (Bialer et al., 1998). 
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CYP3A4/S, CYP2C8 
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E CYP1A2 (position 2- & 3-) 
CYP2C9 (position 3-) 
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FIGURE 1.3. Chemical structure of carbamazepine and the sites of CYP450 
action. Modified from Himes et al. (1981), Pelkonen et al. (2001) and Spina 
(2002). 
1.5.5 Effects of autoinduction on carbamazepine pharmacokinetics 
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Autoinduction of CBZ metabolism involves steroid and nuclear receptors such as the 
constitutive androstane receptor (CAR) and pregnane X receptor (PXR; Fuhr, 2000). 
The involvement of PXR is crucial at the transcription level of CYP3A4 mRNA 
(Wolbold et al., 2003). In addition to PXR and CAR, the human glucocorticoid receptor 
(GR) has also been described as a contributor to CYP3A4 induction by its involvement 
in the GR-PXR/CAR-cytochrome P450 cascade (Dvorak et al., 2003; Pascussi et al., 
2003). Both GR and PXR have been reported to contribute to the transcriptional 
regulation of the CYP3A4 gene mediated by a large number of xenobiotics (El-Sankary 
et al., 2001). Although it is recognised that PXR plays a significant role in the 
transcriptional phase of CYP3A4, genetic variability in the PXR gene does not explain 
the variation in CYP3A4 expression (Schuetz, 2003) or activity (Zhang et al., 2001). 
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Autoinduction of CBZ metabolism is a dose dependent process (Liu & Delgado, 1994). 
Steady-state clearance of CBZ varies between 31 to 110 ml/min depending on the 
maintenance dose and increases linearly with dose increment (Kudriakova et al., 1992). 
The ratio of CBZ-E to CBZ ranges between 0.09 ±0.02 at 100 mg/day and 0.21 ±0.06 at 
1200 mg/day (Kudriakova et al., 1992). Dose effects on these ratios are more 
predominant at a lower dosage range. Surprisingly, age does not influence the degree of 
CBZ autoinduction, despite clear differences in metabolic capacity between young and 
elderly subjects (Battino et al., 2003). 
The effects of autoinduction on CBZ concentrations are critical. Observed 
concentrations of CBZ are 50% lower than expected concentrations at day-4 of therapy, 
with observed concentrations falling further during extended follow-up (Eichelbaum et 
al., 1975). This drop in CBZ plasma concentrations can be detrimental to seizure control 
(Macphee & Brodie, 1985). 
CBZ has been employed as a reference drug in many comparative clinical trials of novel 
AEDs for the treatment of partial seizures and generalised tonic-clonic seizures in either 
adult or pediatric subjects (Brodie et al., 1995; de Silva et al., 1996; Reunanen et al., 
1996; Tanganelli & Regesta, 1996; Chadwick, 1999; Vasudev et al., 2000; Kwan & 
Brodie, 2001; Marson et al., 2002; Fakhoury et al., 2004). Due to the effects of 
autoinduction, the dose of CBZ has to be adjusted (Tanganelli & Regesta, 1996; Arroyo 
& Sander, 1999; Fakhoury et al., 2004). Dose titration often results in a 2- or more-fold 
higher dose at the end of study than the initial target dose. In a study of childhood 
epilepsy, the median doses of CBZ at the start of therapy and after 3 years on therapy 
were 200 mg/day (50 - 400 mg/day) and 400 mg/day (150 - 1000 mg/day), respectively 
(de Silva et al., 1996). The range of maximum dose was reported to be wider in CBZ- 
treated subjects (200 - 1400 mg/day) compared with other AEDs (Chadwick, 1999). 
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This range is similar to that reported as the final dose required (200 - 1600 mg/day) to 
achieve full seizure control (Kwan & Brodie, 2001). In clinical studies, some subjects 
receive a significantly higher dose of CBZ by the end of the study period, however, 
mean CBZ and CBZ-E plasma concentrations do not differ when measured routinely 
over a four week period (Schmidt & Eiger, 2004) or even up to 48 weeks (Brodie et al., 
1995; Hogan et al., 2003). This is a demonstration of how the effect of autoinduction 
can influence plasma concentrations of CBZ over an extended period of time. These 
studies have also shown that the degree of CYP3A4 metabolic capacity among patients 
is varied and may partly associate with interindividual genetic variability. 
1.5.6 Concentration-response relationship 
The association between plasma CBZ concentrations and clinical response has been 
investigated comprehensively in seizure disorders. The therapeutic range for CBZ 
plasma concentrations has been suggested at 4 to 12 mg/l (Bialer et al., 1998), although 
minor variations on this range have been proposed in numerous other studies (Hvidberg, 
1985; Brodie et al., 1995; de Silva et al., 1996; Arroyo & Sander, 1999; Dickinson et 
al., 1999). 
Plasma concentrations of CBZ in excess of 10 to 12 mg/1 are likely to produce adverse 
effects. However, minor signs of toxicity may also be apparent at lower concentrations. 
Interestingly, some patients are able to tolerate higher levels of CBZ without obvious 
deleterious consequences. A relationship between fluctuations in plasma CBZ 
concentration and the emergence of intermittent side effects has also been described 
(Bialer et al., 1998). Optimal CBZ concentrations vary widely among patients, with 
lowest concentrations of approximately 1 to 6 mg/l required for minimal effectiveness 
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(Bialer et a1., 1998). However, CBZ concentrations lower than a threshold of 4 to 6 mg/1 
may not be able to control seizures in difficult to treat epilepsy (Bialer et al., 1998). 
1.5.7 Side effects and adverse reactions 
Most AEDs have the potential to cause side effects or adverse events. CNS related 
events represent more than 60% of overall reported side effects or adverse reactions of 
AEDs (Chadwick, 1999; Carpay et al., 2005). Up to 80% of patients on AEDs 
experience at least one adverse event (Chadwick, 1999). Adverse events are the most 
common reason for AED withdrawal in many clinical trials (Reunanen et al., 1996; 
Fakhoury et al., 2004). The most common side effects of CBZ are CNS related, for 
example drowsiness, dizziness, asthenia, headache, weakness and somnolence (Brodie 
et al., 1995; Reunanen et al., 1996; Tanganelli & Regesta, 1996; Vasudev et al., 2000; 
Hogan et al., 2003). 
CBZ is also associated with severe cutaneous reactions such as Stevens-Johnson 
syndrome, toxic epidermal necrolysis and generalised rash (Rzany et al., 1999). This 
phenomenon has been associated with the production of reactive iminoquinone, which 
is an intermediate metabolite in CBZ metabolism (Ju & Uetrecht, 1999). The initial 
cutaneous reactions may indicate a potentially life-threatening reaction known as 
anticonvulsant hypersensitivity syndrome (Svensson et al., 2000. ). Rash is experienced 
by 3.4 to 10 percent of patients on CBZ (Reunanen et al., 1996; Chadwick, 1999; 
Hogan et al., 2003) and is one of the most significant adverse events leading to CBZ 
withdrawal (Brodie et al., 1995). 
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1.5.8 Potential factors that influence the variability in clinical 
pharmacology of carbamazepinc 
Various factors contribute to variability in pharmacokinetics and pharmacodynamics, 
which may consequently affect the efficacy and toxicity of CBZ. These factors include 
patient age, organ function, drug formulation, concomitant medications and genetic 
status. Age reflects body composition and function. The weight-related Vd of lipophilic 
drugs is usually higher in adults than in children because of the greater proportion of fat 
per kg of body weight (Thomson, 2004). Indeed, it has been reported that the Vd of CBZ 
is strongly associated with body weight and demonstrates an increase when comparing 
children to adults (Reith et al., 2001). Clearance of CBZ also increases linearly with 
body weight and nonlinearly with age. With respect to body weight, infants have a 
higher clearance than older children (Delgado Iribarnegaray et al., 1997; Reith et al., 
2000) and the tl/2 of CBZ is very short in young children. CBZ is more rapidly 
metabolized to CBZ-E in children than in adults. This is in accordance with 
conventional wisdom which suggest that, biotransformation occurs at a faster rate in 
children than in adults (Gilman et al., 2003; Perucca, 2006). Thus, children may require 
a higher dose of CBZ per kg of body weight than adults. 
The effect of hepatic impairment on the pharmacokinetics of CBZ is not known. Given 
that CBZ is primarily metabolized in the liver, it is important to exercise caution when 
initiating CBZ in patients with hepatic dysfunction. The effect of renal impairment on 
the pharmacokinetics of CBZ is similarly unknown. 
Plasma CBZ concentrations can be influenced by drug interactions. These are often 
pharmacokinetic rather than pharmacodynamic in origin, and result from induction or 
inhibition of DMEs (Patsalos, 1999; Perucca, 2001; Bazil & Pedley, 2003). The CBZ-E 
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to CBZ ratio may be significantly increased by the concomitant administration of 
enzyme-inducing AEDs (PHT and PB) or decreased by enzyme inhibitors (VPA). The 
metabolism of CBZ can also be inhibited by a variety of therapeutic agents, including 
macrolide antibiotics, anti-fungals, anti-virals, and anti-hypertensive, all leading to an 
increased CBZ plasma concentration. Such drug-induced changes in CBZ kinetics are 
particularly pronounced in children (Battino et al., 1995). 
Genetic polymorphisms which result in the production of proteins with altered activity 
may also have major implications for the variability in CBZ pharmacokinetics and 
pharmacodynamics. These proteins include DMEs and ion channels. CBZ metabolism 
involves many DMEs (FIGURE 1.2; Pelkonen et al., 2001). Common polymorphisms 
in genes encoding these enzymes have been associated with several functional variants. 
Any such change in the activity of DMEs may consequently influence the plasma and 
brain concentrations of CBZ. This may in turn increase the risk of treatment failure or 
the precipitation of adverse effects with CBZ treatment. Blockade of voltage-gated 
sodium channels is the principal mechanism of CBZ action (Courtney, 1975; Kuo, 
1998; Kwan et al., 2001) and polymorphisms in the genes which encode these proteins 
have been associated with defective channel structure and several forms of epilepsy in 
children (Meisler & Kearney, 2005). These genetic variants may influence the binding 
site for CBZ and the sensitivity of the channel to blockade. As such, they have the 
potential to affect the clinical efficacy and toxicity of the drug. 
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1.6 Lamotrigine 
1.6.1 Indication and efficacy 
LTG (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine) is a modified derivative of 
pyrimethamine, an antifolate compound (FIGURE 1.4). It was approved for the clinical 
management of seizures in the United Kingdom in 1991. LTG was initially introduced 
as an adjunctive agent, but was subsequently proven to be effective as monotherapy in 
the treatment of both partial seizures and primary generalised seizures in newly 
diagnosed and refractory epilepsy patients (Beghi, 2004). Patients with juvenile 
myoclonic epilepsy have also benefited from LTG monotherapy (Schimschock et al., 
2005). Outwith epilepsy, LTG is employed as a mood stabiliser in depression (Herman, 
2004). The effectiveness of LTG monotherapy is comparable to that of CBZ 
monotherapy (Nieto-Barrera et al., 2001; Kaminow et al., 2003). However, LTG has 
better tolerability and a better health related quality of life measures than CBZ (Gillham 
et al., 2000; Nieto-Barrera et al., 2001). Up to 40% of patients who are refractory to 
other AEDs may respond to LTG (Knoester et al., 2005). LTG is also effective as an 
alternative AED for patients who experience intolerable adverse effects (Knoester et al., 
2005). 
1.6.2 Mechanism of action 
LTG was identified during the screening of antifolates as putative antiepileptic agents 
(Ragsdale & Avoli, 1998). However, its anticonvulsant activity does not correlate with 
its weak inhibition of dihydrofolate reductase, an enzyme involved in folate bio- 
synthesis (Bazil & Pedley, 2003). LTG acts mainly by prolonging the inactivation of 
voltage-gated sodium channels. It inhibits sustained repetitive firing of action potentials 
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in a voltage- and frequency-dependent manner (Cheung et al., 1992; Ragsdale & Avoli, 
1998; Kwan et al., 2001). These actions resemble those of the established AEDs, PHT 
and CBZ. LTG also acts on L-, N-, and P- subtypes of calcium channels to reduce post- 
synaptic depolarisation (Wegerer et al., 1997; Perucca, 2001). Blockade of voltage- 
gated sodium and calcium channels by LTG is also believed to prevent the release of 
glutamate, the principle excitatory neurotransmitter in mammalian brain (Patsalos, 
1999; Bazil & Pedley, 2003). LTG has been demonstrated to decrease spontaneous 
glutamate release and to increase GABA release in rat entorhinal cortex (Cunningham 
& Jones, 2000). This wide range of pharmacological effects may explain the broad 
spectrum of clinical activity observed with LTG 
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FIGURE 1.4. Chemical structure of lamotrigine. Arrow shows the main position 
of glucuronidation. 
1.6.3 Clinical pharmacokinetics 
LTG is rapidly and completely absorbed following oral administration and reaches peak 
plasma concentrations at I to 3 hours after administration (T, .; Patsalos, 1999; Bazil & 
Pedley, 2003; Doose et al., 2003). The oral bioavailability approaches 98% (Patsalos, 
1999; Bazil & Pedley, 2003; Doose et al., 2003). LTG absorption is not significantly 
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influenced by the presence of food in the gastrointestinal tract (Patsalos, 1999). The 
constant rate of absorption has been estimated at 3.18 1/h. The Vd and tin are not dose- 
dependent, and Vd has been estimated at approximately 1.14 to 1.36 Vkg (Cohen et a!., 
1987; Ramsay et al., 1991; Hussein & Posner, 1997; Wooton et al., 1997). LTG is 
approximately 55% bound to human plasma proteins. Thus, any interaction with other 
therapeutic agents through displacement from protein binding sites is regarded as 
insignificant. 
In healthy volunteers, the total apparent and renal clearances of LTG have been 
estimated at approximately 0.5 and 0.043 ml/min/kg, respectively (Cohen et al., 1987; 
Wooton et al., 1997). The t112 of LTG ranges from 23 to 36 hours (Cohen et al., 1987; 
Jawad et al., 1987; Rambeck & Wolf, 1993; Wooton et al., 1997; Patsalos, 1999). In 
patients with epilepsy, concomitant administration of LTG with enzyme-inducing AEDs 
(PHT, CBZ, primidone or PB) decreases the mean LTG tin to 14 hours (Jawad et al., 
1987; Ramsay et al., 1991). In contrast, concomitant administration of LTG with 
enzyme-inhibiting AEDs (VPA) significantly increases the ti/2 of LTG (30 - 90 hours; 
Jawad et al., 1987; Patsalos, 1999; Perucca, 2001; Bazil & Pedley, 2003). Doses may be 
adjusted accordingly but the dosing interval is unchanged as the relationship between 
LTG dose and concentration remains linear in both monotherapy and polytherapy 
(Armijo et al., 1999). Other than concomitant AEDs, several other factors may also 
influence LTG concentrations. Oral contraceptives can reduce LTG concentration 
through induction of the glucuronidation process (Sabers et al., 2001) and pregnancy is 
associated with a decrease in LTG concentrations, especially in the second and third 
trimesters (Tran et al., 2002; Petrenaite et al., 2005). Severe liver disease, such as 
cirrhosis, may reduce the elimination of LTG and potentially increase plasma 
concentrations (Marcellin et al., 2001). A modest autoinduction with LTG has been 
demonstrated and is complete within 2 weeks of LTG initiation. As a result, the 
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systemic clearance is increased by an average of 17% and the tin decreased from 27.6 to 
23.5 hours (Hussein & Posner, 1997). 
LTG undergoes 2-N-glucuronidation mainly by UGTIA4 (FIGURE 1.4; Magdalou et 
al., 1992; Rambeck & Wolf, 1993; Vashishtha et al., 2001). Glucuronide conjugates are 
the primary (90%) excreted form of LTG. Approximately 70% of oral LTG doses are 
recovered in the urine (Cohen et al., 1987). The pharmacokinetic profiles of LTG did 
not differ between healthy volunteers and patients with chronic renal failure, suggesting 
that renal impairment has little or no effect on LTG plasma concentrations (Wooton et 
al., 1997). 
1.6.4 Concentration - response relationship 
Patients with focal and generalised epilepsies are known to possess a lower resting 
motor threshold (RMT; Tergau et al., 2003). RMT is an indicator of the level of motor 
cortex excitability. A study performed in healthy volunteers demonstrated a positive 
linear correlation between LTG plasma concentrations and RMT (Tergau et al., 2003), 
suggesting that LTG significantly influences the excitability of the motor cortex in a 
concentration-dependent manner and that higher LTG concentrations may be associated 
with better seizure control. However, there are no clinical studies which have 
successfully reproduced this relationship in the epilepsy population. There is no known 
association between LTG plasma concentration and the percentage reduction in seizure 
frequency (Mahmood et al., 1998) or total seizure control (Kilpatrick et a!., 1996). The 
literature is, however, less clear with regard to the relationship between LTG 
concentration and toxicity (Kilpatrick et al., 1996; Hirsch et al., 2004). Concentrations 
of LTG higher than the recommended therapeutic range (1.5 - 10 mg/1) are often well 
tolerated and may provide better efficacy (Hirsch et a!., 2004), but those greater than 20 
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mg/I have been reported to produce adverse effects in more than 50% of patients 
(Hirsch et al., 2004). 
There is no evidence to support the appropriateness of monitoring plasma LTG 
concentration in association with seizure control. However, it may be useful in patients 
treated with polytherapy, especially when adding or removing concomitant AEDs as 
LTG concentrations are influenced by enzyme inducers such as NIT, CBZ and PB and 
enzyme inhibitors like VPA (Perucca, 2001; Bazil & Pedley, 2003). Significant changes 
in plasma LTG concentrations as a result of the withdrawal of concomitant agents may 
be detrimental to seizure control or increase the risk of adverse effects. 
1.6.5 Adverse effects 
The typical adverse effects experienced with LTG are similar to those of CBZ (Brodie 
et al., 1999; Kaminow et al., 2003). However, the number of patients who experience 
adverse effects with LTG is relatively low compared to established drugs, such as CBZ 
and VPA (Nieto-Barrera et al., 2001; Kaminow et al., 2003). Although the incidence of 
rash is higher with LTG than with CBZ, the percentage of patients with intolerable 
rashes that lead to drug withdrawal is lower (Brodie et al., 1999; Kaminow et al., 2003; 
Faught et al., 2004). This was paralleled with a lower number of drop-outs for the LTG 
group compared to the CBZ group in a head to head monotherapy trial (Brodie et al., 
1999). 
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1.6.6 Potential factors that influence the variability in clinical 
pharmacology of lamotrigine 
Numerous factors can lead to variability in pharmacokinetics and pharmacodynamics, 
and consequently affect the efficacy and toxicity of LTG. These include patient age, 
organ function, underlying diseases, drug formulation, concomitant medications and 
genetic status. Body composition and function are reflected by age. The weight-related 
Vd of lipophilic drugs is usually higher in adults than in children because of the greater 
proportion of fat per kg of body weight (Thomson, 2004). However, the weight- 
normalised Vd for LTG in children aged between 2 to 12 years is higher than that 
reported in adults (Chen et al., 1999). There is no clear explanation for this observation. 
LTG metabolism is mainly mediated by glucuronidation in the liver. The rate of 
glucuronidation is known to be lower in infants aged between 7 and 24 months than in 
older children or adults (Strassburg et al., 2002). Hence, children under 2 years may 
exhibit a lesser degree of LTG metabolism. Interestingly, the weight-normalised 
clearance of LTG is higher in children aged between 2 and 12 years than in adults (Chen 
et al., 1999). This is in accordance with the observation that, in older children, DMEs 
mature rapidly and biotransformation occurs at a faster rate than in adults (Gilman et al., 
2003; Perucca, 2006). Thus, children may require a higher dose of LTG per kg of body 
weight than adults. LTG metabolism can also be affected by severe liver disease, such 
as cirrhosis (Marcellin et al., 2001), whereas renal impairment does not directly affect 
plasma LTG concentrations but may influence the excretion of glucuronide metabolites 
of LTG (Wooton et al., 1997). Plasma LTG concentrations can also be influenced by 
drug interactions. These are often a result from induction or inhibition of DMEs (Jawad 
et al., 1987; Ramsay et al., 1991; Armijo et al., 1999; Patsalos, 1999; Perucca, 2001; 
Bazil & Pedley, 2003). It is well known that the concomitant use of LTG and enzyme- 
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inducing AEDs such as PB, PHT and CBZ may reduce plasma LTG concentrations 
(Jawad et al., 1987; Ramsay et al., 1991), whereas the interaction between LTG and 
VPA may result in increase of plasma LTG concentrations (Armijo et al., 1999). 
Dosage adjustment of LTG may be required when introducing or withdrawing these 
concomitant AEDs. 
Genetic polymorphisms which result in the production of proteins with altered activity 
may have major implications for the variability in LTG pharmacokinetics and 
pharmacodynamics. These proteins include DMEs, DTPs and specific subunits of 
neuronal ion channels. Polymorphisms in UGT genes can influence the activity of 
glucuronidation enzymes (Sawyer et al., 2003; Thibaudeau et al., 2006), and any such 
change in the activity of UGTs involved in LTG metabolism may consequently affect 
plasma and brain drug concentrations. This may increase the risk of treatment failure or 
the precipitation of adverse effects with LTG treatment. LTG is believed to be a 
substrate for P-gp (Potschka et al., 2002). Polymorphisms in the ABCB I gene which 
encodes P-gp can alter the expression and function of P-gp (Hoffineyer et al., 2000). 
This protein is expressed in various body tissues, including the intestine, liver, kidney 
and brain (Kim, 2002a; Marchi et al., 2004). Variability in the ABCB1 gene has the 
potential to influence the absorption, distribution, and elimination of LTG. 
Polymorphisms in the pharmacodynamic targets of LTG may also have an impact on its 
efficacy. Blockade of voltage-gated sodium channels is the principal mechanism of 
LTG action (Cheung et al., 1992; Ragsdale & Avoli, 1998; Kwan et al., 2001) and 
polymorphisms in the genes which encode the principal protein subunits of these 
channels have been associated with defective channel structure and several forms of 
epilepsy in children (Meisler & Kearney, 2005). These genetic variants have the 
potential to influence the binding site for LTG and the sensitivity of the channel to 
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pharmacological blockade. As such, they might contribute to interindividual variability 
in the clinical efficacy and toxicity of the drug. 
1.7 Drug metabolising enzyme, drug transporter protein 
and sodium channel genes and their common 
polymorphisms 
In accordance to the aims of this project, special attention is given to DMEs that are 
involved in CBZ metabolism, P-gp that has been reported to transport LTG, and 
voltage-gated sodium channels which are blocked by CBZ and LTG in exerting their 
antiepileptic effects. Common polymorphisms in these DME, P-gp and voltage-gated 
sodium channel genes are described in this section. Published studies examining these 
gene variants in association with AED responsiveness are limited. As such, studies 
investigating other pharmacological agents are presented to illustrate the functional 
relevance of these gene variants. The common polymorphisms examined throughout 
this research programme are listed in TABLE 1.6. These are the most widely recognised 
genetic polymorphisms of the respective proteins at the time this project was planned. 
1.7.1 Cytochrome P450: History and structure 
In 1940s, cytochrome P450 monooxygenase was first systematically documented in 
studies exploring the in vivo metabolic pathway of compounds in animals (Schenkman, 
1993). Extended work through the 1960s by many investigators revealed the presence of 
mixed function oxidase in the process of drug and xenobiotic oxidation. In 1958, 
Garfinkel and Klingenberg identified and reported CYP450 as a new pigment in 
mammalian liver microsomes (Lipscomb & Gunsalus, 1973; Sato et al., 1973). When 
Chapter 1: General Introduction 50 
treated with carbon monoxide, the reduced form of the pigment demonstrated an 
unusually strong absorption band at 450 nm. For that reason, the pigment was known as 
Pigment-450 (P450; Sato et al., 1973). Most of these pigments are present in a 
membrane-bound state of several tissues, for example, in the liver, kidney, adrenal 
cortex, intestinal mucosa and several endocrine glands (Sato et al., 1973). CYP450s are 
named with the root CYP derived from CYtochrome P450 followed by an Arabic 
numeral denoting the gene family, a letter for the subfamily and another numeral 
designating the gene number (Gonzalez, 1993). Human CYP450 has more than 30 
isoforms. 
CYP450 has a molecular weight of about 57 000 Daltons (-500 residues) and contains 
one equivalent of ß-type haem per polypeptide. The overall hydrophobicity of CYP450 
is about 36%, and this gives a significant non-polar property to the molecule. 
Computational modelling of CYP450 suggests the existence of an a-helix and a ß-strand 
in the molecule. The structure undergoes `open' and `closed' transitions to facilitate 
substrate binding and product/metabolite release (FIGURE 1.5; Black, 1993). Further 
investigations in 3-dimensional models have demonstrated that CYP450 structure is 
specific for certain substrates (Guengerich, 1987). 
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TABLE 1.6. Single nucleotide polymorphisms in selected drug metabolising 
enzyme, drug transporter protein and sodium channel genes. 
51 
Single nucleotide Amino acid dbSNP reference 
Protein Gene polymorphism substitution number 
CYP3A4 CYP3A4 g. -392A>G - rs2740574 
CYP3A5 CYP3A5 g. 6986A>G Splicing defect rs776746 
CYP1A2 CYPIA2 g. 5734C>A - rs762551 
mEH EPHXI c. 337T>C Y11311 rs1051740 
c. 416A>G H 139R rs2234922 
UGT2B7 UGT2B7 c. 802C>T H268Y rs7439366 
P-gp ABCB 1 c. 1236C>T G412G rs 1128503 
c. 2677G>T/A A893S/T rs2032582 
c. 3435C>T 111451 rs1045642 
Na"1.2 SCN2A c. 56G>A R19K rs17183814 
mEH = microsomal epoxide hydrolase; P-gp = P-glycoprotein; Na,, 1.2 = voltage- 
gated sodium channel alpha-2 subunit; amino acid code, A= Alanine, G= 
Glycine, H= histidine, I= Isoleucine, K= lysine, R= arginine, S= Serine, T= 
Threonine, Y= tyrosine; dbSNP = SNP database from National Center for 
Biotechnology Information available at http: //www. ncbi. nlm. nih. gov/. 
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(3-strand 
FIGURE 1.5. A schematic view of the secondary structure of the ('YI13A4 
protein. The thick arrow shows the substrate pocket. Adapted G-om Williams 'i at. 
(2004). 
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1.7.2 Cytochrome P450 3As 
1.7.2.1 Functions and tissue distribution of CYP3As 
Almost 50% of all clinically used drugs arc mctabolised by ('YP3A isolorms, mainly 
CYP3A4 and CYP3A5 (Kuehl et (il., 2001; Tredger & Stoll, 2002; Schuct/ ct al., 2004). 
Both CYP3As are also involved in the metabolism of more than 50% of Al: I)s. Other 
than xcnobiotics, CYP3A also catalyses the metabolism of endogenous substances such 
as steroids, fatty acids and prostagladins (Ohmori et al., 199 8). ('YP3A proteins are 
present in many tissues throughout the body. CYP3A expression is greatest in the liver, 
which is the main organ of drug elimination. On average, ('YP3A comprises 30 to 40% 
of total hepatic CYP450 (Shimada et al., 1994). In the small intestine, ('YP3A can be 
found in the villus epithelium (Paine et al., I997). CYP3A hepatic expression shows a 
variation as much as 40-1old among surgically excised and organ donated livers (I, amba 
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et al., 2002a; Ozawa et al., 2004). A large interindividual variability has also been 
reported for the CYP3A content in the small intestine (Paine et al., 1997; I. own ct al., 
1994). 
The CYP3A4 isoform is the dominant CYP3A enzyme in the adult liver. In contrast, 
CYP3A5 is expressed mainly in the gastrointestinal tract. Nevertheless, the CYP3A5 
isoform can also be detected in other tissues throughout the body, such as adrenal gland, 
lung, prostate and kidney (Kolars et a!., 1994; Lown el al., 1994; (icrvot et a!., 1996; 
1 laehner et al., 1996; Ilukkanen et al., 2001; Koch et a!., 2002). 
1.7.2.2 CYP3A gene locus 
The CYP3A gene locus is located on position g22. I ol'chromosome 7 (()rawa cf (Il., 
2004). Duplication of an ancestral CYP3A gene cassette of 40-55 kb forms the CYP3A 
locus. Each of the CYP3A genes contains 13 exons, which encode a 503-amino acid 
CYP3A protein (Wojnowski, 2004). The CYP3A family consists of' four members; 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 (FIGURF 1.6; Kuehl el al., 2001). 
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FIGURE 1.6. The location of the ('YP3A gene locus on Chromosome 7 and 
arrangement of'CYP3A genes in the locus. Adapted from Wojnowski (2004). 
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1.7.2.3 Genetics and common polymorphisms of CYP3A4 
54 
Genetic polymorphisms in the flanking, intronic and exonic regions of the CYP3A4 
gene may influence its level of expression and function. In the 5'-flanking region of 
CYP3A4 gene alone, at least six different SNPs have been identified (Lamba et al., 
2002b). The polymorphic alleles of the CYP3A4 present at a lower frequency in 
Caucasians than Oriental populations, except for CYP3A4 g. 747C>G (Hamzeiy et al., 
2002) and CYP3A4 g. -392A>G (Sata et al., 2000; Kuehl et al., 2001; Gracia-Martin et 
al., 2002; Hamzeiy et al., 2002). The CYP3A4 g. -392A>G polymorphism, previously 
known as CYP3A4-V, is a SNP in the promoter region of the CYP3A4 gene and was 
first described in association with the risk of developing prostate carcinoma (Rebbeck et 
al., 1998). 
1.7.2.4 Genetics and common polymorphisms of CYP3A5 
Clear polymorphic CYP3A5 expression is found in the adult liver, small intestine and 
other organs, with individuals presenting a low level of protein (Ilaehner et al., 1996; 
Kuehl eta!., 2001; Lin et a!., 2002). The most recognised polymorphism of CYP3A5 is 
the g. 6986A>G transition (FIGURE 1.7), a SNP within intron-3 which creates a cryptic 
splice site leading to the insertion of exon-313 into the mRNA (Ilustert et al., 2001; 
Kuehl et al., 2001; Lamba et al., 2002a). This SNP prematurely produces a stop codon 
and terminates the expression of CYP3A5 protein (Kuehl et al., 2001). This explains the 
absence of CYP3A5 protein in some individuals. The nonfunctional homozygous 
CYP3A5 6986G/G genotype is present in 70-87% of Caucasians (van Schaik et a!., 
2002; Lee et at., 2003; King et al., 2003; Schuetz et al., 2004). 
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FIGURE 1.7. Distribution of polymorphisms in the CYP3A5 gene. Boxes I to 13 
represent the exons. The *3 symbolizes the g. 6986A>G polymorphism. 
1.7.2.5 Phenotype profile of common CYP3A4 and CYP3A5 variants 
55 
Hepatic CYP3A4 protein expression varies as much as 90-fold among individuals 
(Hustert et al., 2001). The high interindividual variation observed in CYP3A4 levels is 
believed to be genetically related (Chelule et al., 2003; Ingelman-Sundberg, 2004). The 
functional significance of CYP3A4 gene variants for AED metabolism is unknown. For 
substrates such as nifedipine and alphatoxin B1, the significance of genetic variability in 
CYP3A4 activity has been demonstrated among Japanese and Caucasian populations 
(Shimada et al., 1994). This is further supported by a meta-analysis of 16 studies 
employing 10 different CYP3A4 substrates, which revealed strong genetic control on 
the variability of CYP3A4-dependent metabolism of adriamycin, ethylestradiol, 
erythromycin, midazolam, nifedipine and nitrendepine (Ozdemir et al., 2000). Some 
additional 'evidence to support the importance of CYP3A4 gene variants in drug 
metabolism has also been reported. For example, a significant difference in the systemic 
clearance of midazolam, statins, tacrolimus and docetaxel has been demonstrated 
between the carriers of the CYP3A4 -392A and -392G alleles (Wandel et al., 2000; 
Hesselink et al., 2003; Goto et al., 2004; Kajinami et al., 2004; Tran et al., 2006). 
L=J 'u 
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The second most highly expressed CYP3A protein, CYP3A5, provides another potential 
avenue for exploration. Some studies suggest that CYP3A5 might not directly 
contribute to CYP3A variability due to its low protein expression in the liver (Westlind- 
Johnsson et al., 2003). Nevertheless, some investigators have demonstrated positive 
findings. It has been reported that some Caucasian subjects with the CYP3A5 6986A 
allele are able to express CYP3A5 protein at a level which corresponds to 50% of the 
total hepatic CYP3A content (Kuehl et al., 2001). Therefore, polymorphisms of 
CYP3A5 may influence the total CYP3A activity (Kuehl et al., 2001) and there is 
evidence to support this hypothesis. A significant influence of CYP3A5 polymorphisms 
has been demonstrated on the efficacy of drugs which undergo CYP3A5-dependent 
metabolism, such as lovastatin, simvastatin, artovastatin (Kivisto et al., 2004) and 
saquinavir (Frohlich et al., 2004). Carriers of the CYP3A5 6986G allele were found to 
possess a lower midazolam clearance (Wong et al., 2004). However, a similarly 
designed study in a Korean population failed to reproduce this finding (Yu et al., 2004). 
These conflicting results might be explained by ethnic differences between studies, 
which are not uncommon, and further investigation is required for clarification. 
The degree of linkage disquilibrium between common polymorphisms in CYP3A4 and 
CYP3A5 appears to be high (>90%) when calculated from all concordant homozygous 
and heterozygous genotypes (Dally et al., 2004). A 60% homology between the 5'- 
flanking region of CYP3A5 and the corresponding region of CYP3A4, from nucleotide 
-1 to -1432 (Jounaidi et al., 1994), appears to contribute to this association. 
Linkage 
may play an important role in the overall activities of the CYP3A protein (Lamba et al., 
2002b; Wilkinson, 2004). For substrates that are metabolised mainly by one of the 
CYP3A enzymes, effects of the CYP3A5 g. 6986A>G polymorphism are usually 
opposed to the effects of the CYP3A4 g. -392A>G (Saito et al., 2004). 
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The importance of inducer effects on CYP3A4 and CYP3A5 gene polymorphisms has 
been demonstrated in a handful of studies. Subjects who were treated with rifampicin 
and who carry the CYP3A4 -392A and CYP3A5 6986G polymorphisms appear to 
demonstrate higher midazolam clearance (Floyd et al., 2003). The extent of induction 
was also found to be approximately 50% greater in subjects with the CYP3A5 6986G/G 
genotype (Floyd et al., 2003). This evidence suggests that genetic polymorphisms can 
significantly influence the pharmacological induction of drug metabolism. 
1.7.3 Cytochrome P450 1A2 
1.7.3.1 Functions and tissue distribution of CYP1A2 
CYPIA2 is a DME that catalyzes the hydroxylation of xenobiotics such as caffeine, 
theophylline, clozapine and CBZ (Pelkonen et al., 2001). Some of the metabolites 
produced via the CYPIA2 pathway can be mutagenic and carcinogenic to human cells. 
In mammals, CYPIA2 is constitutively expressed in the liver and the olfactory mucosa 
(Zhang et al., 2000). CYP1A2 represents approximately 13% of human liver CYP450 
(Shimada et al., 1994). Interestingly, CYPIA2 was found to be more active in men than 
in women (Rasmussen et al., 2002). CYPIA2 activity can be induced by drugs such as 
CBZ (Parker et al., 1998). 
1.7.3.2 Genetics and common polymorphisms of CYPIA2 
The CYP1A gene locus is located on Chromosome 15q24.1 of the human genome 
(FIGURE 1.8). The CYP 1A locus contains two genes, CYP 1A1 and CYP I A2. The 
CYPIA2 gene comprises 7 exons that encode 515 amino acids. It also contains an 
upstream region of about 3 kb (Quattrochi et al., 1986). The CYP IA2 gene is separated 
by 23 kb from the CYPIAI gene in the CYPIA locus. These two genes are orientated in 
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opposite directions with respect to one another, and share a common 5'flanking region, 
which contains the xenobiotic response elements and hepatic transcription factors, 
including hepatic nuclear J 'actors (I INFs; Corchero ei (il., 2001). 
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FIGURE 1.8. The location of the CYPIA gene locus on Chromosome 15 and 
distribution of polymorphisms in the CYP I A2 gene. Boxes I to 7 represent the 
exons. The * 11' symbolizes the g. 5734C>A polymorphism. 
Currently, more than 13 polymorphisms of CYPIA2 have been identilicd (Human 
Cytochrome P450 (CYP) Allele Nomenclature Conunittce, 2001). Amon; these 
polymorphisms only the CYPIA2 g. -2467del"1' and ('YP I A2 g. 5734C--A arc commonly 
found in Caucasian populations (Sachse et al., 2003; Pavancllo c! (Il., 2005). CYPIA2 
g. -2467del1' is believed to he under strong 
linkage with ('YPIA2 g. 5734(' A in 
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Caucasians (Sachse et al., 2003). Little is known about the influence of CYPIA2 
variants on its metabolic activity, except in the case of the CYPIA2 g. 5734C>A 
substitution, where the CYPIA2 5734A allele has been reported to be highly inducible 
(Sachse et al., 1999) and capable of adjusting the risk of developing disease (Cornelis et 
al., 2005; Moonen et al., 2005). The allele frequency of CYP1A2 5734A is believed to 
be approximately 70%, with only minor differences between ethnic populations (Hamdy 
et al., 2003a; Obase et al., 2003; Moonen et al., 2005). 
1.7.3.3 Phenotype profile of common CYP1A2 variants 
Distribution of a urinary ratio of caffeine metabolites among smokers and non-smokers 
demonstrates the presence of genetic control over CYP1A2 activity (Schrenk et al., 
1998). This is further supported by a study of caffeine metabolism in twin subjects 
(Rasmussen et al., 2002). The CYPIA2 gene variants show phenotype differences only 
in the presence of xenobiotics or environmental pollutants, such as cigarette smoking, in 
which the CYPIA2 5734A allele shows higher metabolic activity (Sachse et al., 1999; 
Sachse et al., 2003). A study using omeprazole as an inducer has established that 
variation in CYPIA2 induction is also associated with the presence of the CYPIA2 
5734C>A polymorphism (Han et al., 2002). This phenomenon may be applicable to the 
study of CBZ because it has the potential to significantly induce CYPIA2 activity, as 
demonstrated in the drug-drug interaction involving concomitant use of CBZ with 
clozapine and olanzapine (Jerling et al. 1994; Lucas et al. 1998). 
1.7.4 Microsomal epoxide hydrolase 
The epoxide hydrolases are categorised under a broad group of hydrolytic enzymes, 
which include esterases, proteases, dehalogenases and lipases (de Vries & Janssen, 
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2003). Epoxide hydrolases play an important function in the activation and 
detoxification of exogenous chemicals, such as polycyclic aromatic hydrocarbons. At 
least five forms of epoxide hydrolases are present in mammalian species. These are 
microsomal cholesterol 5,6-oxide hydrolase, hepoxilin A3 hydrolase, leukotriene A4 
hydrolase, and soluble and microsomal epoxide hydrolases (Fretland & Omiecinski, 
2000). The first four hydrolases participate in the metabolism of endogenous 
compounds. In contrast to other epoxide hydrolases, mEH activity is geared more 
towards the metabolism of xenobiotic agents (Fretland & Omiecinski, 2000). 
1.7.4.1 Tissue distribution and structure of microsomal epoxide hydrolase 
mEH has been found in all tissues studied to date. The highest expression of mEH 
protein is in the liver followed by prostate, lung and kidney (Rebhan et al., 1997). mEH 
is also present in brain tissue and may have an important role in the metabolism of drugs 
that penetrate the BBB, such as AEDs. 
The first description of epoxide hydrolase structure was based on protein derived from 
Agrobacterium radiobacter AD1 (FIGURE 1.9; Nardini et al., 1999). It consists of 2 
domains: the first or the core domain shows a typical feature of the a/ß hydrolase-fold 
topology and the second or the cap domain is primarily comprised of a-helices. 
Substrates enter the active site through a long tunnel that is filled with water molecules. 
The tunnel is located between the core domain and the cap domain. The back of the 
tunnel or the active site of epoxide hydrolase replenishes the water molecules after the 
metabolic reaction (Nardini et al., 1999; de Vries & Janssen, 2003). 
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FIGURE 1.9. A schematic view of' the secondary structure of' the epoxide 
hydrolase protein. Epoxide hydrolase is built From a-helices, ti-strands and coils, 
and has a narrow hydrophobic active site (black arrow). Source from Nardini ei a!. 
(1999). 
1.7.4.2 Microsonial epoxide hydrolase activity 
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mEH catalyzes the trans-addition of water to a broad range of epoxide substrates such as 
xenobiotic alkene and arene oxides. mEl I substrates are quite selective, with little or no 
metabolism by other epoxide hydrolases (Freiland & Omiecinski, 2000). The narrow 
hydrophobic tunnel of the active site limits the ability ofml: l I to catalyze the hydrolysis 
of large epoxide molecules (Fretland & Omiecinski, 2000). 'T'ypical nrllI substrates 
include toxic and procarcinogenic compounds, as well as epoxide metabolites ofAEI)s. 
In an animal study, mEH activity was significantly increased by PB treatment (Slawson 
et at., 1996). 1lowever, the level ofml; l I induction is moderate compared to C'YP450s 
(Pirmohamed et al., 1994; Hassett et cit., 1998). A study employing human lymphocytes 
also demonstrated that mEH activities varied by 3.3-fold and 4.74old in control subjects 
and patients receiving enzyme inducing drugs, respectively (Pirmohamed et al., 1994). 
Chapter 1: General Introduction 62 
Indirect pharmacokinetic evidence in human and animal studies suggests that hepatic 
mEH is also inducible by CBZ (Eichelbaum et al., 1985; Regnaud et al., 1988; 
Kudriakova et al., 1992). 
In a study employing CBZ-E as a substrate for mEII, it was demonstrated that the 
median log metabolic ratio of transdihydrodiol to epoxide was slightly greater in 
chronic PB and PHT treated subjects, compared to subjects not treated with inducing 
agents (Kroetz et al., 1993). However, the distribution of the log metabolic ratios did 
not differ significantly from normality (Kroetz et al., 1993). These findings indicate that 
the rate of CBZ-E metabolism is not significantly influenced by the induction of mEH. 
As such, although CBZ may induce mEH activity, it is unlikely to enhance the 
elimination of CBZ-E. 
1.7.4.3 Genetics and common polymorphisms of EPHX1 
A single functional gene, EPHXI, located at the g42.1 of chromosome 1, encodes the 
human mEH protein (FIGURE 1.10; Skoda et al., 1988; Hassett et al., 1994a). The 
EPHXI gene contains nine exons, although the first exon is noncoding. Protein coding 
begins with the sixth nucleotide of the second exon (Hassett et al., 1994a). As many as 
33 polymorphisms in EPHXI have been reported (Saito et al., 2001). Two 
polymorphisms that have been studied most extensively are the substitution of 
c. 337T>C on exon-3 and c. 416A>G on exon-4, and particularly, in relation to the risk 
of developing cancer (Jourenkova-Mironova et al., 2000; Zhou et al., 2001; Lebailly et 
al., 2002; Sonzogni et al., 2002; Cajas-Salazar et al., 2003), emphysema (Smith & 
Harrison, 1997; Budhi et al., 2003) and liver disease (Sonzogni et al., 2002). The 
frequency distribution reported for the 337C allele is much higher in Oriental 
populations (45-56%; Takeyabu et al., 2000; Budhi et al., 2003; Zhang et al., 2003) 
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compared to African and Caucasian populations (21-41%; Jourcnkova-Mironova et (11., 
2000; London el al., 2000; Wong el al., 2000), while the 416( allele is observed at a 
frequency of around I5-24% in most populations (Jourcnkova-Mironova cat al., 2000; 
Wong el al., 2000; Lebailly et al., 2002). 
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FIGURE 1.10. The location of the EPI IX I gene locus on Chromosome 1. Boxes 
I to 9 represent the exons. The *3 and *4 symbolize the c. 337'1'->(' and c. 416A>G 
polymorphisms, respectively. 
1.7.4.4 Phenotype profile of common E PI IX 1 variants 
In vita eflccts of EPI IX I variants have been demonstrated in some cases ofcancer, and 
in lung and liver diseases, especially in the presence of' xenobiotic or environmental 
factors (London el al., 2000; Wong el al., 2000; Ulrich el a/., 2001; Zhou el al., 2001; 
Cajas-Salazar el al., 2003; Lin el al., 2006). The gene-disease association is believed to 
be related to the ability of EPI IX I variants to convert a less active compound to a more 
active compound in individuals with 416(; (fast nºetaboliser) or a more active 
compound to a less active compound in individuals with 337(' (slow nºetaholiser). It has 
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been proposed that polymorphic expression of EPHX 1 may also contribute to the 
deficiency in mEH, which could be partly responsible for AED-induced idiosyncratic 
reactions such as those observed with CBZ-E (Pirmohamed et al., 1992). 
mEH-mediated hydrolysis of benzo[a]pyrene-4,5-epoxide varied 8.5- and 7-fold 
between liver samples at low and high substrate levels, respectively (Hassett et al., 
1997). This variation might be due to polymorphic expression of the EPIIXI gene. It 
has been reported that the activity of mEH is reduced by 50% in carriers of 337C, and 
increased by 25% in carriers of 416G (Hassett et al., 1994b). In addition, a study of 
EPHXI variant activity in cultures of COS-1 cells demonstrated that expression and 
activity of the EPHXI 416G-containing enzyme were 28% and 40% higher than the 
EPHX1 416A-containing enzyme, respectively (Maekawa et al., 2003). Using cis- 
stilbene oxide and benzo[a]pyrene-4,5-oxide as substrates, the hydrolysis reaction rates 
of mEH were significantly lower for the 337C/416G allele than for other EPHX1 
variants (Hosagrahara et al., 2004). In many studies, diplotypes of 337T>C and 
416A>G polymorphisms are commonly used to predict the levels of net mEH activity 
(Smith & Harrison, 1997; Sarmanova et al., 2000; Takeyabu et al., 2000; Zhou et al., 
2001; Sonzogni et al., 2002; Lebailly et al., 2002; Cajas-Salazar et at., 2003). Using 
these diplotypes, the net mEH activity can be categorised as low, medium or high. 
1.7.5 UDP-glucuronosyltransferases 
Conjugation reactions may involve glucuronidation, sulphation, glutathionation, 
acetylation and methylation. The glucuronidation process is mediated by UGTs. To 
date, 15 functionally active human UGTs have been identified. UGTs catalyze the 
biotransformation of a vast array of structurally diverse endogenous compounds and 
xenobiotics. Substrates of UGT are conjugated with glucuronic acid from a sugar donor. 
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Glucuronidation can affect both parent compounds and metabolites. Other than a 
deactivation property, UGTs may also generate bioactive and even toxic compounds 
(Radominska-Pandya et al., 2001). 
1.7.5.1 UDP-glucuronosyltransferase 2B7: Functions and tissue distribution 
UGT2B7 is an important isoform that participates in glucuronidation of physiologically 
important endogenous compounds and variety of clinically used drugs (Turgeon et al., 
2001; Court et al., 2003; Staines et al., 2004). Examples of UGT2B7 substrates include 
estrogens, catecholestrogens, bile acids, 3'-azido-3'-deoxythymidine, opioids, and CBZ. 
The UGT2B7 protein is highly expressed in liver and kidney; however, it is also 
detected in mammary gland, small intestine, lungs and brain tissue (King et al., 1999; 
Turgeon et al., 2001). 
1.7.5.2 Genetics and common polymorphisms of UGT2B7 
At present, the human UGT2B subfamily includes 7 genes; UGT2B4, UGT2B7, 
UGT2B 10, UGT2B 11, UGT2B 15, UGT2B 17 and UGT2B28 (Riedy et al., 2000; 
Levesque et al., 2001). Most of the UGT2B genes are believed to be located in one gene 
locus on Chromosome 4g13.2 (FIGURE 1.11; Riedy et al., 2000). The UGT2B7 gene 
comprises 6 exons that encode 529 amino acids (Carrier et al., 2000; Riedy et al., 2000). 
More than 80 SNPs have been reported for the UGT2B7 gene (National Center for 
Biotechnology Information, National Library of Medicine, Bethesda, USA; 
http: //www. ncbi. nlm. nih. gov/). Of these SNPs, the UGT2B7 c. 802C>T polymorphism 
has been reported to be present at a significant level in many populations. This 
polymorphism occurs in exon-2 of the UGT2B7 gene, and leads to replacement of 
histidine by tyrosine at codon 268. The presence of the UGT2B7 802T allele is higher in 
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Caucasian populations than other ethnic groups, ranging between 49% - 54'%, (13hasker 
et al., 2000; Lampe et al., 2000). Although the tJ(i' 2f37 802C% I' substitution causes an 
amino acid change, its functional significance in terms of' elidogcnous substrate and 
xenobiotic metabolisms is unclear. 
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1.7.5.3 Phenotype profile of common tJGT2137 variants 
Several studies have been pcrlormed to determine the eficets of the I I( i"I'2137 802('-1'1' 
polymorphism on xenobiotic metabolism, hoNvcver, none of these studies directly 
examined AEI) metabolism. An in vitro investigation using two types of cell culture has 
concluded that the c. 802C>T substitution may not he responsible liar the variability in 
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plasma and urine concentrations of opioid compounds, menthol, oxazepam, propranolol 
or androgens (Coffman et al., 1998). The UGT2B7 802T allele also appears to lack a 
functional effect on morphine 3-glucuronidation (Bhasker et al., 2000; Holthe et al., 
2003). Nevertheless, the carriers of the 802T allele have been shown to possess a 
significantly lower UGT2B7 activity in morphine-6-glucuronidation compared to 
carriers of the 802C allele (Sawyer et al., 2003). This phenomenon may be associated 
with the specificity of UGT2B7 in catalysing glucuronidation of morphine at position-6 
(Soars et al., 2004). 
Although the UGT2B7 802T allele has been identified as a lower activity variant, a 
recent study has demonstrated a contrary finding, with the UGT2B7 802T allele 
exhibiting a 2-fold higher intrinsic clearance in conjugating 4-hydroxy- 
catecholestrogens (Thibaudeau et al., 2006). Structural differences between substrates 
may explain the conflicting findings between these studies (Ekins et al. 2001; Ekins et 
al., 2003; Thibaudeau et al., 2006). 
1.7.6 Drug Transporter Proteins 
DTPs can be important determinants of drug absorption, distribution and excretion. The 
functional significance of DTPs is dependent upon their expression, and this can be 
modulated by genes and many substances (Ishikawa et al., 2004). DTPs are known to be 
involved in drug-drug interactions, for example between CBZ and talinolol (Lowe et 
al., 1997; Kim, 2002a; Giessmann et al., 2004). 
DTPs have also been associated with non-responsiveness to AEDs, as they significantly 
influence intestinal drug absorption and BBB drug permeability (Huai-Yun et al., 1998, 
Potschka et al., 2001; Potschka et al., 2002). Some hepatic DTPs such as P-gp may 
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affect the influx of AEI)s into hepatocytes, and the efflux of All) metabolites into the 
biliary system, which subsequently influences the rate and extent of AEI) metabolism 
(FIGURE 1.12). The expression of intestinal P-gp can also be induced by drugs such as 
C13Z (Giessmann et al., 2004). This phenomenon may further reduce drug absorption 
and enhance clearance. 
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I 1'11III[I IA %I UMI'N 
l. ipophilic 
dnil_ 
Ui 
Mctabolitcs 
FIGURE 1.12. A postulated model representing drug and metabolite movement 
in the intestinal epithelium and hepatocyte. OATP Organic Anion Transporter 
Protein, P-gp = P-glycoprotein, MRP Multidrug Resistance Associated Protein. 
Adapted from Kim (2002h). 
Drug distribution into brain tissues is determined by a host of factors including barrier 
systems such as the 131313, physicochemical properties of the drugs themselves, cerebral 
blood flow, drug metabolism, and pathological conditions (dc Lange & I)anhofl 2002). 
Expression of P-gp at the luminal membrane of' ccrebrovascular endothelial cells and 
within the brain parenchyma has been suggested to restrict drug, accumulation at 
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neuronal target sites (FIGURE 1.13; Tsuji & Tamai, 1997; Marchi e1 al., 2004). P-gp 
has also been reported to reduce the penetration of' several AI? I)s into the brain 
(Potschka el al., 2002). These findings support the functional relevance of P-gp in 
influencing the distribution of'AEl)s into brain tissue. 
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FIGURE 1.13. A postulated model representing the location of A13('13l 11- 
glycoprotein in the blood-brain harrier and brain parcnchynrr. Adapted from 
Marchi ei al., 2004). 
1.7.6.1 P-glycoprotein 
In the 1970s, a surface glycoprotein was first identified on ('Irinesc hamster ovary cells 
with altered permeability to colchicine (Juliano & Ling, 1976). "I'he 170 kI) 
glycoprotein was then designated as P-gp. The N-terminus of the I'-gp molecule 
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contains 6 transmembrane domains, followed by a large cytoplasmic domain with an 
ATP binding site, and then a second section with 6 transmembrane domains and a 
further ATP binding site which shows over 65% amino acid homology with the first 
half of the polypeptide (FIGURE 1.14). P-gp has been studied extensively with regard 
to its role in chemotherapy disposition and resistance (Chan et al., 2004). 
c. 3435C>T 
0844 
FIGURE 1.14. The putative 2-D structure of ABCB 1 P-glycoprotein with the 
sites of common polymorphisms. Adapted from Pastan et al. (1991). 
1.7.6.2 Functions and tissue distribution of P-gp 
P-gp is an ATP-dependent transmembrane efflux pump with a wide range of 
amphipathic hydrophobic substrates (Kim, 2002a). P-gp transports substances with 
diverse chemical structures, such as anticancer agents, cardiac drugs, I1IV protease 
inhibitors, immunosuppressants, ß-adrenoceptor antagonists, AEDs and also drug 
metabolites (Potschka et al., 2002; Schwab et al., 2003). Usually, CYP3A generated 
metabolites undergo subsequent sulfation and glucuronidation. In humans, P-gp is 
commonly co-localised and co-regulated with CYP3A in many tissues. Thus, P-gp 
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substrates were originally speculated to include most drug sulfates and glucuronides 
(Thu, 1999). P-gp may serve as a tünctional barrier against drug entry. P-gp knock-out 
mice demonstrate significant elevation in the disposition of P-gp substrates (Schinkcl ei 
at., 1996). P-gp can be detected in many tissues such as the intestine, liver, kidney, 
adrenal gland and brain (Kim, 2002a; Marchi el at., 2004). It can also he Bond in the 
apical membrane of many barrier tissues such as the 13ßI3 and blood-placenta harrier 
(Cascorbi, 2006). 
1.7.6.3 Genetics and common polymorphisms of AB('BI 
P-gp belongs to the transporter supcrI roily of the ATP-hinding cassette (ABC). In 
humans, the ABCB I gene encodes P-gp (Borst, 1997; Kusuhara & Sugiyama, 2001). 
The total length of the A13CB 1 gene is approximately 209 kb, which consists of a core 
promoter region and 29 exons (FIGURE 1.15; 13odor el al., 2005). The gene encodes a 
1280-amino acid transporter (Kim, 2002a; Schwab el eil., 2003). 
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More than 35 SNPs have been identified in the ABCB 1 gene, of which eight SNPs 
cause non-synonymous amino acid changes (Cascorbi, 2006). In many populations, the 
highest allele frequencies have been documented for the c. 1236C>T (21 - 41%), 
c. 2677G>T/A (10 - 44%) and c. 3435C>T (10 - 54%) transitions (Pauli-Magnus & 
Kroetz, 2004; Cascorbi, 2006). Significant ethnic differences exist in the frequency of 
allele and genotype distributions of the 3435C>T polymorphism of ABCBI (Schwab et 
al., 2003). In a Japanese study, strong association was demonstrated between 
c. 2677G>T/A and c. 3435C>T alleles (Tanabe et al., 2001). Carriers of the ABCB 1 *2 
variant, which signified the haplotype of 1236T-2677T-3435T were more commonly 
found among European Caucasians (62%) and South East Asians (40%) than African- 
Americans (13%; Kim et al., 2001; Tang et al., 2002; Tang et al., 2004). 
1.7.6.4 Phenotype profile of common ABCB1 variants 
Among the SNPs that have been documented for the ABCB 1 gene, polymorphisms of 
c. 1236C>T, c. 2677G>T/A and c. 3435C>T have been studied extensively (Kim, 2002a). 
However, study findings are inconsistent. Some investigations have shown that the 
3435T allele is associated with lower P-gp expression and activity, while others have 
demonstrated opposite findings. Lower expression of duodenal P-gp was found to 
correlate with the 3435T allele, resulting in higher digoxin plasma levels (Hoffmeyer et 
al., 2000). Collectively, haplotypes of ABCB 1 harboring the 3435T allele were also 
associated with higher digoxin concentrations (Johne et al., 2002). However, a large 
study has shown no significant difference in digoxin absorption between the 3435C and 
3435T alleles and other variants (Gerloff et al., 2002). A similar conflict was also 
observed with studies related to epilepsy. A higher prevalence of the ABCB 1 3435C/C 
genotype was found among poor-responders to AED treatment (Siddiqui et al., 2003), 
suggesting that the 3435C/C genotype was associated with drug resistant epilepsy. 
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However, three subsequent studies examining this polymorphism failed to confirm the 
original finding (Tan et al., 2004a; Sills et al., 2005; Kim et al., 2006). Some further 
investigations have suggested that haplotypes of these three loci might be more useful in 
predicting drug resistance in epilepsy (Hung et al., 2005) In this regard, a study 
focusing on CBZ has shown that the T-T-T haplotype at the 1236,2677 and 3435 
positions of the ABCB 1 gene was associated with a better response to CBZ therapy 
(Seo et al., 2006a). 
1.7.7 Voltage-gated Sodium Channels 
Voltage-gated sodium channels play a crucial role in the initiation and propagation of 
action potentials in neurones and other electically excitable cells (Goldin, 2003). The 
channel protein consists of a complex of a 260 kDa a-subunit in association with one or 
more auxiliary ß-subunits (Goldin, 2003; Yu & Catterall, 2003). The sodium channel a- 
subunit folds into 4 domains (I-IV), which are similar to one another and each domain 
contains 6 a-helical transmembrane segments (Sl-S6; FIGURE 1.16). The S4 region 
acts as the channel's voltage sensor. When stimulated by a change in transmembrane 
voltage, this region moves towards the extracellular side of the cell membrane allowing 
the channel to become permeable to sodium ions. A re-entrant loop between S5 and S6 
is embedded into the transmembrane region of the channel to form a narrow, ion- 
selective filter at the extracellular end of the channel. The cytoplasmic loop linking 
domains III and IV is important for channel function. This loop plugs the channel after 
prolonged activation and contributes to its inactivation. A total of nine a-subunits 
(Na,, 1.1-Na1.9) have been functionally characterized (Yu & Catterall, 2003). 
The essential properties that enable voltage-gated sodium channels to carry out their 
physiological roles include rapid voltage-dependent activation, which opens the 
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channel, and inactivation, which closes the channel until recovery (Goldin, 2003). The 
inactivation process determines the frequency of' neuronal action potential firing. In 
general, the inactivation process can he divided to two phases, mast and slow. Fast 
inactivation occurs when the cytoplasmic loop occludes the channel. On the other hand, 
slow inactivation does not involve the cytoplasmic loop. The slow inactivation process 
is believed to involve a conformational change of the channel. Many drugs including 
AEDs affect sodium channel inactivation. 
u-subunit 11 subunit 
FIGURE 1.16. Schematic diagram of u- and fl-subunits of sodium channel 
Na,. I. 2. The a-subunit gene has four repeats (domains I- IV). Fach of the repeats 
has six membrane regions (S I -S6). The S4 region is the voltage sensor. The grey 
circle represents the position of the amino acid substitution (R I9K) which results 
from the c. 56G>A polymorphism. Adapted from Goldin (2003). 
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1.7.7.1 Tissue distribution of voltage-gated sodium channels 
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Consistent with a distinct role for each channel in human physiology, sodium channels 
have differential expression profiles during development and different sub-cellular 
localization in adulthood (Mandel, 1992). Na,, l. 1 and Na1.3 are localised to the soma 
of the neurone, where they control neuronal excitability. Na1.2 is expressed in 
unmyelinated axons where action potential conduction takes place. Na,, 1.7, Na,, 1.8 and 
Na,, 1.9 are the most abundantly expressed in the peripheral nervous system (PNS). 
Na,, l. l and Na1.6 are also significantly expressed in the PNS. Finally, Na,, 1.4 and 
Na,, 1.5 are muscle sodium channels that control the excitability of skeletal and cardiac 
myocytes, respectively. 
Within the CNS, the expression of Na1.1 is abundant in medulla oblongata and spinal 
cord. In contrast, the expression of Na 1.2 is highest in the hippocampus and cerebral 
cortex (Gordon et al., 1987). These are the major seizure generating regions of human 
brain and, on the basis of this observation, it is likely that the NaJ. 2 sodium channel is 
involved in epileptic discharges and their responsiveness to sodium channel blocking 
AEDs 
1.7.7.2 Genetics and common polymorphisms of SCN2A 
The a-subunit is the principal subunit of neuronal sodium channels and is expressed by 
at least 5 genes in human brain, namely SCNIA, SCN2A, SCN3A, SCN8A and SCN9A 
(Kohling, 2002). In general, the clusters of genes encoding sodium channels are located 
on chromosomes 2 and 3. The SCN2A gene that encodes the Na 1.2 protein is located 
on Chromosome 2q24.3 (FIGURE 1.17). This gene covers approximately 120 kb of 
g. DNA, contains 29 exons, and encodes a 2005 amino acid protein (Kasai et al., 2001). 
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Several SCN2A SNPs have been identified (Kaplan & Lacey, 1983; Kasai ('1 a/., 2001; 
heron et al., 2002; Berkovic et al., 2004). however, data regarding the prevalence of 
these polymorphisms is limited. The c. 56G>A substitution in SCN2A is a well known 
non-synonymous polymorphism (Ito et al., 2004). The c. 56G -A polymorphism which 
results in an amino acid substitution at codon- 19 of'the Na 1.2 protein has been reported 
to have a minor allele (56A) frequency at 6% in a Japanese population (Nakayama ei 
al., 2002). 
1.7.7.3 Phenotype profile of common SCN2A variants 
Several non-synonymous SNPs in the SCN2A gene, including the c. 56(i ýA 
substitution, have been associated with paediatric seizure disorders such as lehrile 
seizure and benign familial neonatal inlänlile seizures (Su`gawara el al., 2001; Ileron ei 
al., 2002; 13crkovic et (il., 2004). The 56A allele was found to be more frequent in 
children with febrile seizure than healthy controls (Sugawara ci al., 2001). The 
mechanism by which this polymorphism alters the predispotion of'seizures is unknown. 
However, any significant modification of sodium channel structure night reasonably 
explain seizure generation and could, in theory, influence the response to A1; 1) 
treatment (Ramachandran & Shorvon, 2003). 
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1.8 Study Aims 
The aims of this thesis are listed as follows: 
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1. To identify the prevalence of alleles and genotypes of common CYP3A4, 
CYP3A5, CYP1A2, EPHX1, UGT2B7, ABCB1 and SCN2A polymorphisms in 
a West of Scotland epilepsy population. 
2. To establish an association between common polymorphisms in SCN2A, 
CYP3A4, CYP3A5, CYPIA2, EPHX1, UGT2B7 genes and the optimal dose of 
CBZ. 
3. To establish an association between common polymorphisms in CYP3A4, 
CYP3A5, CYP1A2, EPHX1 and UGT2B7 genes and CBZ adverse effects. 
4. To establish an association between common polymorphisms in ABCB I and 
SCN2A genes and the response to LTG monotherapy. 
5. To establish an association between common polymorphisms in ABCßl and 
SCN2A genes and the optimal dose of LTG. 
6. To establish the influence of common ABCB 1 gene polymorphisms on the 
pharmacokinetics of LTG in newly diagnosed epilepsy patients. 
Studies exploring aim (1) are presented in Chapter 3, studies exploring aims (2) and (3) 
are described in Chapter 4, and studies exploring aims (4), (5) and (6) are presented in 
Chapter 5. 
CHAPTER 2 
Materials, Experimental Principles and Recurrent 
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2.1 Materials 
2.1.1 Chemicals and reagents 
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Promega® wizard DNA purification kit was purchased from Promega (Southampton, 
UK). Bromophenol blue, ethylene diamine tetraacetic acid (EDTA), ethanol, ethidium 
bromide, glacial acetic acid, isopropanol, tris base (Trizma®), and xylene cyanole FF 
were obtained from Sigma-Aldrich Co. Ltd. (Poole, UK). Chlorine tablets were 
purchased from Prime Source (Birmingham, UK). Deoxyribonucleotide triphosphates 
(dNTP mix), magnesium chloride (MgCl2), lOx PCR buffer (200 mM Tris HCl & 500 
mM KCI), and Taq polymerase were purchased from Invitrogen Ltd. (Paisley, UK). 
Molecular biology grade water was obtained from Eppendorf AG (Hamburg, Germany). 
PCR primers were purchased from MWG-Biotech (Ebersberg, Germany). 
Agarose powder was obtained from BioGene Ltd. (Kimbolton, UK). Bovine serum 
albumin (100x), lOx NE buffer, restriction enzymes (DdeI, DpnIl, EcoO1091, EcoRV, 
FokI, PspOMI, Pstl and Rsal), and DNA ladders (25 and 50 bp) were bought from New 
England Biolabs (Hitchin, UK). AMPure® system, DYEnamic ET Terminator Cycle 
Sequencing Kit and DYEnamic® ET Terminator dilution buffer were purchased from 
Beckman Coulter Ltd. (High Wycombe, UK). Ethyl acetate and methanol were bought 
from Rathburn Chemicals Ltd. (Walkerburn, UK). Sodium hydroxide was purchased 
from Fisher Scientific UK Ltd. (Loughborough, UK). 
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2.1.2 Pharmaceuticals 
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LTG and the internal standard (BWA725C) for high performance liquid 
chromatography (HPLC) were obtained from Glaxo Smith Kline (Stevenage, UK). 
2.1.3 Materials for gel electrophoresis 
2.1.3.1 Electrophoresis buffer 
A total of 3.7224 g of EDTA was dissolved in I litre of distilled water. The p11 of the 
EDTA solution was adjusted to 7.0 by slow addition of 5N sodium hydroxide. In a 
separate container, 48.4 g of tris base (Trizma®) was dissolved in 5 litres of distilled 
water. The Tris Base solution was then added to the EDTA solution. The p1! of the final 
solution was slowly adjusted to 8.0 with glacial acetic acid. Finally, distilled water was 
added to a total volume of 10 litres. 
2.1.3.2 Agarose gel 
Appropriate quantities of agarose powder (2.0,2.5 and 3.0 g) were dissolved in 100 ml 
of electrophoresis buffer to make 2.0,2.5 and 3.0% gels, respectively. The mixture was 
boiled in a microwave oven. After the agarose powder was completely dissolved, 0.5 µl 
of ethidium bromide (10 mg/ml) was added and mixed thoroughly. The mixture was 
poured into a gel tray and allowed to set for approximately 1 hour. 
2.1.3.3 Loading dye 
Small pinches (approximately 1 mg) of both bromophenol blue and xylene cyanole FF 
were mixed with 20 ml of 50% glycerol/water solution. 
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2.1.4 Equipment 
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Centrifugation: Blood samples were centrifuged in a ALC® PK130 centrifuge (DJD 
Labcare Ltd., Newport Pagnell, UK). 
DNA quantification: genomic DNA samples were quantified using a WPA Biotech 
photometer model UV 1101 (Biochrom Ltd., Cambridge, UK) 
DNA storage: The genomic DNA samples were stored in a NapCOIL UF400 -80°C 
freezer (Jencons-PLS, Forrest Row, UK). 
Direct sequencing assay: The sequencing equipment consisted of MegaBACE 1000 
DNA Analysis System and SPRIPIate 96R® plate (Beckman Coulter Ltd., High 
Wycombe, UK) 
LTG assay: The experimental equipment consisted of Shimadzu SIL-9A autosampler, 
Shimadzu SPDF-6A UV detector, Shimadzu LC-IOAT pump (Shimadzu UK Ltd., 
Milton. Keynes, UK) and Heto Maxi Dry Plus vacuum centrifuge (Iieto-Holten A/S, 
Allered, Denmark). The HPLC column was a Zorbax sil column (250 x 4.6 mm; 
DuPont UK Ltd., Stevenage, UK) 
Polymerase chain reaction: PCR was performed in a PxE 2.0 Thermal Cycler® (Thermo 
Electron Co., Basingstoke, UK) 
Restriction fragment length polymorphism assay: Separation of DNA fragments was 
performed in a Sub-cell® GT tank. A PowerPac Basic was used as a power system for 
the electrophoresis process. Separation of DNA fragments was visualised under 
ultraviolet light using Gel Doc 1000 system (all Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK). 
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2.2 Experimental Principles 
2.2.1 Polymerase chain reaction 
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PCR provides a sensitive means of amplifying small quantities of DNA. PCR was 
invented by Kary B. Mullis in 1983 (Rabinow, 1996). The discovery of polymerase 
derived from the bacterium Thermus aquaticus (Taq) which is found in the region of hot 
springs makes this method feasible. Taq polymerase is stable at the high temperatures 
required to perform the amplification, whereas other polymerases would denature. The 
concept of PCR is based on the fundamentals of natural DNA polymerization reaction. 
2.2.1.1 Polymerase chain reaction components 
PCR requires several basic components which include a DNA template that contains the 
region of the DNA to be amplified, two primers which are complementary to the DNA 
regions at the 5' and 3' ends of the DNA sequence to be amplified, a DNA polymerase 
(Taq polymerase) used to synthesize a DNA copy, dNTPs from which the DNA 
polymerase builds new DNA, buffer solution which provides a suitable chemical 
environment for optimum activity and stability of the DNA polymerase, and the 
divalent cation magnesium which is a necessary cofactor for Taq polymerase activity. 
Magnesium concentration is a crucial factor that can affect the success of the 
amplification. Template DNA concentration, dNTP concentration and the presence of 
proteins can affect the amount of free magnesium in the reaction. In the absence of 
adequate free magnesium, Taq polymerase is inactive. In contrast, excess free 
magnesium reduces enzyme fidelity and may increase the level of nonspecific 
amplification 
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2.2.1.2 PCR primer design 
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Good primer design is essential for successful reactions. A number of criteria have been 
proposed for optimal primer design. A primer length of 18-24 bases is appropriate for 
most PCR applications. Shorter primers lead to amplification of nonspecific PCR 
products. The specificity of PCR depends strongly on the primer melting temperature 
(Tm), a temperature at which half of the primer has annealed to the DNA template. 
Usually, optimal amplification is achieved when the Tm for both primers is between 52- 
58°C. The G and C nucleotide content of a primer should be between 40 and 60%. To 
assist in fulfilling these criteria, several online resources and software programmes have 
been created, such as Primer3 (Rozen & Skaletsky, 2000) and GeneFisher (Giegerich et 
al., 1996). The template DNA sequence that is required by these programmes can be 
obtained from established DNA databases, such as GenBank (National Center for 
Biotechnology Information, National Library of Medicine, Bethesda, USA; 
http: //www. ncbi. nlm. nih. gov/Genbank/). The specificity of a primer produced by these 
programmes can be examined using Basic Local Alignment Search Tool (BLAST; 
National Center for Biotechnology Information, National Library of Medicine, 
Bethesda, USA; http: //www. ncbi. nlm. nih. gov/BLAST/). This evaluation program 
compares the primer sequence to DNA sequences available in a comprehensive 
genomic database and calculates the statistical significance of matches between primer 
and targeted DNA sequence. 
2.2.1.3 Polymerase chain reaction assay 
There are three major steps in a PCR, which are repeated for 30 to 40 cycles. This is 
done on an automated thermocycler, which can heat and cool PCR tubes within a very 
short period of time. It is common that additional denaturation and extension steps are 
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included before and after the PCR cycles, respectively. In each cycle, the DNA template 
is denatured at 94°C, the primers are annealed to the target sequence at 50-60 °C and the 
two new strands are extended by Taq polymerase at 72 °C, doubling the amount of 
DNA present in a single cycle. The PCR is usually terminated with soaking at 4 °C to 
prevent any further reaction before the PCR product undergoes further sequence 
analyses. 
During the denaturation, the double strand melts open to single stranded DNA, and all 
enzymatic reactions stop. During the annealing stage, ionic bonds are constantly formed 
and broken between the single stranded primer and the single stranded template. The 
more stable bonds last a little longer (especially where primers that fit exactly) and on 
that piece of double stranded DNA (template and primer), the polymerase can attach 
and start to copy the template. Once 3 to 4 dNTPs are incorporated, the ionic bond 
between template and primer is sufficiently strong to prevent further breakage. During 
the extension phase, primers have a stronger ionic attraction to the template than the any 
forces attempting to break these attractions. Primers in positions with no exact match 
are loosely bound and do not support extension. The dNTPs are successively coupled to 
the primer in the 5' to 3' direction and in direct complementary to the DNA template. 
Approximately 1000 dNTPs can be linked to form a complementary DNA sequence in I 
minute at 72°C. 
2.2.1.4 Examining the PCR product 
The PCR product has to be examined before it is used in further applications. Not every 
PCR is successful. There is a possibility that the quality of amplified DNA is poor 
because one of the primers was poorly designed, there were too many annealing site for 
the primers or that the annealing temperature or magnesium concentration was not 
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optimised. It is also possible that there is a PCR product but of incorrect size. In this 
case, one of the primers likely anneals to a part of the gene closer (or further) than 
expected. It is also possible that both primers might anneal to a totally different gene. In 
some cases, it is possible that the primers anneal firmly to the desired locations, but also 
to other locations in the genome. In this case, multiple DNA fragments will be formed. 
Multiple DNA fragments can also produced if a lower than optimal annealing 
temperature is employed. In such cases, the primers anneal in a non-specific manner to 
the DNA template. Examination of PCR product is tarried out by gel electrophoresis. 
The size of the PCR product should be known in advance and can be confirmed by a 
DNA ladder which is included in the electrophoresis process. For successful DNA 
sequence analysis, a single PCR product of uniform size should be produced. 
2.2.2 Identification of single nucleotide polymorphisms 
SNPs can be detected using many methods, including hybridization, primer extension, 
oligonucleotide ligation, allele-specific PCR and restriction enzyme cleavage. However, 
each of these methods has its advantages and disadvantages (Syvanene, 2001; Zhang et 
al., 2005). 
2.2.2.1 Restriction fragment length polymorphism assay 
RFLP assays are based on the principle of restriction enzyme cleavage to identify the 
individual alleles of a genetic polymorphism. This method is classic, relatively 
inexpensive and reliable (Zhang et al., 2005). However, it is not recognised as a high- 
throughput technique. 
RFLP is a technique in which genotypes are differentiated by analysis of fragments 
derived from cleavage of a larger DNA fragment by restriction enzyme. The restriction 
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enzyme makes two incisions, one through each of the sugar-phosphate backbones of the 
double helix without damaging the nitrogenous bases. Any SNP that alters the 
recognition sequence of a restriction enzyme can be genotyped by RFLP. 
When the SNP does not alter the enzyme recognition sequence, mismatched PCR-RFLP 
can be employed to introduce an artificial restriction enzyme site (Haliassos et al., 
1989). This method requires the careful selection of restriction enzymes and the design 
of appropriate mismatched PCR primers. Mismatched PCR-RFLP uses a primer 
containing an additional mismatched nucleotide or nucleotides adjacent to the SNP site. 
This allows restriction recognition sequences to cover the mismatch base and SNP site. 
The artificial restriction enzyme recognition site is introduced in just one of the two 
allelic sequences. 
The presence of genetic polymorphisms is responsible for the variation in the length of 
DNA fragments created by the restriction enzyme digest of PCR products. The 
restriction enzyme is selected such that its recognition sequence contains the nucleotide 
of interest and that the enzyme cuts the target DNA at only one of the two possible 
alleles. Suitable restriction enzymes for a SNP site can be identified using online 
resources, such as RestrictionMapper (http: //www. restrictionmapper. org) and NEB 
cutter (http: //tools. neb. com/NEBcutter2/index. php; Vincze et al., 2003). The restriction 
enzyme recognises specific sequences and cuts the amplified DNA strand into series of 
fragments of different lengths. The length of the fragments can be analysed by gel 
electrophoresis. The pattern of DNA fragments is used to differentiate one allele from 
another. This is a key tool in DNA fingerprinting, reflecting the existence of different 
alleles in the individual. 
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2.2.2.2 Gel electrophoresis 
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Gel electrophoresis is a method that separates macromolecules, either nucleic acids or 
proteins, on the basis of size and electric charge. The term electrophoresis describes the 
migration of charged particles under the influence of an electric field. DNA has a 
negative charge in solution, so it will migrate to the anode in an electric field. Agarose 
and polyacrylamide are the most common separation media used in gel electrophoresis. 
In gel electrophoresis, the DNA is forced to move through a sieve of molecular 
proportions. The end result is that large pieces of DNA move more slowly than small 
pieces. The DNA fragments in the gel are visualised by the inclusion of ethidium 
bromide. This compound binds to DNA and the complex DNA and ethidium bromide 
fluoresces under ultraviolet light. A digital image can be obtained as a permanent record 
of the gel electrophoresis. 
2.2.2.3 Direct sequencing 
The direct sequencing method is a valuable complement to other methods of 
polymorphism identification such as PCR-RFLP (Yandell & Dryja, 1989). One of the 
advantages of direct sequencing is that it detects all polymorphic sites within amplified 
sequence (Engelke et al., 1988). For a small-scale study with a limited number of 
targeted polymorphism sites, direct sequencing can be expensive. In recent years, direct 
sequencing. of DNA has undergone vast development (Yandell & Dryja, 1989). The 
latest sequencing procedures involve hybridisation of an oligonucleotide primer to a 
clean DNA template fragment, extension of the primer with DNA polymerase and 
energy transfer dye-terminator reagent, resolution of the DNA fragment using capillary 
electrophoresis, and nucleotide identification using laser scanning. Most sequencing 
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processes are now undertaken by a fully automated system (Innis et al., 1988). These 
are high-throughput and increasingly economical. 
2.2.3 Methods of assessing the response to antiepileptic drug 
treatment 
The most common difficulty in pharmacogenetic studies, particularly in epilepsy, is the 
ability to identify an unequivocal drug response phenotype. Phenotypes related to AED 
treatment can be pharmacokinetic or pharmacodynamic in nature and can include drug 
dose, plasma drug concentration, response to treatment (efficacy) and occurrence of 
adverse effects (toxicity). Individual drug response can be affected by both 
environmental and genetic factors (Terwilliger & Weiss, 1998). In population-based 
studies, AED response phenotypes can also be influenced by many clinical and 
experimental factors that are directly and indirectly associated with AED treatment, 
such as circadian variability in pharmacokinetics, ethnicity, population size, 
heterogeneity of epilepsy, gradations of response, drug interactions, life-style and 
methods of assessing outcome (Sills et al., 2005; French, 2006). Non-genetic factors 
such as renal and hepatic impairments may directly influence variability in drug 
pharmacokinetics, especially for drugs that are mainly eliminated through both of these 
organs. Ethnicity is usually associated with genetic heterogeneity but also variability in 
diet and life-style, and thus, populations with mixed-ethnicity may also have a broad 
heterogeneity in terms of environmental interaction. Population size can influence 
selection and randomisation biases and epilepsy type may demonstrate different levels 
of response to a given AED, such that differences in the distribution of epilepsy 
syndromes between studies may contribute to conflicting findings. Finally, drug-drug 
interactions can influence the effective dose and concentration of AEDs, and thus, 
influence the response to treatment. 
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Assessing the response to AED treatment is complicated, however various methods 
have been proposed. AED treatment response phenotypes are commonly evaluated by 
two sets of measures related to efficacy and to safety. The primary outcome measures 
related to efficacy are seizure frequency and seizure severity, whereas the primary 
outcome measures related to safety are the incidence of adverse drug effects (Perucca, 
1997; Gilliam, 2005). 
2.2.3.1 Assessing the efficacy of antiepileptic drugs 
In clinical practice, the response of an individual patient to a specific AED cannot be 
known in advance; there is no treatment that is universally effective or universally 
ineffective. As such, it is difficult to establish whether a particular treatment is likely to 
be effective for a particular patient. The most attractive indicator of treatment success is 
complete seizure control (Perucca, 1997; Gilliam, 2005; French, 2006). However, the 
probability of achieving seizure-freedom varies greatly depending on the severity of the 
seizure disorder, pre-treatment seizure frequency and duration of the assessment period 
(Kwan & Brodie, 2000; Gilliam, 2005). The hidden difficulty in using such a definition 
is the time factor. How long the patient must be treated with the medication before 
complete seizure control can be established or discounted? It is important that the 
duration of follow-up is sufficiently long to ensure optimal individualisation of dosage 
and meaningful assessment of response at that dosage. Individuals with low frequency 
pre-treatment seizure frequencies may have to be observed for considerably longer than 
those with higher frequencies. 
Other useful endpoints include the percentage change in seizure frequency for the group 
as a whole, as well as the proportion of patients achieving at least 50% reduction in 
seizure frequency compared with pre-treatment baseline (Perucca, 1997; Gilliam, 2005). 
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However, this approach, while statistically sound, has less practical applicability as it is 
arguable that a 50% reduction in seizure frequency may not be adequate to produce a 
significant improvement in quality of life. Counting of seizures can be done directly by 
the patient or less common by an external observer. Self-reported seizure frequency 
may be inaccurate as some patients are not aware of their seizures. Patients with the 
lowest self-reported seizure frequency often have the highest proportion of 
unrecognised seizures (Gilliam, 2005). In addition, those with newly diagnosed epilepsy 
may not have had a sufficient number of seizures to permit a reliable definition of 
seizure frequency; in such circumstances, the measurement of reduction in seizure 
frequency can be meaningless. Another potential measurement of treatment efficacy is 
the reduction in seizure severity (French, 2006). Seizure severity requires a definition 
that takes several factors into account and physiological consequences of the seizure 
must be quantified. The most obvious factors include fall, loss of consciousness, and 
intensity or duration of postictal effect. It is clear for the above that variability in the 
techniques of assessing the efficacy of AED treatment can contribute to the variation in 
phenotype characterization. 
2.2.3.2 Assessing the adverse effects of antiepileptic drugs 
Evaluation of adverse effects is fraught with difficulties. One of these is the lack of 
current standardisation in the methodology for the detection and categorisation of 
adverse events. Recording of adverse effects is often based on spontaneous reporting by 
the patient, physical examination, laboratory tests or a combination thereof. 
Spontaneous reporting has clear advantages in highlighting effects which are clinically 
relevant, but it is associated with distinct variability in the accuracy of detection and 
with significant under-reporting (Perucca, 1997; Gilliam, 2005). Patients may not be 
able to report signs and symptoms of adverse effects accurately as they emerge 
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(Gilliam, 2005). An alternative to the reliance on spontaneous reporting is the use of 
standardised procedures with respect to clinical questioning and physical examination. 
Of course, a further problem is the ability to quantitatively assess the severity of adverse 
symptoms, especially for CNS-related adverse effects (Perucca, 1997; Gilliam, 2005). 
Another important issue is the need to obtain information about the time course of a 
given adverse effect, as there is a difference in the relative importance between acute, 
transient and chronic effects which persist throughout the treatment period. 
In clinical practice, the assessment of adverse effects may be considered as "biological", 
and "cognitive" or "behavioral". Biological adverse effects are those that are objective 
and evident by examination or measured by clinical tests. This category of adverse 
effects includes- rash, hair loss, liver failure, or nephritis. Supplemental tests may be 
required when the clinical history indicates a particular possibility. Biological adverse 
effects can be divided into acute and chronic events. Acute effects are generally 
idiopathic and by definition cannot be predicted or anticipated for an individual patient, 
for example aplastic anaemia, hepatitis, nephritis, or Stevens-Johnson syndrome. 
Chronic effects include disorders such as folate deficient anemia, AED-induced rickets, 
neuropathy, gingival hyperplasia, and cerebellar degeneration. Chronic adverse effects 
appear to be related more to cumulative toxicity. 
Individual sensitivities to the cognitive and behavioral side effects of AEDs are 
commonly reported by patients and their families. Behavior and cognition are altered by 
many aspects of the epileptic disorder and these may be confused with medication 
effects (Gilliam, 2005). In clinical practice, measuring a change in the patient's 
personality or behavior is almost never objective. There is almost no area of clinical 
medicine more in need of objective measures than the area of adverse drug effects. As 
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with efficacy, variability in the techniques of assessing adverse effects of AEDs may 
contribute significantly to the variation in phenotype characterization. 
2.3 Recurrent Methods 
2.3.1 Study subjects 
Approvals to obtain a peripheral blood sample for the extraction and pharmacogenetic 
analysis of DNA from all appropriate patients with epilepsy was granted by the West 
Research Ethics Committee (North Glasgow University Hospitals NHS Trust; Ref 
02/119(2)) in September 2002. All patients attending the Epilepsy Unit at the Western 
Infirmary, Glasgow, Scotland were invited to participate. The first 400 patients (201 
male; median age 40 years, range 14 to 85 years) who provided informed consent 
contribute to the experiments described in this thesis. Among these patients, 398 self- 
identified as being of European ancestry and the other two subjects were of Asian 
origin. The 400 DNA samples were collected continuously from September 2002 until 
December 2005. Throughout this thesis, this group of 400 patients is denoted as the 
"400-strong study population". A flow chart showing the distribution of these 400 
patients to each individual project is presented in FIGURE 2.1. 
2.3.2 Control DNA samples 
A total of 10 control DNA samples were obtained from members of staff of the 
Epilepsy Unit. All of these subjects self-identified as being of European ancestry. These 
samples were employed for the purposes of assay optimisation and validation and 
thereafter as control samples of known genotype in individual analyses. 
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FIGURE 2.1. Distribution of 400 study subjects to each individual project. 
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2.3.3 DNA extraction 
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A total of 16 ml (4 ml x4 tubes) of venous blood was collected in EDTA-coated tubes 
by qualified clinical personnel and stored at 4 T. Genomic DNA was extracted from 
leukocytes using the Promega® Wizard DNA purification kit as describe below. 
The DNA extraction was started with lysis of the red blood cells and separation of the 
white blood cells. A total of 30 ml of cell lysis solution was placed in a 50 ml centrifuge 
tube and 10 ml of whole blood added. The solution was mixed by inversion and then 
incubated at room temperature (20°C) for 10 minutes. The mixture was then centrifuged 
at 2000 xg for 10 minutes at room temperature (20°C). The supernatant was removed 
and discarded into a waste container containing a chlorine tablet, leaving approximately 
1.4 ml of residual liquid and a white pellet. These steps were repeated if the pellet 
appeared red in color. 
The next step was to release the DNA from the nucleus of the white blood cells. The 
centrifuge tube containing the white pellet was vortexed to resuspend the white blood 
cells. A 10 ml aliquot of nuclei lysis solution was added to the tube and mixed using a 
pasteur pipette. The resulting solution was then incubated at 37 °C for approximately 2 
hours. The next step was to remove the cellular proteins by a salt precipitation 
technique. A 3.3 ml aliquot of protein precipitation solution was added to the nuclear 
lysate and vortexed for 10 - 20 seconds. The solution was then centrifuged at 2000 xg 
for 10 minutes at room temperature (20°C) to separate the cellular protein (dark brown 
pellet). 
The final step was to concentrate and desalt the DNA. Without disturbing the cellular 
protein pellet, the supernatant was decanted to a universal tube containing 10 ml of 
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isopropanol. This solution was then mixed by inversion until the white "thread-like" 
DNA strands formed a visible mass. Following that, the solution was centrifuged at 
2000 xg for 3 minutes at room temperature (20°C) and the DNA emerged as a small 
white pellet. The supernatant was discarded and 10 ml of 70% ethanol was added to the 
DNA pellet. The pellet was resuspended and the tube washed by several inversions. The 
solution was again centrifuged at 2000 xg for 3 minutes at room temperature (20°C). 
The ethanol was decanted, the tube was inverted on clean absorbent paper, and the 
pellet allowed to air-dry for 10 - 15 minutes. A 200 pl volume of molecular biology 
grade water was added to rehydrate the DNA and left overnight prior to quantification. 
Thereafter, the dissolved DNA was transferred to a 250 µl cryovial using a sterile 
pipette and stored frozen at -80 °C. 
2.3.4 DNA quantification 
The concentration of DNA was quantified using ultraviolet spectroscopy. A1 µl aliquot 
of DNA solution was diluted with 70 µl of molecular biology grade water in a 
polystyrene cuvette. The optical density (O. D. ) of the DNA solution was determined at 
a wavelength of 260 nm. The genomic DNA concentration was calculated using the 
following equation: 
genomic DNA (µg/µ1) = 0.05 * O. D. * dilution factor 
2.3.5 Polymerase chain reaction 
2.3.5.1 PCR primers 
Primer sequences were usually obtained from existing publications, however, on 
occasion, an online software package, Primer3 (Rozen & Skaletsky, 2000), was used to 
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design the PCR primers. Some characteristics were standardised for all primer design, 
such as length of primers (18 - 24 bp), GC content (50%) and primer Tm (55°C). The 
genetic sequence of interest was obtained from GenBank. The specificity of the primers 
was evaluated using BLAST. 
2.3.5.2 Optimization of polymerase chain reaction assay 
All PCR assays were optimised using a standard protocol. A total of 10 control DNA 
samples were employed for this purpose. The initial PCR assay was performed in a 30 
µl reaction volume containing 100 ng of genomic DNA, 1U of Taq polymerise, 20 
pmol of each PCR primer, 1.5 mM MgC12,3 µl of IOx PCR buffer and 0.25 mM dNTP 
mix, and the final reaction volume adjusted with molecular biology grade water. The 
initial PCR conditions consisted of denaturation at 94°C for 5 minutes; followed by 35 
cycles at 94°C for 30 seconds (denaturation), 55°C for 30 seconds (annealing), 72°C for 
30 seconds (extension), and thereafter a final extension at 72°C for 5 minutes and 
soaking at 4°C. The initial annealing temperature was close to the mean Tm of both 
PCR primers. The amplified DNA fragment was separated using 2.0% agarose gel 
electrophoresis at 80V for 60 minutes and then visualised under ultraviolet light. The 
size of amplified DNA fragment was estimated relative to a DNA ladder of known size 
(25 bp or 50 bp) that was incorporated in each electrophoresis. The size of observed 
DNA fragment was compared with the size of expected fragment obtained from the 
primer design tool. The quantity of amplified PCR product was assessed based on the 
brightness of the band under ultraviolate light. PCR assays with poor DNA 
amplification were systematically modified and re-evaluated. The annealing 
temperature was adjusted in a stepwise manner without changing any other initial PCR 
conditions. In the case of low quantities of PCR amplification, the annealing 
temperature was reduced by 1 degree each time. In the case of multiple bands, the 
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annealing temperature was increased by 1 degree each time. The annealing temperature 
was typically evaluated between 50 and 60°C. The magnesium concentration was 
adjusted as a second step of optimisation once the optimal annealing temperature has 
been identified. In the case of low quantities of PCR product, the magnesium 
concentration was increased in a stepwise manner by 0.5 mM. In the case of multiple 
bands, the magnesium concentration was reduced in a stepwise manner by 0.5 mM. The 
magnesium concentration was typically evaluated between 0.5 and 2.5 mM. The PCR 
conditions were adjusted until a bright and reproducible PCR product band was 
identified on gel electrophoresis. 
2.3.5.3 Quality control of polymerase chain reaction assay 
To assess risk of contamination, two blank samples were included in each analysis, in 
which the DNA template was replaced by 1 µl of molecular biology grade water. Each 
batch of PCR analyses consisted of 18 reaction tubes (16 patient samples and 2 blanks). 
Blanks were randomly located across the thermal cycler block and also randomly 
assigned to lanes on gel electrophoresis. The blank samples were not expected to 
produce any DNA amplification. 
2.3.6 Restriction fragment length polymorphism assay 
2.3.6.1 Choosing suitable restriction enzymes 
An online restriction enzyme mapping software, NEB cutter (http: //tools. neb. com/ 
NEBcutter2/index. php), was utilised to identify suitable restriction enzymes for a given 
SNP site. On occasion, restriction enzymes were identified from existing publications. 
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2.3.6.2 Optimisation of restriction fragment length polymorphism assay 
98 
Each of the RFLP assays developed in this project was optimised using a standard 
procedure. PCR products from 10 control DNA samples were employed for this 
purpose. Each restriction digest was performed in a 10 pl volume containing 5 µl of 
PCR product, 1 µl x lOx NE buffer, restriction enzyme (2.5,5 to 7.5 U) and the final 
reaction volume adjusted with molecular biology grade water. These reaction mixtures 
were incubated at 37°C for up to 4 hours. At the end of 2 and 4 hours incubation time, 
an aliquot of digest product (5 µl) was removed from reaction tube and each mixed with 
a small quantity of loading dye (1 µl), and immediately loaded onto a 2.0% agarose gel. 
A DNA ladder of known size (25 bp or 50 bp) and one sample of undigested PCR 
product (5 µl) were also included in each electrophoresis run. The electrophoresis 
conditions were set at 80V for 60 to 120 minutes. At the end of electrophoresis, the 
agarose gel was visualised under ultraviolet light. The expected size of digested 
fragments was estimated relative to the DNA ladder. Incomplete digestion was 
evaluated by digesting the PCR product in a high concentration of restriction enzyme 
(10 U) and a longer incubation period (24 hours). In the case of poor resolution between 
fragments, the electrophoresis was repeated using a higher agarose concentration 
(increased in a stepwise manner by 0.5%) to permit clearer separation of digest 
fragments. 
2.3.6.3 Quality control of restriction fragment length polymorphism assay 
Each batch of RFLP analysis comprised one DNA ladder (25 or 50 bp), 2 water blanks, 
16 patient samples, one undigested control sample (PCR product), and three control 
DNA samples of known genotype, corresponding to each of the expected genotypes in 
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the population. Once all 400 patients had been genotyped, 5% were selected randomly 
and re-genotyped for confirmatory purposes. 
2.3.7 Statistical analyses 
MINITAB TM Statistical Software Release 13.32 (Minitab Ltd., Coventry, UK) was used 
to perform all statistical analyses. Logistic regression analysis was used to assess the 
association between genetic predictors and the response to AED therapy. The odds ratio 
(OR) together with its 95% confidence interval (95% Cl) and p-value were used to 
evaluate the strength of association. Genetic predictors for optimal dose of AEDs were 
identified and characterised using univariate and multivariate linear regression analyses. 
To explore interaction effects, cross-product terms were added as independent variables. 
A goodness-of-fit (r) value more than 0.8 indicates a strong predictive model. 
Pearson's correlation (r) value more than 0.8 indicates a strong association between 
variables. For this analysis, p-values less than 0.05 indicate a significant association or 
significant predictor effect. No formal power calculation and multiple testing 
corrections were undertaken for the statistical analysis; therefore, the research projects 
presented in this thesis are considered to be exploratory in an effort to generate research 
hypothesis. 
CHAPTER 3 
POLYMORPHISMS OF DRUG METABOLISING 
ENZYME, DRUG TRANSPORTER PROTEIN AND 
SODIUM CHANNEL GENES 
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3.1 The Prevalences of Common Polymorphisms in the 
Drug Metabolizing Enzyme, Drug Transporter Protein 
and Sodium Channel Genes in a West of Scotland 
Epilepsy Population 
3.1.1 Introduction 
In keeping with the aims of this research project, genes of interest were derived from 
current knowledge regarding the pharmacokinetics and pharmacodynamics of CBZ and 
LTG. Potentially functional variants of these genes were then selected from previously 
published information (as presented in section 1.7). The common genetic 
polymorphisms evaluated in this project are listed in TABLE 1.6. In a population based 
pharmacogenetic study, the prevalence of variant genotypes is expected to adhere to 
Hardy-Weinberg Equilibrium (HWE) conditions (Xu et al., 2002). HWE is based on the 
assumption that, under constant conditions after a generation of random mating, 
genotype frequencies throughout a population at a specified gene locus become fixed at 
a specific equilibrium value (Hosking et al., 2004). The HWE test is carried out by 
comparing the genotype distribution of each SNP against the genotype distribution that 
is predicted by HWE at that locus. Deviation from HWE can be the result of one or 
more of five violations. The first violation is inbreeding, which causes an increase in 
homozygosity for all genes. The second violation is assortative mating, which causes an 
increase in homozygosity only for those genes involved in the trait that is assortatively 
mated. The third violation is the occurrence of new mutations. The fourth violation is 
gene flow through migration in or out of the population. The fifth violation is related to 
population size, which causes a random change in genotypic frequencies, particularly if 
the population is very small. This is due to a sampling effect, and is known as genetic 
drift (Xu et al., 2002). Testing for HWE is also commonly used for the quality control 
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of large-scale genotyping and is one of the few methods which can be useful to identify 
systemic genotyping errors in unrelated individuals (Xu et al., 2002; Hosking et al., 
2004; Salanti et al., 2005; Wittke-Thompson et al., 2005). 
3.1.2 Aims 
The aim of this project was to evaluate the prevalences of common gene polymorphisms 
(TABLE 1.6) in a West of Scotland epilepsy population and to compare the allele and 
genotype distributions with previously published data from different ethnic groups. The 
genotype distribution was further examined using the HWE test as an early quality 
control measure for the genotyping methodology. 
3.1.3 Methods 
3.1.3.1 DNA samples and extraction 
A total of 400 DNA samples from the study population described in section 2.3.1 were 
utilised in this project. DNA extraction was performed following the method described 
in section 2.3.3. 
3.1.3.2 PCR-RFLP optimization 
Each PCR-RFLP methods presented below have been optimised using the method 
described in Chapter 2 (sections 2.3.5.2 and 2.3.6.2). 
3.1.3.3 Identification of CYP3A4 g. -392A>G polymorphism by PCR-RFLP 
The method described by van Schaik et al. (2000) was modified for the purposes of this 
study. Modification was undertaken to optimise the yield of PCR product which 
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included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The 5'-flanking promoter region 
of the CYP3A4 gene containing the g. -392A>G polymorphism was amplified using 
forward, 5'-GGA CAG CCA TAG AGA CAA CTG CA-3' and reverse, 5'-CTT TCC 
TGC CCT GCA CAG-3' primers. A PCR product containing the CYP3A4 -392G allele 
with restriction site for the Pstl enzyme was produced by incorporating the underlined 
mismatched nucleotides into the forward primer. The PCR assay was performed in a 30 
pl reaction volume containing 100 ng of genomic DNA, 1U of Taq polymerase, 20 
pmol of each primer, 2 mM MgCI2,3 pl of lOx PCR buffer, 0.25 mM dNTP mix, and 
an appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 7 minutes; 35 cycles 
of 94°C for 1 minute (denaturation), 56°C for 1 minute (annealing), 72°C for 1 minute 
(extension); and followed by a final extension at 72°C for 7 minutes and soaking at 4°C. 
A PCR product with a size of 334 bp was expected from the amplification. 
The CYP3A4 -392A allele was discriminated from the -392G allele by digesting the 
PCR product with PstI endonuclease. The PCR product was digested for at least 2 hours 
at 37°C in a 20 µl reaction volume containing 15 µl of PCR product, 5U of Pstl 
restriction'enzyme, 2 pl of lOx NE buffer, 0.2 pl of 100x BSA (10 mg/ml) and an 
appropriate volume of molecular biology grade water. Pstl cut the PCR product at 
position 5'-CTGCA/G-3', and produced 220-bp, 81-bp and 33-bp fragments for the 
CYP3A4 -392A allele; and 199-bp, 81-bp, 33-bp and 21-bp fragments for the CYP3A4 
-392G allele. 
A total of 5 µl of digest product was mixed with 1 µl of loading dye and loaded on a 
2.5% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
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conditions were set at 100 V for 100 minutes. A digital image of' the agarose gel was 
captured at the end of' the electrophoresis process under ultraviolet transillumination 
(FIGURE 3.1). 
CYP3A4 g. -392A>(; 
A/G A/A A/A A/A (i/(i 
, ý"nI 
. I 
FIGURE 3.1. Electrophoresis patterns tür CYI'3A4 g. -392A -(i genotypes 
analysed with PCR-RFLP assay. 
3.1.3.4 Identification of CYI'3A5 g. 6986A>C polyroorphisnI by I'('R-RFI. I' 
The method described by Fukuen et cd. (2002) was modified for the purposes of this 
study. Modification was undertaken to optimise the yield of' PUR product which 
included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The intronic region of the 
CYP3A5 gene containing the g. 6986A>G polymorphism was amplified using förward, 
5'-CTT TAA AGA GCT CTT 'IT(; TC'l' CT C A-3' and reverse, 5'-('('A GGA AGC 
CAC; ACT 'FI'G Ai'-3' primers. A PCR product containing the ('YP3A5 69866 allele 
with restriction site tür the Dclet enzyme was produced by incorporating tile tilidellned 
mismatched nucleotide into the lörward primer. The P('l( assay was pert rmed in a 30 
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pl reaction volume containing 100 ng of genomic DNA, 1U of Taq polymerase, 20 
pmol of each primer, 1.5 mM MgCIZ, 3 µl of lOx PCR buffer, 0.25 mM dNTP mix, and 
an appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 95°C for 10 minutes; 35 
cycles of 94°C for 30 seconds (denaturation), 56°C for 30 seconds (annealing), 72°C for 
30 seconds (extension); and followed by a final extension at 72°C for 5 minutes and 
soaking at 4°C. A PCR product with a size of 200 bp was expected from the 
amplification. 
The CYP3A5 6986A allele was discriminated from the 6986G allele by digesting the 
PCR product with DdeI endonuclease. The PCR product was digested for at least 2 
hours at 37°C in a 10 µl reaction volume containing 5 µl of PCR product, 5U of DdeI 
restriction enzyme, 1 pl of lOx NE buffer and an appropriate volume of molecular 
biology grade water. DdeI cut the PCR product at position 5'-C/TNAG-3', and 
produced 129-bp and 71-bp fragments for the CYP3A5 6986A allele; and 107-bp, 71-bp 
and 22-bp fragments for the CYP3A5 6986G allele. 
A total of 5 µl of digest product was mixed with 1 µl of loading dye and loaded on a 
3.0% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
conditions were set at 100 V for 80 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination 
(FIGURE 3.2). 
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FIGURE 3.2. I: Icctrophuresis patterns for (')"I'; n5 g. 09S(, A (i ýcnýýtyIýý. ti 
analysed with PCR-RFTP assay. 
3.1.3.5 Identification of CYPIA2 g. 5734C>A polymorphism by P('R-RFLP 
106 
A new, self-designed PCR-RFLP method for the identification of CYP I A2 g. 5734C -A 
was utilised in this study. The intron- I region of the CYPIA2 gene containing the 
g. 5734C>A polymorphism was amplified using forward, 5'-C('(' T 'l (i (i(i'U A"I'A '1'G( i 
AAG GTA-3' and reverse, 5'-C"f'"I' GAG CAC CCA GAA 'I'AC ('A-3' primers. The 
PCR assay was performed in a 30 pl reaction volume containing 100 ng of genomic 
DNA, IU of Taq polymerase, 20 pmol of each primer, 2 mM Mg('I 3 µl of I Ox PCR 
buffer, 0.25 mM dNTP mix, and an appropriate volume of molecular biology grade 
water. 
The PCR conditions consisted ol'an initial denaturation at 94°(' I'm 5 minutes; 35 cycles 
of 94°C for 30 seconds (denaturation), 56°C für 30 seconds (annealing), 72"(' für I 
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minute (extension); and followed by it final extension at 72°C fi- 5 minutes and soaking 
at 4°C. A PCR product with it size of'5I8 hp was expected Irom the amplification. 
The CYP I A2 5734C allele was discriminated from the 5734A allele by digesting the 
PCR product with PspOM I endonuclcase. The PCR product was digested four at least 2 
hours at 37°C in a 10 pl reaction volume containing 5 pi of* P('R product, 5U of 
PspOM I restriction enzyme, I pl of IOx NI? huller and an appropriate volume of' 
molecular biology grade water. PspOM I cut the l'CR product at position 
3' and produced 268-bp and 250-bp fragments for the ('YP I A2 5734(' allele. The 518- 
hp PCR product remained uncut for the ('YP I A2 5734A allele (11( it IRE 3.3). 
('Y PI n2 g. 5734C>A 
A/C ý1/A 
." Ihl, 1 ý 
. 'i,:. J'u LI, 
FIGURE: 3.3. I. lectruhhoresis Patterns Iiir 1,11.1 I( A , 1& II ý pc 
analysed with PCR-RFLP assay. The 268-bp and 250-hp li'agments did [lot 
resolve clearly aller 45 minutes electrophoresis on a 2.0% agarose rel. 
('11C ' A/( ' . A, A 
A total of 5 µl of digest product was mixed with I pl of loading dye and loaded on a 
2.0% agarose gel containing 300 ng/mI ethidium bromide. The gel electrophoresis 
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conditions were set at 90 V for 45 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination. 
The 268-bp and 250-bp fragments did not resolve clearly after 45 minutes 
electrophoresis, however, this did not affect the genotype identification. 
3.1.3.6 Identification of EPHX1 c. 337ThC polymorphism by PCR-RFLP 
The method described by Budhi et al. (2003) was modified for the purposes of this 
study. Modification was undertaken to optimise the yield of PCR product which 
included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The exon-3 region of the 
EPHX1 gene containing the c. 337T>C polymorphism was amplified using forward, 5'- 
GAT CGA TAA GTT CCG TTT CAC C-3' and reverse, 5'-CAA TGT TAG TCT TGA 
AGT GAG GAT-3' primers. The reverse primer contains mismatched nucleotides for 
codon 113 (shown as bold and underlined) and codon 119 (shown as underlined only). 
The mismatched nucleotide at codon 113 was introduced to create a restriction site for 
the EcoRV enzyme and recognition of the 337T allele (Smith & Harrison, 1997). The 
mismatched nucleotide at codon 119 was introduced to eliminate the effect of the 
adjacent c. 357G>A polymorphism, which is reported to influence the estimation of 
genotypes at codon 113 (Budhi et al., 2003). The PCR assay was performed in a 30 pl 
reaction volume containing 100 ng of genomic DNA, 1U of Taq polymerase, 20 pmol 
of each primer, 2 mM MgC12,3 µl of lOx PCR buffer, 0.25 mM dNTP mix, and an 
appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 7 minutes; 35 cycles 
of 94°C for 1 minute (denaturation), 56°C for 1 minute (annealing), 72°C for 1 minute 
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(extension); and followed by a final extension at 72°C fir 7 minutes and soaking at 4°C. 
A PCR product with a size of 164 hp was expected from the amplification. 
The EP I IX 1337T allele was discriminated from the 337(' allele by digesting the P('R 
product with EcoRV endonuclease. The PCR product was digested for at least 2 hours at 
37°C in a 10 pi reaction volume containing 5 pl of PCR product, 5U of EcoRV 
restriction enzyme, I pl of lOx NE bufirr, 0.1 pl of I00x RSA (10 mg/ml) and an 
appropriate volume of molecular biology grade water. The P'eoRV cut at position 5'- 
GAT/ATC-3' and produced 140-hp and 24-hp fragments for the EPI IX 1337T allele. 
The 164-hp PUR product remained uncut for the EPIIX1 337(' allele (FIGURE 3.4). 
A total of 5 pl of digest product was mixed with I µl of loading dye and loaded on a 
3.0% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
conditions were set at 80 V for 100 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination. 
I: PHX I c. 337T>C 
i( ll i( I (I 
16 16p 
'1 Iq, 
FIGUItI? 3.4. Electrophoresis patterns lor FTIIXI c. 337T--(' genotypes analysed 
by PCR-RI' LP assay. 
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3.1.3.7 Identification of EPHX1 c. 416A>G polymorphism by PCR-RFLP 
110 
The method described by Smith & Harrison (1997) was modified for the purposes of 
this study. Modification was undertaken to optimise the yield of PCR product which 
included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The exon-4 region of the 
EPHXI gene containing the c. 416A>G polymorphism was amplified using forward, 5'- 
ACA TCC ACT TCA TCC ACG T-3 and reverse, 5'-ATG CCT CTG AGA AGC CAT- 
3' primers. The PCR assay was performed in a 30 µl reaction volume containing 100 ng 
of genomic DNA, 1U of Taq polymerase, 20 pmol of each primer, 1.5 mM MgCl2,3 µl 
of lOx PCR buffer, 0.25 mM dNTP mix, and an appropriate volume of molecular 
biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 5 minutes; 37 cycles 
of 94°C for 30 seconds (denaturation), 56°C for 30 seconds (annealing), 72°C for 30 
seconds (extension); and followed by a final extension at 72°C for 5 minutes and 
soaking at 4°C. A PCR product with a size of 210 bp was expected from the 
amplification. 
The EPHXI 416A allele was discriminated from the 416G allele by digesting the PCR 
product with RsaI endonuclease. The PCR product was digested for at least 2 hours at 
37°C in a 10 µl reaction volume containing 5 pI of PCR product, 5U of Rsal restriction 
enzyme, 1 µl of lOx NE buffer and an appropriate volume of molecular biology grade 
water. Rsal cut the PCR product at position 5'-GT/AC-3' and containing the EPHXI 
416G allele and produced 164-bp and 46-bp sized fragments for the EPHXI 416G 
allele. The 210-bp PCR product remained uncut for the EPHXI 416A allele. 
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A total of 5 µl of digest product was mixed with I il of loading dye and loaded on a 
2.5% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
conditions were set at 80 V for 80 minutes. A digital image of' the agarose gel was 
captured at the end of the electrophoresis process under ultra\ iuIet truisillunºination 
(FI(iURE 3.5). 
EPIIXI c. 416A>G 
A/A (i/(i n/(i nin iý, (i 
`InI'ý 
It, 1 hl 
If, Ill 
FIGURE 3.5. I: Icctrophoresis patterns for I: I'I IX I c. 41 6A -( igcnotyprs euialvsrd 
by PCR-RFLP assay. 
3.1.3.8 Identification of UGT2137 c. 802('>"1' polymorphism by I'('It-Itl'I, I' 
The method described by 13hasker el ul. (2000) was modified for the purposes of' this 
study. Modification was undertaken to optimise the yield of' PUR product which 
included alteration in the total reaction volume, the quantity of' reagents and the 
annealing temperature (as described in section 2.3.5.2). The exon-2 region of' the 
UGT2137 gene containing the c. 802C T polymorphism was amplified using forward, 
5'-TGC CTA CAT "I"AT TCT AAC C-3' and reverse, 5'-TUT (1(1 AAA Al ('"1'G 
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CAC T-3' primers. The PCR assay was performed in a 30 µl reaction volume 
containing 150 ng of genomic DNA, IU of Taq polymerase, 20 pmol of each primer, 2 
mM MgC12i 3 µl of lOx PCR buffer, 0.25 mM dNTP mix, and an appropriate volume of 
molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 5 minutes; 35 cycles 
of 94°C for 30 seconds (denaturation), 59°C for 30 seconds (annealing), 72°C for 30 
seconds (extension); and followed by a final extension at 72°C for 5 minutes and 
soaking at 4°C. A PCR product with a size of 579 bp was expected from the 
amplification. 
The UGT2B7 802C allele was discriminated from the 802T allele by digesting the PCR 
product with FokI endonuclease. The PCR product was digested for at least 2 hours at 
37°C in a 10 µ1 reaction volume containing 6 µl of PCR product, 4U of FokI restriction 
enzyme, 1 µl of 10x NE buffer and an appropriate volume of molecular biology grade 
water. FokI cut the PCR product at position 5'-GGATG(N)9/-3' and produced 457-bp, 
79-bp and 42-bp fragments for the UGT2B7 802T allele; and 346-bp, II l-bp, 79-bp and 
42-bp fragments for the UGT2B7 802C allele. 
A total of 10 µl of digest product was mixed with I µl of loading dye and loaded on a 
2.5% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
conditions were set at 80 V for 45 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination 
(FIGURE 3.6). 
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FIGURE 3.6. Electrophoresis patterns for UGI'2137 c. 802C-. T genotypes analysed with 
PCR-RFLP assay 
3.1.3.9 Identification of ABC131 c. 1236C>T polymorphism by I'CR-RFLI' 
The method described by Tang et al. (2002) was modified fir the purposes ot'this study. 
Modification was undertaken to optimise the yield of' PCR product which included 
alteration in the total reaction volume, the quantity of reagents and the annealing 
temperature (as described in section 2.3.5.2). The exon-12 region of the AI3C13I gene 
containing the c. 1236C>T polymorphism was amplified using forward, 5'-TCF "I'TG 
TCA CU' TAT CCA GC-3' and reverse, 5'-'1'("I' CAC ('Al' 'C('(' CT CC 'l'(i"1'-3' 
primers. The PCR assay was performed in a 20 pl reaction volume containing 100 ng of' 
genomic DNA, IU ofTaq polymerase, 20 pmol ol'each primer, 1.5 mM MgCI,, 2 pl of 
lOx PCR buffer, 0.25 mM dNTI' mix, and an appropriate volume of molecular biology 
grade water. 
The PCR conditions consisted of an initial denaturation at 94°(' I'or 10 n. inutes; 35 
cycles of 94°C for 30 seconds (denaturation), 60°C Im- 30 seconds (annealing), 72°C I'm 
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30 seconds (extension); and followed by a final extension at 72°C firr 5 minutes and 
soaking at 4°C. A PCR product with a size of 502 hp was expected from the 
amplification. 
The A13CBI 1236C allele was discriminated fi-om the 12361' allele by digesting the 
PCR product with EcoOl091 endonuclease. The PCR product was digested fir at least 
2 hours at 37°C in a 20 p1 reaction volume containing 10 fil of PCR product, 5U of 
F. coOl091 restriction enzyme, 2 pl of I Ox NE huficr, 0.2 pI of I ()Ox 13SA (10 mg/mI) 
and an appropriate volume of molecular biology grade water. EcoOlO91 cut the PCR 
product at position 5'-RG/GNCCY-3' and produced 380-bp and 122-hp fragments 1*6r 
the ABCBI 1236C allele. The 502-bp PCR product remained uncut fior the A13C13I 
1236T allele (FIGURE 3.7). 
A1=3CI31 c. 123GC? "1' 
T/T Cu' IC/C C/T ('/C 
In. ' Ll, 
;, M) I, I, 
I ý, iy 
1,1GUItl? 3.7. I: IrrU-()hh()[-csis patterns I'Or A Ii('I3I r. l? _; 0(' 
1ý pc,, anaIý,; ct I h\ 
PCR-R1 LP assay. 
A total of 5 µl of digest product was mixed with I µI of' loading dye and loaded on a 
2.5% agarose gel containing 300 ng/mI ethidium bromide. I he f_'CI electrophoresis 
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conditions were set at 80 V for 90 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination. 
3.1.3.10 Identification of ABCB1 c. 2677G>T/A polymorphism by PCR-RFLP 
The method described by Cascorbi et al., (2001) was modified for the purposes of this 
study. Modification was undertaken to optimise the yield of PCR product which 
included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The exon-21 region of the 
ABCB I gene containing the c. 2677G>T/A polymorphism was amplified using two PCR 
assays, one for the identification of the 2677A allele (PCRI) and the other for the 
identification of the 2677T allele (PCR2). PCRI was performed using forward, 5'-TGC 
AGG CTA TAG GTT CCA GG-3' and reverse, 5'-GTT TGA CTC ACC TTC CCA G- 
3' primers. PCR2 was performed using the same forward primer as PCRI, together with 
the reverse, 5'-TTT AGT TTG ACT CAC CTT CCC G-3' primer. A mismatched 
nucleotide (underlined) in the reverse primer of PCR2 was employed to introduce a 
restriction site for the Banl enzyme. 
PCRI and PCR2 reaction components and conditions were identical. The PCR assay 
was performed in a 20 µl reaction volume containing 100 ng of genomic DNA, IU of 
Taq polymerase, 20 pmol of each primer, 2 mM MgC12,2 µl of I Ox PCR buffer, 0.25 
mM dNTP mix, and an appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 2 minutes; 35 cycles 
of 94°C for 30 seconds (denaturation), 62°C for 30 seconds (annealing), 72°C for 30 
seconds (extension); and followed by a final extension at 72°C for 7 minutes and 
soaking at 4°C. A PCR product with a size of 220 bp was expected from the PCRI 
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amplification. A PCR product with a size of 224 bp was expected from the PCR2 
amplification. 
The ABCB 1 2677non-A allele was discriminated from the 2677A allele by digesting the 
product of PCR1 with Rsal endonuclease. The PCR1 product was digested for at least 2 
hours at 37°C in a 10 pl reaction volume containing 5 µl of PCR1 product, 5U of RsaI 
restriction enzyme, 1 µl of lOx NE buffer and an appropriate volume of molecular 
biology grade water. Rsal cut the PCR1 product at position 5'-GT/AC-3', and produced 
118-bp and 102-bp fragments for the ABCB 1 2677non-A allele; and I18-bp, 82-bp and 
20-bp fragments for the ABCB 12677A allele. 
The ABCB 1 2677non-T allele was discriminated from the 2677T allele by digesting the 
product of PCR2 with Banl endonuclease. The PCR2 product was digested for at least 2 
hours at 37°C in a 10 µl reaction volume containing 5 µl of PCR2 product, 5U of Ban! 
restriction enzyme, 1 µl of lOx NE buffer and an appropriate volume of molecular 
biology grade water. BanI cut the PCR2 product at position 5'-G/GYRCC-3', and 
produced 198-bp and 26-bp fragments for the ABCB 1 2677non-T allele. The 224-bp 
product of PCR2 remained uncut for the ABCB 1 2677T allele. 
The electrophoresis conditions for both PCR1 and PCR2 assays were identical. A total 
of 5 µl of digest product was mixed with I µl of loading dye and loaded on a 3.0% 
agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis conditions 
were set at 80 V for 120 minutes. A digital image of the agarose gel was captured at the 
end of the electrophoresis process under ultraviolet transillumination. Images from both 
PCR1 and PCR2 were analysed simultaneously to determine one of the 6 possible 
genotypes (GIG, G/T, T/T, G/A, A/A, T/A; FIGURE 3.8). 
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analysed by PCR-RI l assay. I'CR I and I'('R2 were carried-om in two separate 
reactions. The product of PC'R I was digested by Bain and the product of' P('R2 
was digested by Rsal. Digital images of' the gels from both Pt. R-RI: IT assays 
were examined simultaneously to determine the genotype. No liagment for the 
2677A allele was observed in either gel. SI to SS represent individual subjects, 
their respective electrophoresis patterns, and A13('U I c. 2677(i -'I /A genotypes. 
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3.1.3.11 Identification of ABCB1 c. 3435C>T polymorphism by PCR-RFLP 
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The method described by Hamdy et al. (2003b) was modified for the purposes of this 
study. Modification was undertaken to optimise the yield of PCR product which 
included alteration in the total reaction volume, the quantity of reagents and the 
annealing temperature (as described in section 2.3.5.2). The exon-26 region of the 
ABCBI gene containing the c. 3435C>T polymorphism was amplified using forward, 
5'-ACT CTT GTT TTC AGC TGC TTG-3' and reverse, 5'-AGA GAC TTA CAT TAG 
GCA GTG ACT C-3' primers. The PCR assay was performed in a 20 µl reaction 
volume containing 100 ng of genomic DNA, 1U of Taq polymerase, 20 pmol of each 
primer, 1.5 mM MgCl2,2 µl of lOx PCR buffer, 0.25 mM dNTP mix, and an 
appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 5 minutes; 33 cycles 
of 94°C for 30 seconds (denaturation), 56°C for 30 seconds (annealing), 72°C for 30 
seconds (extension); and followed by a final extension at 72°C for 5 minutes and 
soaking at 4°C. A PCR ' product with a size of 231 bp was expected from the 
amplification. 
The ABCB 13435C allele was discriminated from the 3435T allele by digesting the 
PCR product with DpnII endonuclease. The PCR product was digested for at least 2 
hours at 37°C in a 20 µl reaction volume containing 10 pI of PCR product, 5U of DpnII 
restriction enzyme, 2 pl of lOx NE buffer and an appropriate volume of molecular 
biology grade water. DpnII cut the PCR product at position 5'-/GATC-3' and produced 
163-bp and 68-bp fragments for the ABCBI 3435T allele. The 231-bp PCR product 
remained uncut for the ABCB 13435C allele. 
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A total of 5 µl of digest product was mixed with I µl of loading dye and loaded on a 
2.5% agarosc gel containing 300 ng/ml ethidium hronºide. The gel electrophoresis 
conditions were set at HO V for 120 minutes. A digital image of' the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet transillumination 
(FIGURE 3.9). 
Al3('U I c. 3435(' 
II (ý( (i iI ii 
FIGURI': 3.9. I. IýrUýýýIýlýýýrrsis Iýallýrn. ý liir ; 1IWI{I 
analysed by I'C'R-RFI. P assay. 
3.1.3.12 Identification of SCN2A c. 56(; >; k pol. N nºurphisnº h) I1('ll-IlI-I. 1' 
The method described by Nakayama ei <1/. (2002) as modified Iii[- the purpose, it Iiis 
study. Modification was undertaken to optimise the yield of I'('l( product which 
included alteration in the total reaction volume, the yu: uºtity of' reagents and the 
annealing temperature (as described in section 2.3.5.2). 'I he exon-2 region of the 
SC'N2A gene containing the c. 56(i -A polymorphism was amplified using forward, 5'- 
AA"I' CAC ('III' FA 'F l'(' 'IAA 'I'(i(i '1'('-3' and re\ erse, 5'-('A(L 'I'(jA A66 ('AA 
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CTT GAC TAA GA-3' primers. The PCR assay was performed in a 20 µl reaction 
volume containing 100 ng of genomic DNA, IU of Taq polymerase, 20 pmol of each 
primer, 1.5 mM MgC12,2 µl of lOx PCR buffer, 0.25 mM dNTP mix, and an 
appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 95°C for 10 minutes; 35 
cycles of 94°C for 30 seconds (denaturation), 60°C for 30 seconds (annealing), 72°C for 
30 seconds (extension); and followed by a final extension at 72°C for 7 minutes and 
soaking at 4°C. A PCR product with a size of 400 bp was expected from the 
amplification. 
The SCN2A 56G allele was discriminated from the 56A allele by digesting the PCR 
product with ScrFI endonuclease. The PCR product was digested for at least 2 hours at 
37°C in a 20 µl reaction volume containing 10 µl of PCR product, 5U of ScrFI 
restriction enzyme, 2 µl of lOx NE buffer and an appropriate volume of molecular 
biology grade water. ScrFI cut the PCR product at position 5'-CC/NGG-3', and 
produced 178-bp, 130-bp, 64-bp and 28-bp fragments for the SCN2A 56G allele; and 
206-bp, 130-bp and 64-bp fragments for the SCN2A 56A allele. 
A total of 5 pl of digest product was mixed with 1 pl of loading dye and loaded on a 
3.0% agarose gel containing 300 ng/ml ethidium bromide. The gel electrophoresis 
conditions were set at 80 V for 120 minutes. A digital image of the agarose gel was 
captured at the end of the electrophoresis process under ultraviolet trans illumination 
(FIGURE 3.10). 
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FIGURE 3.10. Electrophoresis patterns for SCN2A c. 56G'-A genotypes analysed 
by PCR-RFLP assay. 
3.1.3.13 Identification of EPIIXI c. 337T>C polymorphism by direct sequencing 
121 
The genotype distribution of EPHXI c. 3371'>C identified by PCR-RFLP assay (section 
3.1.3.6) was not consistent with IIWE' (p < 0.05). ']'his was believed to be the result of 
the close proximity of a polymorphism at codon 119, and its consequent influence on 
the accuracy of genotyping by the R11 , I) technique. For this reason, a newly designed 
direct sequencing assay was employed to re-analyse all 400 1)NA samples. Four steps of 
sample preparation are required before the DNA fragment can he analysed by the 
automated MegaBACE 1000 " DNA Analysis System 
PCR amplification of the target DNA fragment: Forward (5'-(i"I'A (iCC AG'l' (iAT 
GTG (1-3') and reverse (5'-CAT G'I'A "I( i"f (ill' ('('"1' G('(' TA-3') primers were used 
to amplify a DNA fragment of exon-3 of the I: I'I lX I gene. The I'CR assay was 
performed in a 30 pl reaction volume containing 100 ng of"genomic I)NA, IU of'Yaq 
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polymerase, 20 pmol of each primer, 2 mM MgC12,3 pl of IOx PCR buffer, 0.25 mM 
dNTP mix and an appropriate volume of molecular biology grade water. 
The PCR conditions consisted of an initial denaturation at 94°C for 5 minutes, followed 
by 35 cycles of 94°C for 30 seconds (denaturation), 60°C for 30 seconds (annealing), 
72°C for 30 seconds (extension) and finally followed by 72°C for 5 minutes (final 
extension) and soaking at 4°C. A PCR product with a size of 542 bp was expected from 
the amplification. 
Purification of PCR product: The purification step was based on protocol 000601v024 
published by Agencourt Bioscience Corporation, Beverly, MA, USA 
(http: //www. agencourt. com). The purification reaction was performed in a 96-well 
plate. In each well, a total of 15 µl of PCR product was mixed with 27 pl of a magnetic 
bead solution (AMPure). The reaction was mixed thoroughly by vortexing for 30 
seconds. The reaction mixtures were then left to incubate for 3-5 minutes at room 
temperature (20°C). The magnetic beads were separated from the reaction mixture by 
placing the plate onto a magnetic plate (SPRIP1ate 96R) for 5-10 minutes. The 
supernatant was aspirated from the reaction plate and discarded. With the reaction plate 
remaining on the SPRIPIate 96R®, 200 µl of 70% ethanol was dispensed into each well 
and the plate incubated for a further 30 seconds at room temperature (20°C). A total of 
two washes were performed using 70% ethanol. The reaction plate was then placed on 
the bench to air-dry, before 40 µl sterile water was added to each well for elution of the 
purified PCR product. The plate was vortexed for 30 seconds to promote maximum 
elution. The eluant was then used in the sequencing PCR step. 
Sequencing PCR: The sequencing PCR process was based on DYEnamic ET 
Terminator Cycle Sequencing Kit (product instruction US81050PL 2002) by Amersham 
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Biosciences (http: //www4. gelifesciences. com/aptrix/uppOI077. nsf/content/). A 96-well 
plate was used to run the sequencing PCR. The PCR was performed in a 10 µl reaction 
volume containing 4 µl of purified DNA template, 5 pmol of the reverse primer (5'- 
CAT GTA TGT GTT CCT GCC TA-3'), 1 µl of DYEnamic® ET Terminator reagent, 3 
µl of DYEnamic® ET Terminator dilution buffer and I µl of sterile water. The PCR 
conditions consisted of 25 cycles of 95°C for 20 seconds (denaturation), 50°C for 15 
seconds (annealing) and 60°C for 60 seconds (extension). The sequencing PCR product 
was then cleaned using C1eanSEQ® system (Agencourt Bioscience Corporation, 
Beverly, MA, USA). 
Removal of dye-terminator: The dye-terminator removal process was based on protocol 
000600vO31 published by Agencourt Bioscience Corporation, Beverly, MA, USA 
(http: //www. agencourt. com). The cleanup reaction was performed in a 96-well plate. In 
each well, 5 µl of the sequencing PCR product was mixed with 10 µl of magnetic bead 
solution (C1eanSEQ®) and 31 pl of 85% ethanol. The magnetic beads were separated 
from the reaction mixture by placing the plate onto a SPRIPIate 96R® for 3 minutes. The 
clear supernatant was aspirated from the reaction plate and discarded. With the reaction 
plate remaining on the SPRIPlate 96R®, 100 µl of 85% ethanol was dispensed into each 
well and the plate incubated for 30 seconds at room temperature (20°C). The ethanol 
was then aspirated from the reaction plate and discarded. A total of two washes with 
85% ethanol were performed. After the washes, the reaction plate was placed on the 
bench to air-dry, before 20 µl of sterile water was added to each well for elution. The 
eluant was then used in the MegaBACE 1000TM sequencing analysis. 
MegaBACE 1000TMsequencing analysis: MegaBACE 1000TM DNA Analysis System 
utilised parallele capillary electrophoresis. High-pressure nitrogen gas was used to inject 
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the capillaries with linear polyacrylamide, a separation matrix. Eluant was loaded into 
the analyser in a 96-well plate and a electrical current was established at the tip of each 
capillary, where it came into contact with the sample. Samples were electro-kinetically 
injected into the linear polyacrylamide and travelled the length of the capillary during 
the course of the run. All sequencing samples were automatically base-called and 
presented as DNA sequencing chromatograms. The DNA sequencing signals for each 
genotype of the EPHX1 c. 337T>C polymorphism are presented in FIGURE 3.11. 
3.1.3.14 Predicting the net activity of mEH 
The net activity of mEH was predicted on the basis of an association between EPHX1 
gene variants and in vitro activity of mEH described by Hassett et al. (1994b). 
Individuals who carry the 337 + 416 diplotypes of C/C + A/A, C/C + A/G, TIC + A/A 
and C/C + GIG were predicted as having the low activity mEH, those with 337+416 
diplotypes of T/T + A/A, T/C + A/G and TIC + GIG were predicted to have medium 
activity mEH, and those with 337+416 diplotypes of T/T + GIG and T/T + A/G were 
predicted to have high activity mEH. This categorical method was also described by 
Sarmanova et al. (2000). 
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FIGURE 3.11. DNA sequencing signals of the four nucleotides around the EPHXI 
c. 337T>C polymorphism for the T/T, T/C, and C/C genotypes. 
3.1.3.15 Comparison of allele and genotype distributions between ethnic groups 
Allele and genotype distributions identified in the current study population were 
compared with data from other populations that are available in the literature. Fisher's 
Exact test or X2 test was employed for this purpose. A p-value of greater than 0.05 
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indicated that no significant differences in the allele and genotype distributions between 
study populations. 
3.1.3.16 Hardy-Weinberg Equilibrium test 
The HWE test is one of the quality control measures for genotyping method as 
suggested by several authors (Xu et al., 2002; Hosking et al., 2004; Salanti et al., 2005; 
Wittke-Thompson et al., 2005). Adherence to HWE was tested using an online 
calculator, freely available on an established website (The Online Encyclopedia for 
Genetic Epidemiology, available from <http: //www. genes. org. uk/software/hardy- 
weinberg. shtml>). The online calculator compared the genotype distribution identified 
in the current study with a distribution predicted by HWE using X2 test. A p-value of 
greater than 0.05 indicated that the observed genotype distribution was consistent with 
HWE assumptions. 
3.1.4 Results 
3.1.4.1 Allele and genotype distributions of CYP3A4 g. -392A>G and CYP3A5 
g. 6986A>G polymorphisms 
Allele and genotype distributions of the CYP3A4 g. -392A>G and CYP3A5 g. 6986A>G 
polymorphisms in comparison with other populations are presented in TABLE 3.1 and 
TABLE 3.2, respectively. The CYP3A4 -392A and CYP3A5 6986G alleles were 
predominant in the 400-strong study population, with allele frequencies of 96.5% and 
92.6%, respectively. Only one individual was homozygous for the CYP3A4 -392G/G 
genotype and four individuals were homozygous for the CYP3A5 6986A/A genotype. 
The allele and genotype distributions of CYP3A4 g. -392A>G and CYP3A5 g. 6986A>G 
polymorphisms observed in the current study were consistent with UWE (p > 0.05) and 
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comparable (p > 0.05) with other Caucasian populations but different (p < 0.05) from 
previously published Oriental and African-American populations. 
TABLE 3.1. Allele and genotype distributions of the CYP3A4 g-392A>G 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study AG A/A A/G GIG Ref. 
Current studyt, n= 400 0.965 0.035 0.932 0.065 0.003 
Chinese & Japanese:, n= 80 1.000 0.000 1.000 0.000 0.000 1 
Hispanics, n= 121 0.890 0.110 0.800 0.180 0.020 1 
African-Americans, n= 116 0.455 0.545 0.190 0.530 0.280 1 
Caucasian (German)°, n= 432 0.971 0.029 0.944 0.054 0.002 2 
Caucasian (American)°, n= 230 0.935 0.065 0.891 0.087 0.022 3 
African-American#, n= 64 0.477 0.523 0.281 0.391 0.328 3 
to vs G, 0.965 vs 0.035 (95% CI, 0.024 - 0.050); HWE: X2 = 0.57, p=0.752; 
Allele and genotype distributions in comparison with current study findings, tp < 
0.05 and °p > 0.05; References: 1= Paris et al. (1999), 2= Dally et al. (2003), 3= 
Zeigler-Johnson et al. (2004). 
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TABLE 3.2. Allele and genotype distributions of the CYP3A5 g. 6986A>G 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study AG A/A A/G G/G Ref. 
Current studyt, n= 400 0.074 0.926 0.010 0.128 0.862 
Japanesel, n= 400 0.232 0.768 0.070 0.325 0.605 1 
Caucasian (German)°, n= 432 0.063 0.937 0.002 0.121 0.877 2 
Caucasian (American)°, n= 230 0.048 0.952 0.011 0.073 0.915 3 
African-Americans, n= 64 0.638 0.362 0.446 0.385 0.169 3 
to vs G, 0.074 vs 0.926 (95% CI, 0.906 - 0.942); HWE: X2 = 1.78, p=0.410; 
Allele and genotype distributions in comparison with current study findings, tp < 
0.05 and °p > 0.05; References: 1= Sata et al. (2000), 2= Dally et al. (2003), 3= 
Zeigler-Johnson et al. (2004). 
3.1.4.2 Allele and genotype distributions of CYPIA2 g. 5734C>A polymorphism 
Allele and genotype distributions of the CYPIA2 g. 5734C>A polymorphism in 
comparison with other populations are presented in TABLE 3.3. Most (93.2%) of the 
400-strong study population carried at least one 5734A allele. Only small numbers were 
homozygous for the 5734C allele (6.8%). The allele and genotype distributions of the 
CYP1A2 g. 5734C>A polymorphism observed in the 400-strong study population were 
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consistent with HWE (p > 0.05), and comparable (p > 0.005) with other Caucasian 
populations. 
TABLE 3.3. Allele and genotype distributions of the CYPIA2 g. 5734C>A 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study CA C/C A/C A/A Ref. 
Current studyt, n= 400 0.275 0.725 0.068 0.415 0.517 
Caucasian (German)°, n= 236 0.322 0.678 0.102 0.441 0.457 1 
Caucasian (Italian)°, n= 95 0.332 0.668 0.095 0.474 0.431 2 
Caucasian (Dutch)°, n= 94 0.280 0.720 0.080 0.400 0.520 3 
Egyptian°, n= 212 0.320 0.680 0.108 0.420 0.472 4 
Hispanic & Mestizo°, n= 932 0.300 0.700 0.090 0.420 0.490 5 
Japaneset, n= 159 0.386 0.614 0.163 0.447 0.390 6 
tC vs A, 0.27 vs 0.73 (95% CI, 0.69 - 0.77); HWE: X2 = 0.66, p=0.717; Allele 
and genotype distributions in comparison with current study findings, tp < 0.05 
and °p > 0.05; References: 1= Sachse et al. (1999), 2= Pavanello et al. (2005), 3 
= Moonen et al. (2005), 4= Hamdy et al. (2003a), 5= Cornelis et al. (2005), 6= 
Obase et al. (2003). 
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3.1.4.3 Allele and genotype distributions of EPIIXI c. 337T>C and c. 416A>G 
polymorphisms 
When analysed with PCR-RFLP, the genotype distribution of EPHX1 c. 337T>C was 
inconsistent with HWE (p < 0.05). This was believed to be the result of the close 
proximity of a polymorphism at codon 119, and its consequent influence on the 
accuracy of genotyping by the RFLP technique. For this reason, the 400-strong study 
population was re-analysed by direct sequencing. The genotype distribution of EPHX1 
c. 337T>C identified this method was consistent with FHWE (p > 0.05), was deemed to 
be accurate, and has subsequently been reported and employed in the remainder of this 
thesis. 
Allele and genotype distributions of the EPHX1 c. 337T>C and EPHX1 c. 416A>G 
polymorphisms in comparison with other populations are presented in TABLE 3.4 and 
TABLE 3.5, respectively. The allele and genotype frequencies of EPHX 1 337T>C and 
EPHX1 416A>G polymorphisms were consistent with HWE (p > 0.05) and comparable 
(p > 0.05) to those of other Caucasian populations. Most of study subjects were 
predicted to carry low and medium net activities of mEH, accounting for 39.5% and 
40.5% of the 400-strong study population, respectively (FIGURE 3.12). Patients who 
carried a diplotype of 337T/T and 416A/A dominated the medium mEII activity group 
(69.8%). 
3.1.4.4 Allele and genotype distributions of UGT2B7 c. 802C>T polymorphism 
Allele and genotype distributions of the UGT2B7 c. 802C>T polymorphism in 
comparison with other populations are presented in TABLE 3.6. The genotype 
distribution of the UGT2B7 c. 802C>T polymorphism in the 400-strong study 
population was consistent with UWE (p > 0.05) and comparable (p > 0.05) with other 
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Caucasian populations. Allele frequency of the UGT2137 c. 802C>T polymorphism 
approached equivalence (50%) for the C and T substitutions. The 802C/T genotype 
(54.7%) was the most common genotype observed in the study population. 
TABLE 3.4. Allele and genotype distributions of the EPHXI c. 337T>C 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele 
Study 
Current study§, n= 400 
(PCR-RFLP) 
Current studyt, n= 400 
(Direct Sequencing) 
Caucasian (American)°, n= 458 
African-Americana, n= 242 
Caucasian (Australian)°, n= 496 
Chinese$, n= 252 
Japanese$, n= 172 
TC 
0.640 0.360 
0.689 0.311 
0.718 0.282 
0.791 0.209 
0.672 0.328 
0.443 0.557 
0.558 0.442 
Genotype 
T/T T/C C/C Ref. 
0.468 0.345 0.187 
0.482 0.413 0.105 
0.517 0.402 0.081 1 
0.632 0.318 0.050 1 
0.452 0.439 0.109 2 
0.302 0.282 0.416 3 
0.326 0.465 0.209 4 
The genotype distribution identified by PCR-RFLP was inconsistent with IIWE 
(X2 = 25.26, p<0.001) and was reanalysed using direct sequencing; 
tT vs C, 0.69 
vs 0.31 (95% CI, 0.28 - 0.34); HWE: X2 = 0.57, p=0.750; Allele and genotype 
distributions in comparison with current study findings, tp < 0.05 and °p > 0.05; 
References: 1= London et al. (2000), 2= Gsur et a!. (2003), 3= Zhang et al. 
(2003), 4= Budhi et al. (2003). 
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TABLE 3.5. Allele and genotype distributions of the EPIHXI c. 416A>G 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study AG A/A A/G GIG Ref. 
Current studyt, n= 400 0.806 0.194 0.650 0.312 0.038 
Caucasian (American)°, n= 458 0.806 0.192 0.659 0.297 0.044 1 
African-Americana, n= 242 0.709 0.291 0.492 0.434 0.074 1 
Caucasian (Australian)°, n= 496 0.822 0.178 0.677 0.290 0.032 2 
Japanese°, n= 172 0.848 0.152 0.744 0.209 0.067 3 
to vs G, 0.81 vs 0.19 (95% Cl, 0.17 - 0.22); HWE: X2 < 0.0 1, p=0.999; Allele 
and genotype distributions in comparison with current study findings, tp < 0.05 
and °p > 0.05; References: 1= London et al. (2000), 2= Gsur et al. (2003), 3= 
Budhi et al. (2003). 
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FIGURE 3.12. The distribution of predictive net activity of mFII in the 400-strong 
study population. The net activity of ml; l I was predicted using a series of diplotypes 
derived from the EPHX I c. 337T>C and EPl lX l c. 410A (i polymorphisms. Low 
activity mEH = C/C+A/A, C/C+A/G, 'I'/C f A/A and ('/C f G/(i, medium activity mEl I 
T/C+A/G, T/T+A/A and T/C+G/G, and high activity ml-I'll '1'/I f A/(i and '1/I' I G/(i. 
References: Hassett el at. (I 994b); Sarmanova el at. (2000). 
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TABLE 3.6. Allele and genotype distributions of the UGT2B7 c. 802C>T 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study CT C/C C/T T/T Ref. 
Current studyt, n= 400 0.476 0.524 0.203 0.547 0.250 
Caucasian (American) °, n= 202 0.463 0.537 0.218 0.490 0.292 1 
Caucasian (Australian) °, n= 91 0.511 0.489 0.275 0.472 0.253 2 
Japanese, n= 84 0.732 0.268 0.512 0.440 0.048 2 
Chinese, n= 218 0.675 0.325 0.440 0.470 0.090 3 
tC vs T, 0.48 vs 0.52 (95% CI, 0.47 - 0.57); HWE: X2 = 3.80, p=0.149; Allele 
and genotype distributions in comparison with current study findings, 
tp < 0.05 
and °p > 0.05; References: I= Lampe et al. (2000), 2= Bhasker et al. (2000), 3= 
Lin et al. (2005). 
3.1.4.5 Allele and genotype distributions of ABCB1 c. 1236C>T, c. 2677G>T/A 
and c. 3435C>T polymorphisms 
Allele and genotype distributions of the ABCB 1 c. 1236C>T, ABCB I c. 2677G>T/A and 
ABCB 1 c. 3435C>T polymorphisms in comparison with other populations are presented 
in TABLE 3.7, TABLE 3.8 and TABLE 3.9, respectively. The allele and genotype 
distributions of the ABCB 1 c. 1236C>T, ABCB 1 c. 2677G>T/A and ABCB I c. 3435C>T 
polymorphisms in the 400-strong study population were consistent with HWE (p > 
0.05) and comparable (p > 0.05) to those of other Caucasian populations. The majority 
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of patients were heterozygous for these polymorphisms (47.0% for 1236C/T, 44.3% for 
2677G/T and 48.5% for 3435C/T). 
TABLE 3.7. Allele and genotype distributions of the ABCBI c. 1236C>T 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Study 
Allele Genotype 
CT C/C C/T T/T Ref. 
Current studyt, n= 400 0.520 0.480 0.285 0.470 0.245 
Caucasian (American)°, n= 100 0.540 0.460 
African-Americans, n= 100 0.805 0.195 
Chinesen, n= 92 0.380 0.620 
Malays, n= 92 0.375 0.625 
Indians, n= 95 0.347 0.653 
1 
1 
I 
I 
I 
Japanese:, n= 69 0.348 0.652 0.101 0.493 0.406 2 
tC vs T, 0.52 vs 0.48 (95% CI, 0.43 - 0.53); HWE: X2 = 1.37, p=0.504; Allele 
and genotype distributions in comparison with current study findings, tp < 0.05 
and °p > 0.05; `-' mark indicates unavailable data; References: 1= Tang et al. 
(2004), 2= Goto et al. (2002). 
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TABLE 3.9. Allele and genotype distributions of the ABCB 1 c. 3435C>T 
polymorphism in comparison to previously published data from different 
populations. 
Frequency 
Allele Genotype 
Study CT C/C C/T T/T Ref. 
Current studyt, n= 400 0.425 0.575 0.183 0.485 0.332 
Caucasian (Scottish)°, n= 190 0.480 0.520 0.240 0.480 0.280 1 
Japanesel, n= 69 0.557 0.443 0.304 0.507 0.188 2 
Chinese:, n= 98 0.460 0.540 0.240 0.440 0.320 3 
Malays:, n= 99 0.480 0.520 0.250 0.460 0.280 3 
Indians:, n= 93 0.380 0.620 0.180 0.390 0.430 3 
tC vs T, 0.42 vs 0.58 (95% CI, 0.53 - 0.63); HWE: X2 = 0.02, p=0.988; Allele 
and genotype distributions in comparison with current study findings, Tp < 0.05 
and °p > 0.05; References: I= Ameyaw et al. (2001), 2= Goto et al. (2002), 3= 
Balram et al. (2003). 
3.1.4.6 Allele and genotype distributions of SCN2A c. 56G>A polymorphism 
Allele and genotype distributions of the SCN2A c. 56G>A polymorphism in comparison 
with a Japanese population are presented in TABLE 3.10. The genotype distribution of 
the SCN2A c. 56G>A polymorphism in the 400-strong study population was consistent 
with HWE (p > 0.05) and comparable (p > 0.05) with the reported Japanese population. 
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The 56G/G genotype (87.5%) was the most common genotype observed in the study 
population. 
TABLE 3.10. Allele and genotype distributions of the SCN2A c. 56G>A 
polymorphism in comparison to previously published data from a different 
population. 
Frequency 
Allele Genotype 
Study GA GIG G/A A/A Ref. 
Current studyt, n= 400 0.931 0.069 0.875 0.112 0.013 
Japanese°, n= 100 0.940 0.060 0.880 0.120 0.000 1 
tG vs A, 0.93 vs 0.07 (95% CI, 0.05 - 0.10); HWE: p=0.052; Allele and 
genotype distributions in comparison with current study findings, 
°p > 0.05; 
References: 1= Nakayama et al. (2002). 
3.1.5 Discussion 
3.1.5.1 The prevalence of common polymorphisms in DME, DTP and sodium 
channel genes in comparison with other ethnic groups 
The frequencies of minor alleles ranged between 3.5% (CYP3A4 -392G) and 48.0% 
(ABCBI 1236T). A relatively low frequency of the CYP3A4 g. -392G allele has also 
been observed in many other studies (Paris et al., 1999; Sata et a!., 2000; Kuehl et a!., 
2001; Gracia-Martin et al., 2002; Hamzeiy et al., 2002; Dally et al., 2003; Zeigler- 
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Johnson et al., 2004). This low frequency may indicate that, in Caucasian populations, a 
large sample size is required to identify a statistically meaningful association between 
the CYP3A4 g. -392A>G variant and any respective phenotype. The g. -392A>G allele 
and genotype frequencies for the 400-strong study population were distinct from 
previously published data in Asian, Hispanic and African-American populations (Paris 
et al., 1999; Chelule et al., 2003; Zeigler-Johnson et al., 2004). In contrast, the non- 
functional CYP3A5 genotype (6986G/G) has been identified at a high frequency (30 - 
87%) in many populations (Fukuen et al., 2002; van Schaik et al., 2002; King et al., 
2003; Lee et al., 2003; Schuetz et al., 2004), including the current study population. 
These CYP3A5 variant allele and genotype frequencies are similar to those of other 
studies performed in Caucasian populations (van Schaik et al., 2002; King et al., 2003; 
Lee et al., 2003; Schuetz et al., 2004), but different to those of Japanese and African- 
American populations (Fukuen et al., 2002; Zeigler-Johnson et al., 2004). These 
findings may signify that, in most Caucasian individuals, including the current 400- 
strong study population, CYP3A activity is mainly dependent on CYP3A4. However, a 
contribution of the CYP3A5 protein to overall CYP3A activity may be important in 
around 14% of individuals who carry at least one CYP3A5 6986A allele. 
The g. 5734C>A polymorphism is the most studied CYPIA2 gene variant (Saclise et al., 
1999; Moonen et al., 2005; Pavanello et al., 2005). In the current study population, the 
genotype distribution of the CYPIA2 g. 5734C>A polymorphism is almost identical to 
that of other populations. The high frequency of the 5734A allele observed in our study 
was similarly reported for other Caucasian, Egyptian and Hispanic populations (Sachse 
et al., 1999; Hamdy et al., 2003a; Cornelis et al., 2005; Pavanello et al., 2005). In 
contrast, a study performed in Japanese subjects has reported a much higher 5734C/C 
frequency than in other ethnic populations (Obase et al., 2003). 
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mEH plays a vital role in metabolising drugs and detoxifying environmental pollutants 
(de Vries & Janssen, 2003). The common EPHXI gene variants, c. 337 >C and 
c. 416A>G, that express polymorphic mEH have been associated with the risk of 
developing several types of cancers and other diseases (London et al., 2000; Wong et 
al., 2000; Ulrich et al., 2001; Zhou et al., 2001; Cajas-Salazar et al., 2003). The EPHXI 
337T and EPHX1 416A alleles predominate in the majority of patients in the current 
study population. EPHX1 c. 337T>C and c. 416A>G allele and genotype distributions 
observed in the 400-strong study population were similar to those of other Caucasian 
populations (Smith & Harrison, 1997; London et al., 2000; Zhou et al., 2001; Cajas- 
Salazar et al., 2003; Gsur et al., 2003). However, the 337C allele frequency was 
different from that of previously published Chinese, Japanese and African-American 
populations (Takeyabu et al., 2000; Budhi et al., 2003; Zhang et al., 2003), whereas the 
416G allele frequency was different only to that of an African-American population 
(London et al., 2000). 
It has been shown that the expression and activity of mEH is influenced by the 
c. 337T>C and c. 416A>G polymorphisms (Hassett et al., 1994b; Maekawa et al., 2003). 
Therefore, diplotypes of these polymorphisms have been used to predict the net activity 
of mEH (Smith & Harrison, 1997; Sarmanova et al., 2000; Takeyabu et al., 2000; Zhou 
et al., 2001; Lebailly et al., 2002; Sonzogni et al., 2002; Cajas-Salazar et al., 2003). 
Most of the 400-strong study population were predicted to have low and medium 
activity mEH, which associates mainly with the T/C-A/A and T/T-A/A diplotypes, 
respectively. However, the frequency of patients with high net mEll activity may be 
important as they accounted for up to 20% of the study population. The implications of 
this are on the clinical pharmacology of drugs which are metabolised by this pathway. 
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The most studied UGT2B7 variant is the c. 802C>T polymorphism (Sawyer et al., 2003; 
Wiener et al., 2004; Lin et al., 2005; Thibaudeau et al., 2006). Allele and genotype 
distributions of the UGT2B7 c. 802C>T polymorphisms in the current study population 
were comparable with other Caucasian populations from two different continents, North 
America and Australia (Bhasker et al., 2000; Lampe et al., 2000). However, the 
prevalence of the 802C/C genotype was 2-fold higher in the present study than that 
reported in Oriental populations (Bhasker et al., 2000; Saeki et al., 2004; Lin et al., 
2005). 
The most widely investigated ABCB 1 gene variants are the c. 1236C>T, c. 2677G>T/A 
and c. 3435C>T polymorphisms. In the 400-strong study population, the 1236T, 
2677T/A and 3435C were identified as the minor alleles. The variant allele and 
genotype distributions were similar to those reported in other Caucasian populations 
(Hoffineyer et a!., 2000; Tan et al., 2004b; Tang et a!., 2004), but different from those 
in Asian populations (Goto et al., 2002; Balram et al., 2003; Park et al., 2007). A 
previous study employing a non-epileptic Scottish population reported distributions of 
c. 3435C>T alleles and genotypes that were comparable to the current study (Ameyaw et 
al., 2001). A significant difference in allele and genotype distributions of the ABCB1 
c. 1236C>T polymorphism is observed between Caucasians and African-Americans 
(Tang et al., 2004). Although pharmacogenetic studies in epilepsy have focused on 
these specific polymorphisms, the functional significance of ABCB I variants remains 
controversial (Siddiqui et al., 2003; Tan et al., 2004a; Sills et al., 2005; Kim et al., 
2006). Nevertheless, several studies have suggested that haplotypes based on these three 
SNPs may be useful in predicting drug resistance in epilepsy (Hung et al., 2005) An 
investigation focusing specifically on CBZ has shown that the T-T-T haplotype at the 
1236,2677 and 3435 positions of the ABCB 1 gene was associated with a better 
response to CBZ treatment (Seo et al., 2006a). 
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The SCN2A c. 56G>A polymorphism has previously been associated with febrile 
seizures in children (Nakayama et al., 2002). Information regarding the prevalence of 
SCN2A c. 56G>A variants is limited, especially in Caucasian populations. In the current 
study, the 56A allele was identified in just 1.3% of the population. Unlike most other 
SNPs reported here, the SCN2A c. 56G>A allele and genotype distributions in the 400- 
strong study population were comparable with a Japanese population (Nakayama et al, 
2002). 
Differences in allele and genotype distributions between ethnicities are not uncommon 
(Tishkoff & Kidd, 2004). In general, most of the variant allele and genotype 
distributions identified in the 400-strong study population were different from those 
reported for non-Caucasian populations. Greater differences were observed between 
populations of Caucasian and African ancestry than between Caucasian and Asian 
populations. This might be explained by the length of genetic divergence, which is 
approximately twice as long between Caucasoid and Negroid than between Caucasoid 
and Mongoloid (Ameyaw et al., 2001). Genetic divergence is the process of one species 
diverging over time into more than one species: Passing small random characteristic 
changes over time from one generation to the next generations. Genetic divergence 
operates on a genetic level favoring 2 or more alleles or 2 or more mix of alleles over 
the original mixture of alleles in a population. There is increasing evidence that different 
ethnic groups demonstrate significant differences in SNP distribution and linkage 
disequilibrium profiles (Tishkoff & Kidd, 2004). Furthermore, the frequency of minor 
alleles observed for CYP3A4 g. -392A>G, CYP3A5 g. 6896A>G and SCN2A c. 56G>A 
is low, which suggests that a large sample size is required to obtain sufficient statistical 
power in any study comparing the effects of the major and minor alleles at these 
loci. 
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3.1.5.2 Hardy-Weinberg equilibrium test 
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With the exception of the PCR-RFLP derived data for EPHX 1 c. 337T>C, the genotype 
distributions of all polymorphisms reported in this project were consistent with IIWE. 
This would indicate that the distribution of variant genotypes in the 400-strong study 
population did not violate HWE assumptions and that there was no apparent systematic 
error in the genotyping assays (Xu et at., 2002; Hosking et al., 2004; Salanti et al., 
2005). As reported in section 3.1.4.3, the genotype distribution of EPIHXI c. 337T>C 
polymorphism identified by PCR-RFLP assay was inconsistent with IIWE. Re-analysis 
using a direct sequencing technique redressed this inconsistency. This would suggest 
that the PCR-RFLP assay is not the optimal method for identification of EPHXI 
c. 337T>C polymorphisms. Other investigators have reported similar difficulties in 
detecting this polymorphism by PCR-RFLP (Takeyabu et al., 2000; Gsur et al., 2003; 
Godderis et al., 2004). It is believed that the recognition site for the EcoRV restriction 
enzyme may be altered when the mismatched reverse primer anneals to another SNP 
(c. 357G>A) adjacent to the c. 337T>C polymorphism (Takeyabu et al., 2000; Gsur et 
al., 2003). As a result, the DNA fragment amplified loses the recognition site for EcoRV 
and the prevalence of the 337C/C genotype is overestimated. A modified reverse primer 
containing a second mismatched nucleotide for the c. 357G>A site has been suggested to 
improve the performance of PCR-RFLP-based analysis (Budhi et al., 2003). However, 
the effectiveness of this second mismatched nucleotide in improving the accuracy of the 
assay remains questionable. This was the approach employed in the current study 
without significant advantage. Any conclusions from previous studies which utilised a 
PCR-RFLP assay to identify the EPHX1 c. 337T>C polymorphism may be undermined 
and should be interpreted with caution. 
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3.1.6 Conclusion 
The prevalences of common polymorphisms in genes encoding DMEs, DTPs and a 
voltage-gated sodium channel in a West of Scotland epilepsy population are comparable 
with data previously reported for other Caucasian populations. The heredity of common 
polymorphisms in DME, P-gp and sodium channel genes are consistent with HWE 
assumptions. Based on HWE, no apparent systematic errors in the genotyping assays 
were identified, except in the PCR-RFLP assay for EPHXI c. 3371>C. 
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4.1 Genetic Predictors of Carbamazepine Optimal Dose 
4.1.1 Introduction 
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The response to CBZ therapy varies from patient to patient; some will have full seizure 
control and others will fail to show any response. Finding the optimal dose of CBZ that 
maintains complete seizure control with minimal side effects is a challenge. The CBZ 
optimal dose is commonly reached by dosage adjustment based on the level of clinical 
response, the occurrence of side effects, and the effects of autoinduction. Patients that 
show modest but progressive seizure reductions might undergo continuous dosage 
adjustment for more than 1 year before the optimal dose is finally found. Within this 
period, quality of life might be compromised by ongoing seizures. Most patients are 
controlled on 600 mg/day but some patients may require up to 1600 mg/day of CBZ to 
attain complete seizure control (Kwan & Brodie, 2001). Patients with a high dose 
requirement are not easily distinguished from complete non-responders. Therefore, it 
may be useful to determine the individual CBZ dosage requirement in order to limit 
unnecessary or unreasonable titration to high doses of CBZ. 
Some studies have reported that optimum treatment response and target therapeutic 
concentrations of CBZ are achieved with a broad range of doses (200 - 1600 mg/day; 
Brodie et al., 1995; Chadwick, 1999; Kwan & Brodie, 2001). The variability in dosage 
requirement is believed to be associated with interindividual differences in CBZ 
pharmacokinetics and pharmacodynamics. CBZ pharmacokinetics are predominantly 
influenced by the DMEs (Browne, 1998; Kim, 2002b; Ramachandran & Shorvon, 
2003), while on the other hand, CBZ pharmacodynamics are primarily affected by the 
function of ion channels. 
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Polymorphisms in genes that encode DMEs and Na1.2 sodium channel could alter the 
expression and function of their respective proteins (as described in Chapter 3) and, in 
turn, affect CBZ metabolism and the conformation of the sodium channel. These may 
consequently influence CBZ concentrations in plasma and in brain and sodium channel 
sensitivity to CBZ. As such, common polymorphisms in the DME and SCN2A genes 
may be able to predict the optimal dose of CBZ. 
4.1.2 Aims 
This study was designed to evaluate the association between common polymorphisms in 
CYP3A4, CYP3A5, CYP1A2, EPHXI, UGT2B7 and SCN2A genes and the optimal 
dose of CBZ. Clinical factors such as age and gender were also evaluated as additional 
candidate predictors. 
4.1.3 Methods 
4.1.3.1 Definitions 
The optimal dose was defined as the final dose given to a patient that successfully 
maintained optimal seizure control without intolerable side effects. Optimal seizure 
control was defined as complete seizure freedom or a significant (>_ 50%) reduction in 
pre-treatment seizure frequency which was maintained over a period of at least 12 
months. 
4.1.3.2 Study subjects 
From the 400-strong study population, 124 patients were identified as being treated with 
CBZ monotherapy. Through retrospective evaluation of individual medical records, 
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fifteen patients were excluded due to insufficient clinical and CBZ dosage information. 
Five patients that had been referred from other centres or from primary care did not 
have sufficient information on the outcome of therapy. Thirty-four of the remaining 104 
patients with complete outcome information did not respond to CBZ (n = 20) or 
experienced intolerable side effects (n =14) which resulted in the premature withdrawal 
of medication. These patients were excluded from the study because an optimal dose 
could not be established. As a result, 70 patients with optimal seizure control on CBZ 
monotherapy and with complete information on dosage regimen and relevant clinical 
data were available for analysis. Information on the clinical response of these patients 
was confirmed by an experienced clinician prior to data analysis. None of these patients 
were concomitantly treated with other AEDs or non-AEDs that may have influenced 
CBZ metabolism. Most of the patients (91.4%) were treated with a sustained release 
formulation and only a minority (8.6%) received standard release tablets. 
4.1.3.3 Genotype analysis and phenotype assessment 
Genotypes of the common CBZ-related DME and SCN2A polymorphisms were 
identified using the PCR-RFLP and direct sequencing assays described in Chapter 3. 
Genotype determination for the DME and SCN2A polymorphisms was completed on 
February 2006. Phenotype assessment was started on March 2006 and completed on 
April 2006. 
4.1.3.4 Statistical analysis 
Clinical and demographic differences between the CBZ cohort and the 400-strong study 
population were investigated using the X2 test. The distribution of age was compared 
using Student's t-test. The possibility of genotype selection bias was explored by 
comparing the distribution of individual polymorphisms between the CBZ cohort and 
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the overall 400-strong study population using the X2 test. Differences in the mean 
optimal dose of CBZ in relation to predictors such as gender and genotype of individual 
DME polymorphisms were initially compared by Student's t-test and/or analysis of 
variance (ANOVA). 
To fit the genetic information into the regression database, a specific score was assigned 
to the genotype of each polymorphisms according to the number of substituting alleles; 
no substituting allele was given score 1, one substituting allele was given score 2 and 
two substituting alleles was given score 3. Interaction between polymorphisms in a 
single gene or genomic region was identified by correlation test, represented by the 
multiplicative value of polymorphism scores, and denoted "SNP interaction". 
Significant predictors of CBZ optimal dose were then identified using univariate and 
multivariate linear regression analysis. An additive model was used in the analysis with 
an assumption that the combined effects of genetic alleles at two or more gene loci are 
equal to the sum of their individual effects. SNP interactions were added to the 
multivariate analysis and acted as a non-linear component. Predictors were added into 
or taken out from the predictive model using a stepwise approach, depending on the 
degree of impact indicated by the p-value. Data transformation was employed to 
optimise the regression modelling, specifically transformation from linear to natural 
logarithmic form. Regression coefficients of predictors that significantly influenced the 
predictive model were used to construct the CBZ optimal dose predictive equation. 
Pearson's correlation (r-value) was used to evaluate the linearity of the predictive model 
by correlating the observed CBZ optimal dose and the predicted CBZ optimal dose. A 
p-value less than 0.05 indicated the presence of a strong predictor effect. Both Pres; d al, 
which represented the p-value of residual analysis, and r2, that represented the 
goodness-of-fit, indicated how well the data fitted the predictive model. 
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4.1.4 Results 
4.1.4.1 Patient characteristics and carbamazepine dosage regimen 
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Demographic information for all 70 patients included in the CBZ cohort is presented in 
TABLE 4.1. Distributions of gender (p > 0.05) and epilepsy syndromes (p > 0.05) were 
comparable with the 400-strong study population. The median age of patients in the 
CBZ cohort was 34 years (range 14 to 72). In 16% of the CBZ cohort the optimal dose 
of CBZ was less than the maximum dose to which those patients had been exposed. 
Thus, the optimal dose represents a composite measure of efficacy and tolerability. 
FIGURE 4.1 shows that increasing age was associated with a modest reduction in CBZ 
optimal dose, however this effect was not statistically significant (r = -0.171, p=0.156). 
Gender and epilepsy syndrome were not associated with mean CBZ optimal dose (p > 
0.05; FIGURE 4.2 and 4.3, respectively). 
4.1.4.2 Genetic predictors of carbamazepine optimal dose 
Genotype distributions for all of the common DME gene polymorphisms were similar 
between the CBZ cohort and the 400-strong study population (p > 0.05, TABLE 4.2). A 
total of 2 SNP interactions were identified, between CYP3A4 c. -392A>G and CYP3A5 
c. 6986A>G (r = -0.285, p=0.017) and between EPHXI c. 337T>C and EPIIXI 
c. 416A>G (r = -0.261, p=0.029). 
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TABLE 4.1. Patient demographics and carbamazepine doses. 
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400-strong 
study 
CBZ cohort population 
(n = 70) (n = 400) p-value 
Gender Male 48.6% 50.3% 0.796 
Female 51.4% 49.7% 
Age (years) Median 34 40 0.343 
Min 14 14 
Max 72 85 
Epilepsy syndrome IGE 27.1% 29.5% 0.689 
LRE 71.5% 67.5% 
UNC 1.4% 3% 
Optimal Dose (mg/day) Mean 874.3 
Median 800 
Min 300 
Max 2000 
Min = minimum; Max = maximum; IGE = idiopathic generalised epilepsy; LRE = 
localisation related epilepsy; UNC = unclassified epilepsy. Statistical significance 
was determined by X2 test. The p-value represents the comparison between the 
WSEP and CBZ cohort. 
Chapter 4: Pharmacogenetics of Carbamazepine 152 
2000 -1 
0 
ý 1500 
"0 
iooo A 
ý cd 
E 
Q 500 
00 
0 
0 
r=-0.171, p=0.156 
"""M""" 
""" """M M "" "" 
................. 
000 Ob* "MM" "M ............ 
00 M" of M M" ""00 
. 
S 
0 
0 
0 15 30 45 60 75 
Age at Optimal Dose (years) 
FIGURE 4.1. Correlation between carbamazepine optimal dose and age of the 
patient at the time optimal dose was attained. Correlation was 
determined by 
Pearson's correlation test. Dotted line represents the linear correlation between 
variables. 
Chapter 4: Pharmacogenetics of Carbamazepine 
p=0.465 
2000 
ý 1500 1 
'O ý 
ý 
aý ä 1000 
A 
ý cd 
E 
.. ý 
500 
0 
0 
N 
" 
""" 
""": """ 
................ 
0NN N 
I 
044" 
000000ý 
ýsý'sasa 
000: 000 
ý 
Male Female 
Gender 
FIGURE 4.2. Distribution of carbamazepine optimal dose between genders. 
Statistical significance was determined by Student's t-test. Dotted line represents 
the mean CBZ optimal dose. 
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syndromes. Statistical significance was determined by Student's t-test. IGE _ 
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TABLE 4.2. Genotype distribution comparison between the carbamazepine 
cohort and the 400-strong study population. 
Genotype frequency 
Variant Sample p-value 
Minor Hetero - Major 
SCN2A c. 56G>A SSP 0.013 0.112 0.875 0.606 
CBZ 0.000 0.100 0.900 
CYP3A4 g. -392A>G SSP 0.003 0.065 0.932 0.333 
CBZ 0.000 0.100 0.900 
CYP3A5 g. 6986A>G SSP 0.010 0.128 0.862 0.290 
CBZ 0.014 0.171 0.815 
CYP1A2 g. 5734C>A SSP 0.068 0.415 0.517 0.792 
CBZ 0.057 0.457 0.486 
EPHX1 c. 337T>C SSP 0.105 0.412 0.483 0.748 
CBZ 0.086 0.386 0.528 
EPHX1 c. 416A>G SSP 0.038 0.312 0.650 0.417 
CBZ 0.057 0.243 0.700 
UGT2B7 c. 802C>T SSP 0.202 0.548 0.250 0.061 
CBZ 0.157 0.457 0.386 
Statistical significance was determined by X2 test or Fisher's Exact test. SSP = 
400-strong study population; CBZ = CBZ cohort with 70 patients; Minor = 
homozygous for minor allele; Hetero = heterozygous for major and minor alleles; 
Major = homozygous for major allele. The p-value represents the comparison 
between CBZ cohort and WSEP. 
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Univariate linear regression analysis showed that none of the candidate predictors was 
significantly associated with CBZ optimal dose (TABLE 4.3). A multivariate predictive 
model (Model 1) incorporating all candidate predictors (gender, age, genotypes of 7 
DME and SCN polymorphisms and 2 SNP interactions) identified age as the only 
predictor of CBZ optimal dose (p = 0.026). However, the overall model fit was not 
statistically significant (r2 = 19.3%, Presidual = 0.270, TABLE 4.4). Remodelling of 
Model 1 using stepwise regression analysis produced Model 2 which identified age, 
EPHXI c. 337T>C and EPHX1 c. 416A>G as potential predictors (p = 0.023 to 0.059) 
with a significant overall model fit (r2 = 13.3%, Presidual = 0.023). Enhancement of 
Model 2 using simple data transformation (from linear form to natural logarithmic form) 
further improved the overall model fit (r2 = 15.50%, Presidual = 0.011) and revealed 3 
significant predictors (age, p=0.023; EHPX1 c. 337 >C, p=0.019; EPHX1 c. 416A>G, 
p=0.027; TABLE 4.4). 
A predictive equation for optimal dose of CBZ was constructed from the constant value 
and regression coefficients given by Model 3. The predictive equation is presented 
below: 
lnODcBz = 6.477 - 0.006*Age + 0.156*Polyl + 0.164*Poly2 
Where InODCBZ is the natural logarithm of the optimal dose (mg/day) of CBZ, Polyl is 
the genotype score for EPHX1 c. 337T>C (T/T = 1, T/C = 2, C/C = 3), and Poly2 is the 
genotype score for EPHX1 c. 416A>G (A/A =1, A/G = 2, GIG = 3). 
The correlation between the observed CBZ optimal doses and the predicted CBZ 
optimal doses generated by the predictive equation was statistically significant (p = 
0.002) but moderate in strength (r = 0.362,95%CI 0.14 to 0.55; FIGURE 4.4). 
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TABLE 4.3. Summary of univariate regression analysis of variables predicting 
the optimal dose of carbamazepine. 
Predictor 
Gender 
Age 
Coef. r2 (%) p-value 
-55.72 0.8 0.460 
-3.581 2.9 0.156 
SCN2A c. 56G>A -82.5 0.0 0.512 
CYP3A4 g. -392A>G 76.2 0.5 0.545 
CYP3A5 g. 6986A>G -57.58 0.6 0.508 
CYPIA2 g. 5734C>A -5.11 0.0 0.935 
EPHXI c. 3377>C 95.75 4.0 0.098 
EPHXI c. 416A>G 80.71 2.3 0.208 
UGT2B7 c. 802C>T 55.66 1.6 0.301 
The relative impact of each predictor is denoted by the coefficient value (Coef. ). 
The goodness-of-fit value (r2) indicates how well the individual predictors fit the 
model. The p-value indicates the probability that the predictor influences CBZ 
optimal dose. 
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TABLE 4.4. Summary of hierarchical multivariate regression analysis of 
variables predicting the optimal dose of carbamazepine. Models were developed 
in a stepwise manner from Model 1 to Model 3. 
Model 3 
Model 1 Model 2 
Predictor (natural log) 
Coef. p-value Coef. p-value Coef. p-value 
158 
Constant 173.10 0.856 649.50 <0.001 6.477 <0.001 
Gender -93.63 0.249 ---- 
Age -6.36 0.026 -4.68 0.059 -0.006 0.023 
SCN2A c. 56G>A -148.90 0.263 ---- 
CYP3A4 g. -392A>G 591.10 0.402 ---- 
CYP3A5 g. 6986A>G 174.60 0.603 ---- 
CYP3A SNP interaction -189.30 0.497 ---- 
CYP1A2 g. 5734C>A 25.57 0.695 ---- 
EPHXI c. 337T>C 255.40 0.172 132.79 0.023 0.156 0.019 
EPHX1 c. 416A>G 283.80 0.181 127.77 0.035 0.164 0.027 
EPHXI SNP interaction -115.8 0.435 ---- 
UGT2B7 c. 802C>T 
27.72 0.637 ---- 
r2 (%) 19.3 13.3 
15.5 
PresiAual 0.270 . 
0.023 0.011 
The relative impact of each predictor is denoted by the coefficient value 
(Coef. ). The p- 
value indicates the probability that the predictor influences 
CBZ optimal dose. The 
goodness-of-fit value (r) indicates how well the individual predictors 
fit the predictive 
model. The significance of model fitting is represented 
by the p-value of residual 
analysis (presiduai)" `-' mark represents a predictor that was eliminated 
by stepwise 
regression analysis. 
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FIGURE 4.4. Correlation between the observed and predicted CBZ optimal doses 
based on the optimal multivariate regression model. Correlation was determined 
by Pearson's correlation test. Dotted line is the linear correlation between 
observed and predicted doses. 
4.1.5 Discussion 
l59 
The main objective of epilepsy pharmacotherapy is to achieve complete seizure control 
without apparent adverse effects. The ability to predict the required CBZ dose for an 
individual patient may improve the CBZ dosage decision in patients who are 
responders, and limit the inevitable titration of CBZ in patients who may be refractory. 
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Therefore, early prediction of the CBZ optimal dose may shorten the time to achieve 
optimal seizure control and reduce unnecessary exposure to a high CBZ doses. 
The optimal dose of CBZ is determined by individual pharmacokinetic and 
pharmacodynamic characteristics. Both characteristics are regulated by many factors 
including physiological and genetic factors. Candidate genetic predictors of optimal 
dose of CBZ were identified from current knowledge regarding the pharmacokinetics 
and pharmacodynamics of the drug. The ability of each candidate to predict optimal 
dose of CBZ was examined through regression modelling. This analysis was not only 
able to identify potential predictors, but also to describe how much each predictor 
contributed to interindividual variation in the optimal dose of CBZ. 
This study revealed that increasing age was associated with a reduction in the required 
CBZ dose. A similar observation has been reported in a study examining the 
relationship between CBZ dose and plasma concentrations (Battino et al., 2003). These 
investigators found that elderly patients required less CBZ to achieve the recommended 
therapeutic concentration. Increasing age is known to influence multiple physiological 
functions, including the drug elimination process, most likely as a result of decreased 
function of excretory organs such as liver and kidney (Bourdet et. al., 2001). Advancing 
age may also increase individual sensitivity to drugs and increase the risk of developing 
side effects (Bourdet et. al., 2001). Therefore, elderly patients are likely to require a 
lower amount of drug to achieve a similar response to that of younger patients. 
Genetic factors influencing both pharmacokinetics and pharmacodynamics contribute to 
the overall CBZ pharmacogenetic profile. Interindividual differences in 
pharmacokinetics are commonly associated with DME and DTP gene polymorphisms. 
However, the role of DTPs, such as P-gp, in CBZ disposition is controversial (Owen et 
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al., 2001) and potentially minimal as the CBZ molecule is highly non-polar, easily able 
to penetrate cell membranes and distributed well in many body tissues (Spina, 2002). A 
previous study failed to demonstrate any correlation between a common polymorphism 
in the ABCB 1 gene encoding P-gp and the maximum dose of CBZ (Tate et al., 2005). 
For this reason, the present study focused solely on genetic polymorphisms of DMEs as 
potential contributors to interindividual variability in CBZ pharmacokinetics. 
In this study, only two common polymorphisms in the EPHXI gene were identified as 
significant predictors of CBZ optimal dose when included in a predictive model 
incorporating patient age. It is possible that polymorphisms in other DMEs do not 
significantly influence the expression and activity of their respective proteins or that 
these proteins do not play a principal and/or irredeemable role in the metabolism of 
CBZ. 
The g. -392A>G transition is the most widely studied polymorphism in the CYP3A4 
gene. The CYP3A4 -392G allele has also been associated with a reduced capacity to 
metabolise drugs such as nifedipine and tacrolimus (Shimada et al., 1994; Hesselink et 
al., 2003). The g. 6986A>G substitution is the most commonly recognised 
polymorphism in the CYP3A5 gene. Variation in CYP3A5 metabolic capacity 
associated with the g. 6986A>G polymorphism has been observed for drugs such as 
midazolam, statins, alprazolam and tacrolimus (Hesselink et al., 2003; Goto et a!., 2004; 
Kivisto et al., 2004; Wong et al., 2004; Park et al., 2006). The present study, did not 
identify any significant difference in the mean optimal dose of CBZ between individual 
genotypes of CYP3A4 g. -392A>G and CYP3A5 g. 6986A>G. Even in the multivariate 
regression analysis, both polymorphisms failed to predict CBZ optimal dose. The reason 
why these polymorphisms do not appear to influence CBZ dosing is unclear, however, 
one possible explanation may be related to the strong linkage between these SNPs. In 
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Caucasian populations, the CYP3A4 -392G allele is usually co-localised with the 
CYP3A5 6986A allele and vice versa (Dally et al., 2003). Low activity of CYP3A4 
associated with the -392G allele is therefore balanced out by possession of a functional 
CYP3A5 enzyme in carriers of the 6986A allele (Ohmori et al., 1998; Huang et al., 
2004). Thus, there is some degree of redundancy in the genetic influences on CYP3A- 
mediated metabolism, at least in the Caucasian population. This redundancy is not 
observed in Japanese subjects, who do not express the CYP3A4 -392G allele (Paris et 
al., 1999; Seo et al., 2006b). In the resulting absence of compensatory linkage between 
CYP3A polymorphisms, the CYP3A5 c. 6986A>G variant is associated with 
interindividual variability in CBZ pharmacokinetics in this population (Seo et al., 
2006b). 
The CYPIA2 5734A allele has been reported to be highly inducible especially among 
smokers (Sachse et al., 1999), and is capable of affecting the risk of developing heart 
disease and cancer (Cornelis et al., 2005; Moonen et al., 2005; Pavanello et al., 2005). 
Although hydroxylation of CBZ involves the CYP1A2 enzyme, the present study did 
not find any association between the CYPIA2 g. 5734C>A polymorphism and the CBZ 
optimal dose. Up to 25% of the parent CBZ compound undergoes hydroxylation, but at 
least 4 DMEs other than CYPIA2 have been reported to catalyze the hydroxylation 
pathway (FIGURE 1.2; Pelkonen et al., 2001). Thus, the contribution of CYPIA2 to 
CBZ hydroxylation is potentially very minor, reducing the likelihood of detecting any 
association between CYP I A2 variants and CBZ dose. 
The importance of mEH in the metabolism of CBZ can be predicted from the CBZ 
metabolic pathway (FIGURE 1.2; Pelkonen et al., 2001). mEH may be responsible for 
more than 30% of overall CBZ metabolism. The EPHXI c. 337T>C transition causes 
substitution of tyrosine with histidine at codon-113 and the EPHXI c. 416A>G 
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transition causes substitution of histidine to arginine at codon-139. In an in vitro study, 
these amino acid changes were shown to influence the stability of mEli (Bassett et at., 
1994b). As a potential consequence of this alteration in mEH stability, and its 
recognised ability to metabolise several carcinogens, both polymorphisms have been 
associated with an adjusted risk of developing cancers and other diseases (Smith & 
Harrison, 1997; Jourenkova-Mironova et at., 2000; Sonzogni et al., 2002; Budhi et at., 
2003). Studies employing benzo(a)pyrene-4,5-epoxide and cis-stilbene oxide as 
substrates have shown that EPHX1 337C and EPHX1 416G alleles are associated with 
lower and higher mEH activities, respectively (Hassett et al., 1994b; Hassett et al., 
1997). Interestingly, the opposite was observed in a study employing CBZ-E as a 
substrate (Nakajima et at., 2005). This would indicate that the influence of EPHX1 
variants on enzyme activity is substrate-specific. This is supported by an investigation 
which examined the hydrolytic activity of mEH on three substrates: cis-stilbene, CBZ- 
E, and naphthalene oxide, in a panel of microsome samples obtained from human livers 
(Kitteringham eta!., 1996). Thus, the functional significance of EPHX1 variants and the 
percentage of mEH involvement in CBZ metabolism would support the notion that 
polymorphisms of EPHX1 gene are potential predictors of CBZ optimal dose. The 
predictive model that was constructed in the current study further strengthens this 
postulation. A significant alteration in the capacity for CBZ-E metabolism has been 
demonstrated in patients with haplotypes of EPHX1 harbouring both 337C and 416G 
alleles (Nakajima et at., 2005). As CBZ-E is commonly associated with the occurrence 
of adverse effects arising from CBZ therapy (Ramsay & Wilder, 2002) and mEH is the 
major determinant of CBZ-E metabolism, these EPHX1 polymorphisms may also be 
useful in predicting the maximum tolerable dose which should not be exceeded when 
adjusting CBZ treatment regimens. 
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Approximately 15% of parent CBZ compound undergoes glucuronidation which is 
predominantly mediated by UGT2B7. The c. 802C>T substitution is a recognised 
polymorphism in the UGT2B7 gene, but its functional significance is controvesial. The 
802T allele has been associated with an altered capacity for the metabolism of morphine 
and 4-hydroxy-catecholestrogens (Sawyer et al., 2003; Thibaudeau et al., 2006), but 
other substrates such as oxazepam, propranolol and androgens are unaffected (Coffman 
et al., 1998). In the present study, the c. 802C>T polymorphism, did not significantly 
predict the optimal dose of CBZ, suggesting that this variant does not significantly 
influence the role of UGT2B7 in the glucuronidation of CBZ. 
CBZ acts predominantly on voltage-gated sodium channels to exert its antiepileptic 
effects. Changes in the structure of sodium channels may influence their sensitivity to 
CBZ. In the current study, there was no association between the SCN2A c. 56G>A 
polymorphism and the optimal dose of CBZ. This might suggest that the SCN2A 
c. 56G>A polymorphism does not significantly affect the function of the Na,, 1.2 protein 
or its sensitivity to blockade by CBZ. Of course, CBZ can also act on other voltage- 
gated sodium channels, potentially compensating for any functional or structural defect 
in the Na,, 1.2 protein. A previous study has reported that the maximum dose of CBZ is 
significantly associated with a polymorphism located within intron-5 of SCN1A gene 
(Tate et al. 2005). However, there was a clear difference in the definition of dose 
between the Tate et al. (2005) study and the current investigation. The measure of 
optimal dose considers both efficacy and tolerability to CBZ treatment, whereas 
maximum dose reflects tolerability alone. Nevertheless, this SCN1A polymorphism 
is a 
potential candidate for future pharmacogenetic investigations of CBZ optimal 
dose and 
may be able to explain additional interindividual variability 
in the CBZ dose 
requirement. 
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The predictive model of CBZ optimal dose proved statistically relevant only when a 
physiological factor (age) was combined with genetic predictors. When each candidate 
predictor was analysed in isolation, none showed significant ability to predict the 
optimal dose, indicating that individual dosing requirement are determined by multiple 
factors, many of which remain to be discovered. The present study showed that 
potentially important predictors for CBZ optimal dose include patient age and 
polymorphisms in the EPHX1 gene. Although the model revealed a significant 
correlation between predicted and observed optimal doses, the strength of the prediction 
was not sufficient for application in clinical practice. The small size of the CBZ cohort 
and the retrospective design of this study have influenced its findings and their 
applicability. This study has revealed an intriguing and potentially significant role of 
EPHX1 SNPs in individual CBZ dose requirements, however it should be repeated 
independently and prospectively. The predictive model that was established in this study 
may serve as a springboard for future studies of SNP-based prediction of optimal drug 
doses. 
4.1.6 Conclusion 
None of the input factors, gender, age, and polymorphisms in DME and SCN2A genes 
can be used as a single predictor for CBZ optimal dose. However, the EPIIXI 
c. 337T>C & c. 416A>G polymorphisms appear to be potential predictors for optimal 
dose in a predictive model incorporating age. More candidate predictors in a larger 
population are required to strengthen the model. The additional candidate predictors 
may include factors that influence CBZ pharmacodynamics such as polymorphisms in 
genes encoding other voltage-gated ion channels that represent the pharmacological 
targets of CBZ. 
Chapter 4: Pharmacogenetics of Carbamazepine 166 
4.2 A Preliminary Genetic Analysis of Drug Metabolising 
Enzymes in Patients with Carbamazepine Adverse 
Effects 
4.2.1 Introduction 
Major adverse drug reactions associated with CBZ treatment can be divided into two 
categories; CNS toxicity and idiosyncratic reactions. Several mechanisms have been 
proposed to explain the occurrence of CBZ adverse effects. One hypothesis is that CNS 
toxicity is dependent on CBZ dose and concentration (Delcker et al., 1997). The 
severity of adverse effects has been reported to be directly associated with increasing 
plasma CBZ concentrations (Weaver et al., 1988; Semah et al., 1994). In addition, this 
has also been demonstrated by the relationship between intermittent CNS effects and the 
dosing-interval fluctuation in CBZ concentrations at steady-state (Tomson, 1984). In 
some patients, CNS related adverse effects are experienced at modest CBZ doses (less 
than 600 mg/day), suggesting that these individuals possess low activity DMEs, which 
result in higher plasma CBZ concentrations. Polymorphisms in genes that encode DMEs 
may be responsible for this phenomenon. Another hypothesis is that CNS related 
adverse effects are associated with the rate of rise in plasma CBZ concentrations (Lesser 
et al., 1984; Wildin et al., 1993; Delcker et al., 1997). An adaptation effect of the brain 
in response to changes in CBZ concentration is believed to be responsible for the 
occurrence of these adverse effects (Lesser et al., 1984). 
Idiosyncratic reactions are independent of CBZ dose and/or concentration. Rashes are 
the most common cutaneous manifestation of CBZ idiosyncratic reactions, and a 
cardinal sign of CBZ hypersensitivity. Idiosyncratic reactions to CBZ can arise as a 
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result of cross-sensitivity to other AEDs (Shear & Spielberg, 1988; Moss et al., 1999). 
Although a relatively small proportion of patients experience idiosyncratic reactions, 
unattended cases can result in severe morbidity and even fatality (Shear & Spielberg, 
1988; Moss et al., 1999; Rzany et al., 1999; Maldonado et al., 2002; Pirmohamed & 
Park, 2003). Idiosyncratic reactions are believed to be associated with an increased 
activation and/or decreased deactivation of reactive intermediate metabolites 
(Pirmohamed & Park, 2003). In an animal model, the production of reactive metabolites 
of CBZ such as arene oxides and quinones is mediated by CYP450 isoenzymes such as 
CYP3As and CYPIA2 (Madden et al., 1996; Pearce et al., 2002). In contrast, the 
deactivation process is largely mediated by mEH and UGTs (Green et al., 1995; Maggs 
et al., 2000). 
Evidence suggests that polymorphisms in DME genes are able to alter enzyme activity 
(as described in Chapter 3). Polymorphisms in genes that encode activation and 
deactivation enzymes for CBZ may be causal in the precipitation of adverse drug 
effects. Together with other physiological and immunological factors, genetically 
compromised DMEs may contribute to the generation of both categories of CBZ-related 
adverse effects. Collectively, these polymorphisms may produce a unique adverse effect 
phenotype. As a result, common genetic polymorphisms of DMEs that are involved in 
CBZ metabolism were examined as potential genetic markers of CBZ adverse effects. 
4.2.2 Aims 
In an effort to identify a potentially unique phenotype of CBZ adverse effects, the 
incidence of common DME polymorphisms in patients experiencing intolerable CBZ 
adverse effects was investigated. 
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4.2.3 Methods 
4.2.3.1 Study subjects 
168 
From the 400-strong study population, 104 patients treated with CBZ monotherapy and 
possessing sufficient outcome data were identified and retrospectively screened for any 
incidence of adverse effects. A total of 14 patients had experienced at least one 
intolerable adverse effect that led to CBZ withdrawal (9 CNS-related, 5 idiosyncratic). 
The remaining 90 patients did not experience any adverse effect of sufficient severity to 
necessitate drug withdrawal, despite at least 6 months exposure to CBZ. These patients 
were employed for control purposes and randomely assigned to one of two distinct 
control groups using an online random number generator (http: //www. randomizer. 
org/form. htm). A total of five individuals were selected at random from control group 1 
and employed for comparison with those patients experiencing idiosyncratic reactions 
with CBZ. Control group 2 was first pared to include only those patients who had been 
exposed to CBZ at doses above 800 mg/day and then nine individuals were selected at 
random for comparison with those patients experiencing intolerable CNS-related 
adverse effects. Applying a minimum dose exposure criterion ensured that control group 
2 was relatively free from dose-related adverse events and sufficiently distinct from 
those patients who discontinued CBZ due to CNS-related adverse effects and who had 
done so at a median maximum dose of just 400 mg/day. 
4.2.3.2 Adverse reaction documentation 
Major adverse effects were divided into two categories, CNS-relatcd effects and 
idiosyncratic reactions. Information regarding CBZ adverse effects was obtained 
retrospectively from patient medical records. None of the patients was concomitantly 
treated with other medications (AEDs or non-AEDs) at the time of CBZ adverse effect. 
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4.2.3.3 Genotype analysis and phenotype assessment 
169 
The genotypes of recognised polymorphisms in DMEs associated with CBZ metabolism 
were identified using the PCR-RFLP and direct sequencing assays described in section 
3.1.3. Genotype determination for the DME polymorphisms was completed on February 
2006. Phenotype assessment was started on March 2006 and completed on April 2006. 
4.2.3.4 Genotype-phenotype analysis 
Minor alleles were chosen as potential genetic markers for CBZ adverse effects. The 
minor alleles were represented by the CYP3A4 -392G, CYP3A5 6986A, CYPIA2 
5734C, EPHX1 337C, EPHX1 416G and UGT2B7 802C variants. CYP3A4, CYP3A5 
and CYP1A2 were regarded as potential activation enzymes in the precipitation of 
CBZ-related idiosyncratic reactions, whereas UGT2B7 and EPHXI were regarded as 
potential deactivation enzymes. The incidence of the minor alleles of the recognised 
polymorphisms in DME genes was compared between the adverse effects groups and 
their respective control groups by the method proposed by Green et al. (1995). 
4.2.3.5 Statistical analysis 
The distributions of gender and epilepsy syndromes were initially compared by X2 test. 
The pattern of genetic polymorphisms was evaluated by allelic term. The distribution of 
minor and major alleles between adverse effect and respective control groups was 
compared using an appropriate contingency table test (Fisher's Exact test or X2 test). P- 
values less than 0.05 represented a significant difference in the distribution of minor and 
major allele between the two groups. 
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4.2.4 Results 
4.2.4.1 Patient characteristics and adverse effect profile 
170 
There was no significant difference in the distribution of gender (p = 0.388) or epilepsy 
syndrome (p = 0.503) between adverse effect and control groups (TABLE 4.5). In the 
majority of cases, adverse effects were observed at lower median CBZ 
doses (400 
mg/day) than was employed in the population as a whole (800 mg/day; p=0.001; 
TABLE 4.5). 
TABLE 4.5. Demographic profile of patients who experienced intolerable 
carbamazepine adverse effects. 
Intolerable Adverse Events 
Yes, n=l4 No, n=90 p-value 
Gender Male 60% 48% 0.388 
Female 40% 52% 
Epilepsy Syndrome IGE 13% 28% 0.503 
LRE 87% 70% 
UNC 0% 2% 
CBZ maximum dose (mg/day) Median 400 
800 0.001 
Min 400 300 
Max 1200 2000 
IGE, idiopathic generalised epilepsy; LRE, localisation related epilepsy; 
UNC, 
unclassified epilepsy. Statistical significance was 
determined by X2 test for gender 
and epilepsy syndrome, and Student's t-test 
for CBZ maximum dose. Thep-value 
represents the comparison between patients who experienced 
intolerable CBZ and 
the population from which they are drawn. 
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Drowsiness and dizziness (6 out of 14 cases) and rash (5 out of 14 cases) were the most 
common intolerable adverse effects leading to CBZ withdrawal. Some patients 
experienced more than one adverse event simultaneously. In all patients, the adverse 
effects resolved with discontinuation of CBZ. 
4.2.4.2 The pattern of polymorphisms in drug metabolising genes in patients 
with carbamazepine adverse effects 
The incidence of common polymorphisms in DME genes are presented in TABLE 4.6 
and TABLE 4.7 for the CNS-related adverse effects and idiosyncratic reaction groups, 
respectively. For CNS related adverse effects, there was a marginally lower incidence of 
minor alleles in the adverse effect group compared to the control group (total = 20 vs 25 
alleles, p=0.402). For idiosyncratic reactions, the presence of minor alleles in DME 
genes was similar between adverse effect and control groups (total = 10 vs 11 alleles, p 
= 0.882). The presence of minor alleles in activation DMEs was comparable between 
the idiosyncratic reaction group and controls (3 vs 2 alleles, p=0.999) and there was 
similarly no difference in the distribution of minor alleles in the deactivation DME 
genes between the idiosyncratic reaction group and respective control group (7 vs 9 
alleles, p=0.559). Overall, there was no single polymorphism that was evidently 
related to the occurrence of CBZ adverse effects. 
4.2.5 Discussion 
The risk of developing adverse drug effects has been associated with several 
polymorphisms in DME genes, such as CYP2C9 and CYP2D6 (Royer, 1997). The 
expression and activity of DMEs may be decreased or increased by the effects of 
genetic polymorphisms. A decrease in DME activity may result in higher plasma drug 
concentration at routine dose, increasing the risk of developing dose or concentration 
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dependent adverse effects. This low activity phenotype may also be associated with 
accumulation of reactive metabolites that could in turn be responsible for idiosyncratic 
reactions. In contrast, the high activity phenotype may also be partly responsible for the 
development of idiosyncratic reactions through increased production of reactive 
metabolites (Shear & Spielberg, 1988; Green et al., 1995; Royer, 1997; Pirmohamed & 
Park, 2003). Accordingly, polymorphisms in genes encoding DMEs that mediate CBZ 
metabolism were hypothesised to be causal factors in the development of CBZ adverse 
effects. However, there was no clear association between the incidence of common 
polymorphisms in DME genes and CBZ adverse effects that might be considered as the 
sole determinant of treatment withdrawal. Common polymorphisms in DME genes such 
as CYP3A4, CYP3A5, CYP1A2, EPHX1 and UGT2B7 are unlikely to be a 
predominant factor in the development of CBZ adverse reactions. It is more likely that 
other factors acting concurrently with DMEs may be responsible in predisposing an 
individual to CBZ adverse effects. The overall balance between physiological factors, 
bioactivation, detoxification and immune responsiveness probably determines whether 
an adverse effect will occur. 
In many studies, the occurrence of CNS-related adverse effects is associated with the 
rate of rise in plasma CBZ concentration (Lesser et al., 1984; Wildin et al., 1993; Oiling 
et al., 1999). The CNS symptoms are manifested when the brain attempts to adapt to the 
increasing CBZ concentrations (Lesser et al., 1984; Wildin et a!., 1993). The rising 
phase of plasma CBZ concentration is controlled by three principle 
factors, absorption, 
distribution and elimination. The influence of absorption is most pronounced in the 
immediate aftermath of drug intake, early in the dosing interval and when the rate of 
rise in concentration is at its greatest. Therefore, factors that affect the rate of 
CBZ 
absorption may be more responsible for the generation of 
CNS-related adverse effects 
than those which influence distribution and elimination. 
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Factors that affect the rate of absorption include gastrointestinal function and drug 
formulation (Wildin et al., 1993; Oiling et al., 1999). Any given CBZ formulation is 
subject. to high interindividual variability in the rate of absorption (Cotter et al., 1977; 
Perucca et al., 1980a; Oiling et al., 1999), highlighting important differences in 
gastrointestinal function between individuals. Gastrointestinal disease may also alter 
intestinal motility and the potential for drug absorption. The pattern of dosing-interval 
fluctuation in plasma CBZ concentrations can also be affected by formulation (May & 
Rambeck, 1989; Stevens et al., 1998) and is closely associated with the intensity of 
adverse effects (Tomson, 1984). The dosing-interval fluctuation in concentrations 
observed with extended-release formulations is lower than that observed with standard 
release tablets and consequently fewer adverse effects are noted (Miller et al., 2004). 
Idiosyncratic reactions may be associated with the imbalance between activation and 
deactivation of reactive metabolites of CBZ, and also immune responsiveness (Shear & 
Spielberg, 1988; Green et al., 1995; Royer, 1997; Pirmohamed & Park, 2003). The 
reactive metabolites, arene oxides, can precipitate cellular damage if not sufficiently 
deactivated (Madden et al., 1996). Low molecular weight drugs and reactive 
metabolites bind covalently to cellular proteins and form haptens that trigger an 
immunological response (Svensson et al., 2000). The isoforms of CYP450 involved in 
CBZ metabolism are present in human skin (Wolkenstein et al., 1998) and stable 
binding between reactive metabolites of CBZ and skin CYP450s has been demonstrated 
(Wolkenstein et al., 1998). The hapten produced can precipitate a cutaneous reaction. 
As a result, the production of hapten has been postulated as one possible explanation for 
the occurrence of CBZ cutaneous reactions. The presence of anti"CYP450 antibodies in 
patients who suffer hypersentivity reactions further supports this hypothesis (Leeder et 
al., 1992). The findings of the current study suggest that common DME polymorphisms 
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do not significantly influence the pathway of activation/deactivation or the binding 
between DMEs and reactive metabolites. 
Previous studies have also failed to demonstrate any association between 
polymorphisms in the EPHX1 gene and CBZ hypersensitivity (Green et al., 1995; 
Pirmohamed & Park, 2003). Polymorphisms in genes that express DMEs may be less 
important than those that express immunological factors. The human major 
histocompatibility complex (MHC) which determines immune system recognition and 
which responds to CBZ-related antigen production is a possible causal immunological 
factor. Expression of genetically polymorphic MHCs has been identified (Leeder et al., 
1992). Furthermore, haplotypes of MHC and other immunological factors such as 
tumour necrosis factor have been associated with the severity of drug hypersensitivity 
reactions (Pirmohamed et al., 2001). 
The present study should be considered as preliminary because of the limited number of 
patients who experienced intolerable CBZ-related adverse effects. In addition, the study 
findings may also be influenced by the method of assessing adverse effects as described 
in section 2.2.3.2. Most of the adverse effects documented in this study arose from 
spontaneous reporting. Spontaneous reporting has advantages in highlighting effects 
which are clinically relevant, but is associated with extreme variability in the accuracy 
of detection and with significant under-reporting (Perucca, 1997; Gilliam, 2005). The 
retrospective nature of this study may have further compromised the accurate' 
identification and recording of relevant adverse effects. Accordingly, this study focused 
only on those adverse effects which were sufficiently severe to necessitate CBZ 
withdrawal. 
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4.2.6 Conclusion 
This preliminary study failed to reveal any association between CBZ adverse effects and 
common polymorphisms in DME genes. A large prospectively designed study is 
required to establish whether there is any functional relevance of DME gene 
polymorphisms in the development of CBZ adverse effects. Genetic variability in drug 
absorption and in proteins which contribute to the immune response should be targeted 
as potentially causal precipitants of CBZ adverse effects in future explorations. 
CHAPTER 5 
PHARMACOGENETICS OF LAMOTRIGINE 
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5.1 Association between ABCB1 and SCN2A gene 
polymorphisms and the Response to Lamotrigine 
Therapy in Newly Diagnosed Epilepsy Patients 
5.1.1 Introduction 
Partially responsive and non-responsive epilepsy patients may try a number of AEDs 
over a long period of time before they are definitely identified as being refractory. This 
may result in an increased exposure to adverse drug effects, seizure progression and an 
elevation in the cost of treatment (Elger, 2003). Resistance to AED treatment remains as 
a major therapeutic challenge, despite the increasing numbers of AEDs in routine 
clinical use. Two major theories have been proposed to explain the phenomenon of 
therapeutic failure in epilepsy (Elger, 2003; Loscher, 2005), both arising from a basic 
knowledge of clinical pharmacology. Firstly, the pharmacokinetic hypothesis suggests 
that AEDs do not reach the epileptic focus in sufficient concentration (Elger, 2003; 
Loscher, 2005; Szoeke et al., 2006), and secondly, the pharmacodynamic hypothesis 
suggests that alteration in the subunit composition of ion channels and neurotransmitter 
receptors reduces their sensitivity to AEDs (Elger, 2003; Loscher, 2005). 
The pharmacokinetic profile of AEDs is predominantly determined by the activities of 
DMEs and DTPs. Brain tissue obtained from patients with medically intractable 
seizures has been shown to express a higher level of the efflux transporter protein, P-gp 
(Tishler et al., 1995; Marchi et al., 2004) and several AEDs are believed to be substrates 
for P-gp-mediated transport (Potschka et al., 2002). Overexpression of P-gp may result 
in an insufficient penetration of AEDs into brain tissue (Ramachandran & Shorvon, 
2003) and has been proposed to be responsible for the phenomenon of 
pharmacoresistance in epilepsy. Seizure activity itself can increase the expression of P. 
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gp (Rizzi et al., 2002; van Vliet et al., 2004), suggesting that any delay in achieving 
optimal seizure control might increase the likelihood of long-term intractability to AED 
treatment. 
A significant percentage of newly diagnosed epilepsy patients have been shown to 
respond poorly to LTG monotherapy (Kwan & Brodie, 2000) and one could argue that 
overexpression of P-gp may contribute to this poor response. It is widely recognised that 
the expression of P-gp can be influenced by polymorphisms in the ABCB 1 gene 
(Hoffineyer et al., 2000; Tanabe et a!., 2001; Nakamura et a!., 2002) and that these 
genetic variants may influence the ability of P-gp to transport substrates across 
biological membranes. Given that LTG is believed to be a substrate for P-gp (Potschka 
et a!., 2002) and that this protein is up-regulated in epileptic brain tissue, it is not 
unreasonable to suggest that common polymorphisms in the ABCB1 gene could impact 
on the efficacy and/or toxicity of LTG monotherapy in newly diagnosed epilepsy. 
The most commonly recognised SNPs in the human ABCB 1 gene are the c. 1236C>T, 
c. 2677G>T/A and c. 3435C>T substitutions. Several studies have explored the 
functional relevance of the ABCB1 c. 2677G>T/A and c. 3435C>T variants but 
inconsistent findings have been reported when employing drug pharmacokinetics as a 
phenotype (Hoffmeyer et al., 2000; Kim et a!., 2001; Nakamura et a!., 2002; Oselin et 
al., 2003). Other studies have evaluated the association between the ABCB 1 c. 3435C>T 
polymorphism and response to AED treatment and again have produced conflicting 
results (Siddiqui et al., 2003; Tan et al., 2004a; Sills et al., 2005; Kim et a!., 2006). The 
3435C allele was initial associated with poor response to AED treatment (Siddiqui et 
al., 2003), but at least three further studies have failed to corroborate this original 
finding (Tan et a!., 2004a; Sills et al., 2005; Kim et al., 2006). Rather than investigate 
single genotypes, some investigators have suggested that haplotypes of the three 
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common polymorphisms in ABCB 1 could be more useful in predicting drug 
responsiveness in epilepsy (Hung et al., 2005; Seo et al., 2006a). 
Discrepancies between the results of individual studies may be attributed to sample size, 
or genetic background of the respective cohorts, or they may simply have arisen by 
chance (Sills et al., 2005). Differences in AED regimens between invidual studies may 
have also significantly influenced the findings. Not all AEDs are believed to be 
transported by P-gp (Owen et al., 2001; Potschka et al., 2004). Therefore, examining 
the association between ABCB I polymorphisms and the response to monotherapy 
treatment with an AED that has been shown to be a substrate of P-gp may be more 
appropriate. 
In contrast to the transporter hypothesis discussed above, the pharmacodynamic theory 
of refractory epilepsy suggests that variations in the structure and subunit composition 
of ion channels may be associated with poor response to AED treatment (Ramachandran 
& Shorvon, 2003). This phenomenon may also contribute to poor seizure control with 
LTG therapy. LTG acts mainly on voltage-gated sodium channels to exert its 
antiepileptic effect (Zona & Avoli, 1997; Kohling, 2002), and any changes in sodium 
channel structure may affect the activity of LTG. As described in Chapter 3, the SCN2A 
c. 56G>A substitution, results in a nonsynonymous amino acid change from arginine to 
lysine at codon 19 of the Na, 1.2 a-subunit protein (Ito et al., 2004). This polymorphism 
has the potential to affect the conformation of the sodium channel and consequently its 
sensitivity to LTG. As such, this SCN2A variant may also 
be associated with 
interindividual variability in the responsiveness to LTG treatment. 
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In light of the pharmacokinetic and pharmacodynamic hypotheses of pharmacoresistant 
epilepsy, the prevalences of the ABCB 1 c. 1236C>T, ABCB I c. 2677G>T/A, ABCB I 
c. 3435C>T and SCN2A c. 56G>A polymorphisms were investigated in a series of newly 
diagnosed epilepsy patients in an attempt to predict the response to LTG monotherapy. 
5.1.3 Methods 
5.1.3.1 Study subjects 
From the overall 400-strong study population, 118 patients were identified as being 
treated with LTG monotherapy. A total of 79 patients from the 118 patients received 
LTG as their first ever AED, irrespective of seizure type. All of these patients were 
involved in a head to head monotherapy trial comparing LTG with VPA (Stephen et al., 
2007). Each patient was treated for at least 1 year with LTG. Patients who withdrew 
from LTG therapy for any reason before the end of the 12-month study period were 
excluded. None of the participants was concomitantly treated with any other medication 
(AEDs or non-AEDs) that might have influenced LTG metabolism. 
5.1.3.2 Genotype analysis and phenotype assessment 
Genotypes of the common SCN2A and ABCBI gene polymorphisms were 
identified 
using the PCR-RFLP assays described in Chapter 3. Genotype determination completed 
for the SCN2A polymorphism on February 2006 and for ABCB I polymorphisms on 
May 2006. Phenotype assessment was started on June 2006 and completed on July 
2006. 
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The haplotypes of ABCB1 polymorphisms were inferred using THESIAS software 
(Testing Haplotype Effects In Association Studies; Tregouet & Garelle, 2007). The 
haplotypes were presented in the arrangement of c. 123 6C>T-c. 2677G>T/A-c. 343 5C>T. 
This study was not powered for this haplotype analysis due to limited sample size, 
therefore, the result was considered observational. ABCBI diplotypes were inferred 
using combination of genotypes of the c. 1236C>T, c. 2677G>T/A and c. 3435C>T 
polymorphisms, as described by Coulbault et al. (2006). 
5.1.3.4 Evaluation of clinical response 
Information regarding the outcome of LTG therapy was obtained retrospectively from 
the clinical study notes. Response to LTG was assessed by an experienced clinician and 
recorded in the study folders and electronic database. Complete medical history, seizure 
type and basic clinical factors such as height, weight, age and gender were documented 
at the first study visit. Progress was evaluated at study visits, scheduled every 4 to 6 
weeks, from the day of treatment initiation and for at least 12 months thereafter. 
However, patients are allowed to contact or visit the clinic at anytime in cases of 
worsening of seizure control and adverse drug reaction. Records of each study visit 
included details of seizure frequency, adverse effects, and complete LTG treatment 
regimen. Patients were categorised as seizure free if no seizure was experienced within 
the last 6 months of the study period. In contrast, patients with uncontrolled seizures or 
those who had experienced seizure break-through within the last 6 months were 
categorised as non-seizure free. 
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Clinical and demographic differences between the seizure free and non-seizure free 
groups were investigated using the X2 test. The distributions of age and maximum LTG 
dose were compared using Student's t-test. The possibility of genotype selection bias 
was explored by comparing the distribution of individual polymorphisms between the 
LTG cohort and the overall 400-strong patient population using the X2 test. 
The genotype distribution of each polymorphism was initially compared between 
seizure free and non-seizure free groups by contingency table tests. Logistic regression 
analysis was then used to evaluate differences in the prevalences of ABCB 1 
c. 1236C>T, c. 2677G>T/A, c. 3435C>T and SCN2A c. 56G>A polymorphisms. The 
analyses were conducted using allele, genotype, diplotype and haplotype frequencies. 
Specifically for haplotype analysis, the haplotype with the highest frequency was 
selected as the default reference. The odds ratio (OR) together with its 95% confidence 
interval (95% CI) was used as a measure of association between the gene 
polymorphisms and response to LTG treatment. All reportedp-values are two-tailed. 
5.1.4 Results 
5.1.4.1 Patient demographics and lamotrigine dosage regimen 
A total of 39 patients became seizure-free within the first 12 months of LTG treatment, 
while the remaining 40 patients continued to experience seizures despite attempts to 
optimise LTG therapy. The median age of patients was 35 years (range 13 to 
80) and 
there were no significant differences in the distribution of gender (p = 
0.216), age at 
evaluation (p = 0.165) or epilepsy syndrome (p = 0.332) between the seizure 
free and 
the non-seizure free groups (TABLE 5.1). At the end of one year, the non-seizure 
free 
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patients had reached a significantly higher daily LTG dose than the seizure free patients 
(p < 0.001; TABLE 5.1). 
TABLE 5.1. Patient demographics and lamotrigine doses. 
Response to LTG Therapy 
Seizure free Non-seizure free 
n= 39 is = 40 p-value 
Gender Male 56.4% _43,6% 
0.216 
Female 42.5% 57.5% 
Age at evaluation Mean 39.4 34.5 0.165 
Median 36.0 32.5 
Min 13 14 
Max 80 78 
Epilepsy syndrome IGE 20.5% 30.0% 0.332 
LRE 79.5% 70.0% 
Maximum dose (mg/day) Mean 180 294 < 0.001 
Median 150 300 
Min 100 150 
Max 400 600 
IGE = idiopathic generalised epilepsy; LRE = localisation related epilepsy. 
Statistical significance was determined by X2 test for gender, age and epilepsy 
syndrome, and Student's t-test for LTG maximum dose. The p-value represents 
the comparison between seizure free and non-seizure free groups. 
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5.1.4.2 Associations between polymorphisms in the ABCB1 and SCN2A genes 
and the response to lamotrigine monotherapy 
There was no significant difference in the genotype distributions of ABCB I c. 1236C>T, 
c. 2677G>T/A, c. 3435C>T and SCN2A c. 56G>A polymorphisms between the LTG 
cohort and the overall 400-strong study population (p > 0.05; TABLE 5.2). The 
distributions of ABCB1 c. 1236C>T, c. 2677G>T/A, c. 3435C>T and SCN2A c. 56G>A 
genotypes were similar between the seizure free and the non-seizure free patients (p > 
0.05; TABLE 5.3) and there was no significant association between the alleles or 
genotypes of common ABCB 1 and SCN2A polymorphisms and the response to LTG 
monotherapy (p > 0.05; TABLE 5.4). The distribution of ABCB I haplotypes is 
presented in TABLE 5.5. The major haplotypes of ABCB I in the LTG cohort were the 
T-T-T (38.8%) and C-G-C (36.9%; TABLE 5.5). There was no significant difference in 
the response to LTG treatment when common ABCBI haplotypes were compared with 
the T-T-T default reference haplotype (p > 0.05; TABLE 5.6) There was similarly no 
association between the major diplotypes in ABCB I and the response to LTG treatment 
(p > 0.05; TABLE 5.7). 
5.1.5 Discussion 
Overexpression of P-gp has been postulated to be one explanation for the poor response 
to AED treatment. Brain tissue from patients with medically intractable seizures has a 
high level of P-gp expression and several AEDs are believed to be transported by this 
protein (Tishler et al., 1995; Potschka et al., 2001; Marchi et al., 2004). LTG has been 
shown to be a substrate for P-gp (Potschka et al., 2001) and thus, it is possible that a P- 
gp-related mechanism might be responsible for any poor clinical response to LTG 
treatment. 
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TABLE 5.2. Genotype distributions of common SCN2A and ABCBI 
polymorphisms between the lamotrigine cohort and the overall 400-strong study 
population 
Genotype frequency 
Polymorphism Cohort Minor Ilelero Major p-value 
SCN2A c. 56G>A SSP 0.013 0.112 0.875 0.532 
LTG 0.025 0.140 0.835 
ABCB 1 c. 1236C>T SSP 0.245 0.470 0.285 0.657 
LTG 0.203 0.599 0.278 
ABCB 1 c. 2677G>T/A SSP 0.23 0.45 0.32 0.457 
LTG 0.10 0.52 0.30 
ABCB1 c. 3435C>T SSP 0.182 0.485 0.333 0.723 
LTG 0.177 0.532 0.291 
SSP = 400-strong study population (n = 400); LTG = LTG cohort (n = 79); Minor 
= homozygous of minor allele; Hetero = heterozygous of minor and major alleles; 
Major = homozygous of major allele. Statistical significance was determined by 
X2 test. Thep-value represents the comparison between LTG cohort and SSP. 
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TABLE 5.3. Comparison of the genotype distribution of common polymorphisms 
in SCN2A and ABCB 1 between seizure free and non-seizure free groups. 
Seizure free Non-seizure free p- 
Gene Polymorphism Genotype n=39 n=40 value 
SCN2A c. 56G>A GG 34 32 0.755 
GA 47 
AA 11 
ABCB 1 c. 1236C>T CC 12 10 0.605 
CT 21 20 
TT 6 10 
ABCB 1 c. 2677G>T GG 13 11 0.908 
GT 19 22 
TT 67 
TA 10 
ABCBI c. 3435C>T CC 770.985 
CT 21 21 
TT 11 12 
Statistical significance was determined by X2 test or Fisher's Exact test. The p- 
value represents the comparison of the genotype distribution between seizure 
free 
and non-seizure free groups. 
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TABLE 5.4. Logistic regression analysis of response to lamotrigine monotherapy on 
the basis of genotype and allele of common polymorphisms in SCN2A and AICB 1 
genes. 
Gene Polymorphism Genotype Allele Odds Ratio 95% Cl p-value 
SCN2A c. 56G>A GG vs not GG 1.70 0.50-5.74 0.393 
GAvsnotGA 0.54 0.14-2.01 0.357 
AA vs not AA 1.03 0.06-17.01 0.986 
GG vs AA 1.06 0.06 -17.71 0.966 
G vs A 0.66 0.22 -1.94 0.448 
ABCB 1 c. 1236C>T CC vs not CC 1.33 0.50-3.58 0.568 
CT vs not CT 1.17 0.48-2.82 0.732 
TT vs not TT 0.55 0.18-1.68 0.292 
CCvsTT 2.00 0.54-7.45 0.301 
C vs T 0.73 0.39-1.37 0.333 
ABCB 1 c. 2677G>T GG vs not GG 1.32 0.50-3.45 0.573 
GT vs not GT 0.78 0.32-1.88 0.577 
TT vs not TT 0.86 0.26-2.82 0.800 
GGvsTT 1.38 0.36-5.34 0.642 
G vs T 0.97 0.43-2.19 0.941 
ABCB 1 c. 3435C>T CC vs not CC 1.03 0.32-3.27 0.958 
CT vs not CT 1.06 0.44-2.56 0.905 
TT vs not TT 0.92 0.35-2.42 0.861 
CC vs TT 1.09 0.29-4.12 0.898 
C vs T 0.96 0.51-1.79 0.887 
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TABLE 5.5. The distribution of ABCB 1 haplotypes between seizure free (n = 39) 
and non-seizure free (n = 40) patients. 
Haplotype frequency 
ABCB 1 haplotype Seizure free Non-seizure free 
T-T-T 0.368 0.408 
C-G-C 0.393 0.346 
C-G-T 0.142 0.026 
T-G-C 0.054 0.078 
C-T-T 0.041 0.028 
T-T-C 0.001 0.014 
TABLE 5.6. Logistic regression analysis of response to lamotrigine monotherapy 
on the basis of ABCB 1 haplotype. Only haplotypes with a frequency of more than 
1% in both seizure free and non-seizure free patients were examined. 
ABCB 1 haplotype Odds ratio 
95% confidence 
interval p-value 
T-T-T 1.00 reference 
C-G-C 0.82 0.43 -1.57 0.559 
C-G-T 0.87 0.36-2.14 0.769 
T-G-C 1.42 0.46-4.44 0.545 
C-T-T 0.71 0.12-4.33 0.702 
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TABLE 5.7. Logistic regression analysis of response to lamotrigine monotherapy 
on the basis of major diplotype of the ABCB 1 gene. 
Diplotype of ABCB1* Odds Ratio 95% Cl p-value 
CC-GG-CC vs not CC-GG-CC 1.03 0.30-3.52 0.393 
CT-GT-CT vs not CT-GT-CT 1.30 0.52-3.27 0.580 
TT-TT-TT vs not TT-TT-TT 0.83 0.23-2.99 0.780 
CC-GG-CC vs TT-TT-TT 1.20 0.23-6.19 0.827 
*Diplotype arrangement: ABCB 1 c. 1236C>T-c. 2677G>T/A-c. 3435C>T. 
Variability in the expression and activity of P-gp can be influenced by polymorphisms 
in the encoding gene (Hoffineyer et al., 2000). Of the three most widely studied 
polymorphisms in ABCB 1, only the c. 2677G>T/A transition is known to produce an 
amino acid change which might in turn be associated with a functionally relevant 
phenotype (Cascorbi, 2006). The common polymorphisms of the ABCB 1 gene are 
strongly linked to each other (Kim et al., 2001; Tanabe et al., 2001; Tang et al., 2002; 
Tang et al., 2004), most likely because they exist within a single block of linkage 
disequilibrium. Accordingly, the association between common ABCB 1 polymorphisms 
and the response to LTG treatment was investigated both individually and in 
combination analyses using allele, genotype, haplotype, and diplotype of the ABCB 1 
gene. 
This study took advantage of an existing monotherapy comparison between VPA and 
LTG in order to isolate a cohort of newly diagnosed epilepsy patients treated with a 
known substrate of P-gp as monotherapy. This allowed the elimination of a number of 
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confounding factors which may have contributed to the conflicting results of previous 
investigations (Siddiqui et al., 2003; Tan et al., 2004a; Sills et al., 2005; Basic et al., 
2006; Kim et al., 2006). Evaluating the response to AED treatment without considering 
the spectrum of individual drugs to which the patients were exposed may have 
undermined the conclusions of previous studies. 
There is currently no firm evident to suggest that all clinically used AEDs are substrates 
for P-gp. This is clearly emphasised in recent studies of both CBZ (Owen et al., 2001; 
Potschka et al., 2001) and levetiracetam (Potschka et al., 2004). It is therefore unlikely 
that any changes in the expression or activity of P-gp resulting from ABCB i gene 
polymorphisms would influence the penetration of these AEDs into brain tissue. Hence, 
their inclusion in efficacy studies would weaken or possibly mask any evidence of 
association between genetic variants and response to AED treatment, particularly where 
significant numbers of CBZ and levetiracetam exposed patients are involved. In 
addition, AED polytherapy is commonly used in the management of patients with 
partially responsive epilepsy and this fact could also have affected study findings. The 
concomitant use of multiple AEDs may result in unpredictable interactions at the level 
of both DMEs and DTPs. Furthermore, some AEDs have been shown to stimulate the 
expression of P-gp (Weiss et al., 2003). Thus, drug-drug and drug-Pgp interactions 
could independently influence the response to AED treatment. This underlines the 
importance of performing such studies in patients with newly diagnosed epilepsy treated 
with AED monotherapy. 
There were no significant differences in the distribution of clinical factors such as age, 
gender and epilepsy syndromes between seizure free and non-seizure 
free groups. This 
would indicate that any variability arising from clinical factors was equally 
proportioned. The significantly higher daily dose of LTG in the non-seizure 
free group 
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is symptomatic of ongoing titration and excludes any suggestion of undertreatment in 
these poor-reponders. Almost 50% of the patients in the LTG cohort failed to achieve 
seizure free status within the first 12 months of LTG monotherapy. This percentage is 
higher than the value previously reported in newly diagnosed epilepsy patients (Kwan & 
Brodie, 2000). Differences in the duration of follow-up may explain this discrepancy. 
No significant association was observed between ABCB 1 c. 1236C>T, c. 2677G>T/A 
and c. 3435C>T polymorphisms and the response to LTG treatment, irrespective of 
whether analyses were based on allele, genotype, haplotype or diplotype frequencies. 
These findings would support the observations reported previously by Tan et al. 
(2004a), Sills et a!. (2005) and Kim et a!. (2006). If P-gp expression and activity are 
genuinely influenced by common polymorphisms in the ABCB I gene, the current study 
findings would question the role of P-gp in mediating resistance to treatment with LTG. 
Either the distribution of LTG in human brain is not significantly affected by P-gp or 
the function of P-gp at the BBB is not influenced by common ABCB I polymorphisms. 
However, there has been a suggestion that pathological overexpression of P-gp in the 
epileptic focus may overcome any genetically determined variability (Sills et al., 2005). 
In addition, it is reasonable to speculate that LTG may also be transported by other, as- 
yet-unidentified DTPs (Cascorbi, 2006). Other DTPs could potentially compensate 
for 
any deficiency in the function of P-gp related to genetic variability. As such, changes in 
P-gp activity secondary to polymorphic expression of the ABCB 1 gene might not be 
demonstrable in a clinical study of drug efficacy. One must also appreciate that the 
response to LTG treatment can be influenced by a multitude of additional 
pharmacokinetic and pharmacodynamic factors, such as the conformation of voltage- 
gated sodium channels and the activity of glucuronidation enzymes. 
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For AEDs such as LTG, which act predominantly on voltage-gated sodium channels, 
changes in the structure or function of the sodium channel may significantly influence 
the response to treatment. In this study, the SCN2A c. 56G>A polymorphism did not 
appear to be associated with the response to LTG treatment. This might suggest that the 
SCN2A c. 56G>A polymorphism does not significantly affect the expression or function 
of the Na,, 1.2 protein in the neuronal tissue or its sensitivity to blockade by LTG. 
However, it is also recognised that LTG can act on other voltage-gated sodium 
channels, potentially compensating for any functional or structural defect in the Nal. 2 
protein. 
This investigation failed to demonstrate any association between the ABCBI 
c. 1236C>T, c. 2677G>T/A, c. 3435C>T and SCN2A c. 56G>A polymorphisms and the 
response to initial LTG monotherapy. Some common issues to pharmacogenetic studies 
that may influence their findings should be considered, especially the consensus of 
phenotype criteria. At the very least, it is important to recognise that results are strongly 
influenced by the duration of follow-up which was, in this case, 12 months of LTG 
therapy. The duration of follow-up can influence the number of patients who are 
categorised as seizure free and non-seizure free. Hence, the conclusions of any such 
study should be considered alongside limitations of study design. 
5.1.6 Conclusion 
There was no evidence of any association between the prevalences of ABCB 1 
c. 1236C>T, c. 2677G>T/A, c. 3435C>T and SCN2A c. 56G>A polymorphisms and the 
response to LTG monotherapy within the first 12 months of treatment. This study 
included only a small number of patients which could have had a significant bearing on 
the results. The influence of ABCB 1 and SCN2A polymorphisms should be investigated 
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prospectively in a considerably larger cohort of patients with newly diagnosed epilepsy 
and treated with AED monotherapy in order that a more definitive conclusion can be 
reached. In the meantime, any functional significance of ABCB 1 and SCN2A gene 
variants on pharmacoresistant epilepsy remains unclear. 
5.2 Genetic Predictors of Lamotrigine Optimal Dose 
5.2.1 Introduction 
AED dosing is typically based on a trial and error approach allied to the individual 
clinical experience. In the absence of a rational approach to identify optimal dose, the 
duration of uncontrolled seizures may be prolonged and some patients may be exposed 
to unnecessarily high AED doses. A wide interindividual variability in dosage 
requirement has been documented for most AEDs. For example, the effective doses 
leading to seizure freedom with CBZ range between 200 and 1600 mg/day, and for 
VPA between 200 and 2500 mg/day (Kwan & Brodie, 2001). Differences in the 
required dose between individuals are believed to be linked to genetic variability in 
genes associated with AED pharmacodynamics and pharmacokinetics. Genetic variants 
that influence dosing regimen have been reported for both PIT and CBZ, with 
maximum doses of these drugs associated with polymorphisms in the SCN1A and 
CYP2C9 genes (van der Weide et al., 2001; Tate et al., 2005). 
A study by Kwan and Brodie (2001) reported that a modest dose of LTG (100 to 200 
mg/day) can provide complete seizure control in a large number of patients. However, 
some patients may require doses up to 600 mg/day to achieve a similar degree of 
efficacy. Interindividual variability in LTG dosage requirement is likely to be 
influenced by both pharmacodynamic and pharmacokinetic factors. Although the 
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previous study (section 5.1) failed to demonstrate any association between the response 
to LTG therapy and common SCN2A and ABCB 1 polymorphisms, it did not directly 
investigate any association between these genetic variants and LTG dose. It is important 
to note that the response to LTG treatment is not correlated with plasma concentration 
or dose (Kilpatrick et al., 1996; Mahmood et al., 1998). 
Thus, it is reasonable to speculate that the SNPs which were studied in the previous 
section may be able to influence the LTG dose requirement. In this section, these 
polymorphisms were investigated in relation to the dose of LTG, rather than its efficacy. 
5.2.2 Aims 
This study was designed to evaluate the association between common polymorphisms in 
the SCN2A and ABCB 1 genes and the optimal dose of LTG. Basic clinical factors such 
as age and gender were also included as potential predictors of optimal dose. 
5.2.3 Methods 
5.2.3.1 Definitions 
Optimal dose was defined as the final dose given to a patient that successfully 
maintained optimal seizure control without intolerable side effects and which was 
maintained throughout the period of follow-up without the need 
for adjustment. Optimal 
seizure control was defined as seizure freedom for at least 1-year on LTG monotherapy. 
5.2.3.2 Study subjects 
From the overall 400-strong study population, a total of 118 patients were 
identified as 
being treated with LTG monotherapy. Through retrospective evaluation of individual 
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patient records, 94 of these patients were identified as having achieved seizure free 
status for a period of at least 1 year. These patients included those who achieved seizure 
free within and after the first 12 months of LTG initiation and those received LTG as a 
second line monotherapy AED. Complete information on LTG dosing regimen and 
other basic clinical data was available for all of these individuals. None was 
concomitantly treated with any other medication (AEDs and non-AEDs) that might 
have influenced LTG metabolism. 
5.2.3.3 Genotype analysis and phenotype assessment 
Genotypes of the common SCN2A and ABCB 1 gene polymorphisms were identified 
using the PCR-RFLP assays described in Chapter 3. Genotype determination completed 
for the SCN2A polymorphism on February 2006 and for ABCB 1 polymorphisms on 
May 2006. Phenotype assessment was started on June 2006 and completed on October 
2006. 
5.2.3.4 Statistical analyses 
Clinical and demographic differences between the LTG cohort and the 400-strong study 
population were investigated using XZ test. The distribution of age was compared using 
Student's t-test. Differences in the mean LTG optimal dose between categorical 
variables (gender and epilepsy syndromes) were compared by t-test or analysis of 
variance (ANOVA), as appropriate. The association between age and optimal dose of 
LTG was evaluated using Pearson's correlation test. Evidence of genotype selection 
bias was investigated by comparing the distribution of each polymorphism between the 
LTG cohort and the overall 400-strong study population. 
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To fit the genetic information into the regression database, a score was assigned to the 
genotype of each polymorphism according to the number of substituting alleles; no 
substituting alleles was given score 1, one substituting allele was given score 2 and two 
substituting alleles was given score 3. Interaction between polymorphisms was 
investigated by Pearson's correlation test and represented by the multiplicative value of 
polymorphism scores. 
Candidate predictors included age, gender and the genotypes of each polymorphism. 
The influence of each predictor on LTG optimal dose was analysed individually using 
univariate linear regression analysis and, in combination, using multivariate linear 
regression analysis. An additive model was used in the analysis with an assumption that 
the combined effects of genetic alleles at two or more gene loci are equal to the sum of 
their individual effects. SNP interactions were added to the multivariate model and 
acted as a non-linear component. Predictors were added or removed using a stepwise 
approach, depending on the degree of impact indicated by the respective p-value. Data 
transformation from linear to natural logarithmic form was employed to optimise 
regression modelling. Coefficients of regression of the predictors which significantly 
influenced the model were used to construct a predictive equation for LTG optimal 
dose. Pearson's correlation test was used to evaluate the relationship between the 
observed optimal doses and the optimal doses predicted by the equation. Pearson's 
correlation value (r) of more than 0.8 indicated a strong correlation between variables. 
A p-value of less than 0.05 indicated a significant predictor effect. Both 
Presiduab which 
represented the p-value of residual analysis, and r1, which represented the goodness-of- 
fit, indicated how well the model fitted the data. 
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5.2.4 Results 
5.2.4.1 Patient demographics and lamotrigine dosage regimen 
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Demographic information for patients in the LTG cohort is presented in TABLE 5.8. 
Distribution of gender (p = 0.887) and epilepsy syndromes (p = 0.429) were comparable 
with the 400-strong study population. The median age of patients in the LTG cohort was 
38.5 years (range 16.5 to 85). 
TABLE 5.8. Patient demographics and lamotrigine doses. 
LTG Cohort 
(n = 94) 
Gender 
400-strong study 
Population p-value 
(n = 400) 
Male 51.0% 50.3% 0.887 
Female 49.0% 49.7% 
Age (year) Median 38.5 40 0.460 
Min 16.5 14 
Max 85 85 
Epilepsy syndrome IGE 35.1% 29.5% 0.429 
LRE 60.6% 67.5% 
UNC 4.3% 3.0% 
Optimal dose (mg/day) Median 200 
Min 50 
Max 600 
Min = minimum, Max = maximum; IGE = idiopathic generalised epilepsy; 
LRE = 
localisation related epilepsy; UNC = unclassified epilepsy. Statistical significant 
was determined by Student's t-test or X2 test, where appropriate. 
The p-value 
represents the comparison between the LTG cohort and 
400-strong study 
population. 
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All of the patients received LTG on a twice-daily basis with total daily dose ranging 
from 50 to 600 mg. Female patients received higher LTG doses in order to achieve 
optimal seizure control (male vs female, 201 vs 279 mg/day respectively, p=0.002; 
FIGURE 5.1). There was no significant association between LTG dose and age of the 
patients (r = -0.096, p=0.356; FIGURE 5.2) or epilepsy syndromes (p = 0.674; 
FIGURE 5.4). 
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FIGURE 5.1. Distribution of lamotrigine optimal dose between genders. 
Statistical significance was determined by Student's t-test. Dotted lines represent 
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FIGURE 5.2. Distribution of lamotrigine optimal dose and age at achieving 12 
months of seizure freedom. Correlation was examined by Pearson's correlation 
test. 
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idiopathic generalised epilepsy; LRE = localisation related epilepsy; UNC = 
unclassified epilepsy. 
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5.2.4.2 Genetic predictors of lamotrigine optimal dose 
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There were no significant differences in the distribution of common polymorphisms in 
the ABCB 1 and SCN2A genes between the LTG cohort and the overall 400-strong 
study population (TABLE 5.9). Three potential SNP interactions were identified 
between ABCB 1 c. 1236C>T and c. 2677G>T/A (r = 0.751, p<0.00 1), c. 1236C>T and 
c. 3435C>T (r = 0.549, p < 0.001), c. 2677G>T/A and c. 3435C>T (r = 0.618, p < 0.001). 
Univariate linear regression analysis demonstrated that single predictors for LTG 
optimal dose included gender (p = 0.002) and genotype of ABCB 1 c. 1236C>T (p = 
0.010). However, the strength of prediction was weak in both cases (r2 < 10%; TABLE 
5.10). In an effort to improve the strength of prediction, the candidate predictors were 
evaluated using a multivariate linear regression analysis (TABLE 5.11). The basic 
regression model (Model 1) represents the combination effects of all candidate 
predictors and showed a better overall model fit (? = 11.2%, p=0.023) than any 
individual univariate analysis. Stepwise multivariate regression analysis identified 
gender and the SNP interaction between ABCB1 c. 1236C>T and c. 3435C>T as the 
optimal combination of predictors (r2 = 14.1%, p < 0.001; Model 2). Transformation of 
optimal dose data from linear to natural logarithmic form further improved the overall 
model fit (r2 = 16.6%, p<0.001; Model 3). A predictive equation for LTG optimal dose 
was constructed from the regression constant and coefficients of Model 3 and is 
presented below: 
1nODcrG = 4.68 + 0.32*Gender + 0.05 *(AßCß 1 c. 1236C>T*c. 3435C>T) 
where; InODLTG = natural log of LTG optimal dose (mg/day); scores 
for gender, 1= 
male, 2= female; scores for ABCB 1 c. 1236C>T and c. 3435C>T genotypes, 
I= C/C, 2 
= C/T, 3= T/T. 
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A statistically significant correlation was observed between predicted and observed 
LTG optimal doses (p < 0.001), however, the strength of the association was modest (r 
= 0.400,95%CI 0.22 to 0.56; FIGURE 5.4). 
TABLE 5.9. Comparison of distributions of common SCN2A and ABCBI 
polymorphisms between the lamotrigine cohort and the 400-strong study 
population. 
Genotype frequency 
Polymorphism Cohort Minor Hetero Major p-value 
SCN2A c. 56G>A SSP 0.013 0.112 0.875 0.974 
LTG 0.010 0.106 0.884 
ABCB 1 c. 1236C>T SSP 0.245 0.470 0.285 0.300 
LTG 0.170 0.521 0.309 
ABCB1 c. 2677G>T/A SSP 0.230 0.450 0.320 0.147 
LTG 0.140 0.500 0.360 
ABCB 1 c. 3435C>T SSP 0.182 0.485 0.333 0.305 
LTG 0.181 0.564 0.255 
SSP = 400-strong study population; LTG = LTG cohort (94 patients); Minor = 
homozygous for minor allele; Hetero = heterozygous for minor and major alleles; 
Major = homozygous for major allele. Statistical significance was determined by 
X2 test. Thep-value represents comparison of LTG and SSP data. 
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TABLE 5.10. Summary of univariate regression analysis of variables predicting 
the optimal dose of lamotrigine. 
Predictor Coef. r= (% p-value 
Gender 78.31 9.2 0.002 
Age -0.72 0.9 0.358 
SCN2A c. 56G>A -35.07 0.0 0.612 
ABCB 1 c. 1236C>T 47.72 5.9 0.010 
ABCB 1 c. 2677G>T/A 27.81 1.3 0.143 
ABCB1 c. 3435C>T 29.01 1.3 0.135 
The relative impact of each predictor is presented by the coefficient value 
(Coef. ). 
The goodness-of-fit value (r2) indicates how well the individual predictors 
fit the 
model. The p-value indicates the probability of the predictor influencing LTG 
optimal dose. 
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TABLE 5.11. Summary of hierarchical multivariate regression analysis of 
variables predicting the optimal dose of lamotrigine. 
Model 3 
Modell Model 2 
Predictor (natural log) 
Coef. p-value Coef. p-value Coefi p-value 
Constant 176.30 0.121 74.79 0.077 4.68 <0.001 
Gender 83.11 0.001 76.13 0.002 0.32 0.001 
Age -0.14 0.853 ---- 
SCN2A c. 56G>A -45.15 0.207 ---- 
ABCB 1 c. 1236C>T -18.12 0.791 ---- 
ABCB 1 c. 2677G>T/A 57.51 0.499 ---- 
ABCB1 c. 3435C>T -100.0 0.382 ---- 
ABCB 1 1236C>T*2677G>T/At 8.87 0.813 
ABCB 1 1236C>T*3435C>Tt -4.13 0.923 12.46 0.015 0.05 0.009 
ABCB 1 2677G>T/A*3435C>Tt 22.48 0.591 
r2 (/) 
Presidual 
11.2 14.1 16.6 
0.023 <0.001 <0.001 
The relative impact of each predictor is presented by the coefficient value (Coef. ). 
The p-value indicates the probability of the predictor affecting LTG optimal dose. 
The goodness-of-fit value (r) indicates how well the predictors fit the model. The 
significance of model fitting is represented by the p-value of residual analysis 
(presidul)" `-' mark represents predictors that were eliminated in the stepwise 
regression analysis. tSNP interaction between predictors. 
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5.2.5 Discussion 
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One of the biggest challenges in the treatment of epilepsy is the identification of the best 
dose of any given AED for a particular patient. Conventionally, optimal doses are 
established through a trial and error method. During the period of dosing adjustment, 
quality of life may be impacted by either under-treatment or over-treatment. This 
concern applies to all epilepsy patients and all AEDs, including LTG. Although 
complete control of seizures can be achieved with doses of 100 to 200 mg/day of LTG 
in a large number of patients, higher doses of up to 600 mg/day may be required by 
some individuals (Kwan & Brodie, 2001). Continuous titration of LTG may be 
undertaken in an attempt to achieve complete seizure control and this may expose non- 
responsive patients to unnecessarily high doses of LTG, increasing the risk of adverse 
effects and the cost of treatment. Prediction of LTG optimal dose may be useful in 
guiding dosing strategies and could improve the usage of LTG by employing slow 
titration and low target doses in potentially sensitive individuals and a quicker titration 
and higher target doses in less sensitive patients. 
In addition to conventional therapeutic drug monitoring, a genetic-based approach to the 
optimisation of AED dose may be useful (Tate et a!., 2005; Ferraro & Buono, 2005). 
Potential genetic predictors of optimum dose are genes which encode proteins involved 
in the pharmacokinetics and pharmacodynamics of LTG such as DMEs, DTPs and 
voltage-gated ion channels. LTG has been suggested to be a substrate 
for P-gp 
(Potschka et al., 2002) and its principle mechanism of action is believed to 
be blockade 
of sodium channels (Zona & Avoli, 1997; Kohling, 2002). Therefore, polymorphisms 
in 
the ABCBI gene that encodes P-gp and the SCN2A gene which encodes the Naj. 2 
sodium channel were evaluated as potential predictors of LTG optimal 
dose. Basic 
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clinical factors such as age and gender were included in the evaluation as additional 
candidate predictors. 
This study failed to demonstrate any association between age and LTG optimal dose. 
This is not surprising given that a previous report suggested that LTG pharmacokinetics 
were not significantly influenced by age in an adult population (Hussein & Posner, 
1997). The SCN2A c. 56G>A polymorphism was similarly unrelated to LTG optimal 
dose when assessed either individually or in combination with other candidate 
predictors. If the function of the Na,, 1.2 sodium channel is genuinely influenced by the 
SCN2A c. 56G>A polymorphism, then it is possible any effect of this polymorphism on 
LTG dosage requirement was masked by the interaction of LTG with other sodium 
channel subtypes (Zona & Avoli, 1997; Kohling, 2002). A polymorphism in the SCNIA 
gene has been associated with maximum doses of both PHT and CBZ (Tate et al., 2005) 
and plasma concentrations of PHT at maintenance dose (Tate et al., 2006). It is 
reasonable to suggest that this particular polymorphism in the SCN1A gene should be 
included in any future search for candidate predictors of LTG optimal dose. 
Gender and the interaction between ABCB 1 c. 1236C>T and c. 3435C>T polymorphisms 
were shown to possess the greatest predictive capacity for the optimal dose of LTG 
when employed together in a multivariate regression model. flow gender might 
influence the LTG optimal dose is unclear, as the pharmacokinetics of LTG are not 
believed to differ between males and females (Hussein & Posner, 1997). It is possible 
that this observation is based on differences in body weight, fat composition, or in sex 
hormone activity between the genders (Gallagher et al., 1996; Tanaka, 1999). Females 
have a higher fat composition than males (Lemieux et al., 1993; Gallagher et al., 1996), 
and this may increase the Vd of lipophilic drugs (Mangoni & Jackson, 2003; Thomson, 
2004). LTG is highly lipophilic in nature (Mashru et a!., 2005) and, therefore, a higher 
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dose may be required by females to achieve a similar target concentration. 
Unfortunately, the current study did not include measures of body weight, or further 
investigate the effect of fat composition, which may have been enlightening with regard 
to the relationship between dose and gender. 
The association between the ABCB 1 c. 1236C>T polymorphism and LTG dose was 
significant, with or without the- presence of gender information. Although the 
c. 1236C>T polymorphism does not result in an amino acid substitution in the encoded 
protein, this polymorphism may be linked to an as yet unidentified causal variant which 
could in theory influence the activity of P-gp or indeed any other LTG-related 
pharmacokinetic and pharmacodynamic factor. Previous studies exploring the 
functional significance of the ABCB 1 gene polymorphisms on drug pharmacokinetics 
have been largely inconclusive (Tanabe et al., 2001; Goto et al., 2002; Nakamura et al., 
2002), with differences in substrate and study design believed to be the major 
contributing factor to the conflicting findings. The c. 3435C>T substitution is the most 
studied polymorphism in the ABCB I gene. There is no general consensus with regard to 
the functional significance of ABCBI variants associated with the c. 3435C>T 
polymorphism. The 3435T allele has been associated with both higher and lower 
expression of P-gp depending on substrate studied (Hoffmeyer et al., 2000; Nakamura 
et al., 2002). Elevation in P-gp expression is believed to decrease absorption and 
increase elimination of many drugs. These effects may explain the association between 
the 3435T allele and reduced concentrations of fexofenadine (Kim et al., 2001) and also 
the poor response to chemotherapy (Sohn et al., 2006). As the 3435C>T and 
1236C>T 
polymorphisms are strongly under linkage disequilibrium (Kim et al., 2001; Tang et al., 
2002; Tang et al., 2004), a similar mechanism may also explain the association 
between 
LTG dose and the 1236T allele. This would, in turn, explain why the association 
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between the c. 1236C>T polymorphism and optimal dose of LTG was much stronger 
when the c. 3435C>T polymorphism was included in the multivariate analysis. 
The small number of participants and the retrospective nature of this study may limit the 
potential significance of the findings. A larger prospective study in newly diagnosed 
epilepsy must be undertaken before the clinical implications of these results can be 
realistically assessed. With respect to LTG therapy, this study provides some 
information which may guide future dosing decisions. The combination of ABCB 1 
c. 1236C>T-c. 3435C>T SNP interaction and gender explains approximately 17% of the 
interindividual variability in LTG optimal dose and may be an important clinical 
indicator of whether a patient will require low or high doses of LTG to achieve 
complete seizure control. This could potentially prevent the under-treatment of 
responsive individuals or reduce the risk of unnecessary exposure to high doses of LTG 
in patients who are non-responders. Despite this encouraging finding, more candidate 
predictors are required to strengthen the model. These should include polymorphisms of 
genes that encode other sodium channel subunits and, given that LTG metabolism, is 
primarily mediated by UGT1A4, any known variants in the UGT1A4 gene (Magdalou 
et al., 1992; Rambeck & Wolf, 1993; Vashishtha et al., 2001). 
5.2.6 Conclusion 
This study suggests that patient gender and the genotypes of ABCB 1 c. 1236C>T and 
c. 3435C>T polymorphisms are useful in predicting the LTG optimal 
dose. In contrast, 
there was no significant association between a common polymorphism 
in the SCN2A 
gene and doses of LTG. The use of genetic markers in predicting LTG optimal 
dose 
may be advantageous in any future dose selection strategies. This study 
has also added 
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further support to the proposed involvement of the ABCB 1 gene and P-gp in epilepsy 
management. 
5.3 The Effects of ABCB1 Gene Polymorphisms on the 
Pharmacokinetics of Lamotrigine Monotherapy 
5.3.1 Introduction 
The single and multiple dose pharmacokinetics of LTG, when used as both 
monotherapy and polypharmacy have been studied in healthy volunteers and patients 
(Jawad et al., 1987; Ramsay et al., 1991; Hussein & Posner, 1997). In general, drug 
pharmacokinetics are affected by both extrinsic factors, such as concomitant 
medications, mealtime and composition, chronopharmacology, and lifestyle, and 
intrinsic factors, such as gender, age, body size, renal and hepatic function, phenotype 
and disease conditions. The influence of some of these factors on the interindividual 
variability in LTG pharmacokinetics has been explored previously, for example, 
comedication with other AEDs and renal impairment (Jawad et al., 1987; Ramsay et al., 
1991; Wooton et al., 1997). 
Common and clinically significant pharmacokinetic parameters include clearance, Vd 
and Ka. In healthy volunteers, the total apparent clearance and renal clearance of LTG 
have been estimated at 0.5 and 0.043 ml/min/kg, respectively (Cohen et al., 1987; 
Wooton et al., 1997). Renal impairment does not influence the clearance of LTG 
(Wooton et al., 1997). LTG has clinically important pharmacokinetic interactions with 
other AEDs. Concomitant administration of LTG with enzyme-inducing AEDs (PUT, 
CBZ, primidone or PB) increases the clearance of LTG through induction of UGT 
enzymes (Jawad et al., 1987; Ramsay et al., 1991), whereas co-medication with VPA 
Chapter 5: Pharmacogenetics of Lamotrigine 213 
decreases the clearance of LTG through inhibition of glucuronidation (Jawad et a!., 
1987; Patsalos, 1999; Perucca, 2001; Bazil & Pedley, 2003). Consequently, the LTG 
concentration/dose ratio can be altered by interactions with other AEDs. LTG 
concentrations can also be affected by oral contraceptives (Sabers et a!., 2001), which 
are believed to induce LTG glucuronidation. The apparent Vd has been reported in the 
range of 1.14 to 1.36 1/kg (Cohen et a!., 1987; Ramsay et a!., 1991; Hussein & Posner, 
1997; Wooton et a!., 1997). No significant relationship has been identified between the 
pharmacokinetic parameters of LTG and either age or gender in adult population 
(Hussein & Posner, 1997). However, in special populations such as pregnancy, the 
clearance of LTG is higher in the second and third trimesters when compared with the 
preconception and postpartum periods (Tran eta!., 2002; Petrenaite et a!., 2005). 
To further understand interindividual variability in LTG pharmacokinetics, additional 
factors should be considered. These should perhaps include genetic variants of P-gp 
since LTG has been suggested to be a substrate for P-gp-mediated transport (Potschka et 
al., 2002). As P-gp is significantly expressed in many organs related to drug absorption 
and elimination (Kim, 2002a), alteration in the activity of P-gp may consequently 
influence the pharmacokinetics of LTG. The expression and function of P-gp has been 
associated with polymorphisms in the encoding gene, ABCB I (Hoffineyer et a!., 2000). 
The ABCB 1 gene has several common polymorphisms including the c. 1236C>T, 
c. 2677G>T/A and c. 3435C>T transitions. However, conflicting results have been 
reported regarding the association between these polymorphisms and their respective 
phenotypes (Hoffmeyer et al., 2000; Kim et a!., 2001; Gerloff et a!., 2002; Johne et al., 
2002; Yates et a!., 2003). 
In the current study, the effects of ABCB 1 c. 1236C>T and c. 3435C>T polymorphisms 
on the pharmacokinetics of LTG monotherapy were examined by utilizing plasma LTG 
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concentration data obtained during a head-to-head monotherapy trial of LTG and VPA 
in newly diagnosed epilepsy patients (Stephen et al., 2007). LTG pharmacokinetic 
parameters were estimated using a population pharmacokinetic approach. A similar 
approach has been used to examine the pharmacokinetics of other AEDs (Ingwersen et 
al., 2000; Jiao et al., 2003). 
5.3.2 Aims 
The aim of this study was to perform an exploratory, retrospective evaluation of: (1) the 
population pharmacokinetics of LTG monotherapy in newly diagnosed epilepsy 
patients; and (2) the influence of ABCB 1 c. 1236C>T and c. 3435C>T polymorphisms 
on LTG pharmacokinetic parameters such as the oral clearance (CL/F; where F= 
bioavailability), volume of distribution (Vd/F) and Ka. 
5.3.3 Methods 
5.3.3.1 Study subjects 
Subjects were identified from the 400-strong study population. A total of 118 patients 
were identified as treated with LTG monotherapy. All of these patients were drawn 
from on going head to head monotherapy trial comparing LTG with VPA in newly 
diagnosed epilepsy (Stephen et al., 2007). Study visits were scheduled every 4 to 6 
weeks, at which demographic data such as age, gender and body weight were 
documented, efficacy and tolerability was recorded, and venous blood samples were 
obtained. A total of 50 patients had sufficient demographic, pharmacokinetic and 
genotypic data to be included in the pharmacokinetic analysis. Routine biochemical data 
representing the level of organ function were not included because blood samples were 
not obtained for this purpose. 
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5.3.3.2 Blood sampling 
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The mean number of blood samples obtained from each patient"was 3 (range I to 4). 
Each of these samples was taken at a different study visit. Blood samples obtained in 
this study were collected at a steady-state concentrations between 0.9 to 13.5 hours post 
dose (mean 3.8; median 3.0). Plasma was separated from whole blood by centrifugation 
at 800 xg for 10 minutes and was stored below -10°C until required for analysis. In 
total, 156 blood samples were available for drug concentration measurement. 
5.3.3.3 ABCB1 c. 1236C>T and c. 3435C>T polymorphism analysis and 
phenotype assessment 
Genotypes of common ABCB 1 gene polymorphisms were identified using the PCR- 
RFLP assays described in Chapter 3. Genotype determination completed for ABCB 1 
polymorphisms on May 2006. Phenotype assessment was started on November 2006 
and completed on March 2007. 
5.3.3.4 Lamötrigine assay 
The LTG concentration was determined by a modified version of the method described 
by Kilpatrick et al. (1996). 
Standards: Blank plasma obtained from drug-free healthy volunteers was used as a 
diluent for the stock and standard solutions. LTG stock solution was prepared by 
dissolving 20 mg of LTG in 20 ml of methanol. The stock solution was then diluted to 
10 mg/I LTG with blank plasma. Further dilution of the 10 mg/I LTG solution with 
blank plasma was required to achieve the full range of calibration standard solutions 
(1, 
2.5,5,7.5 and 10 mg/1). The I mg/I calibration standard solution was also used as a 
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quality control standard. Internal standard solution (2 mg/1) was prepared by dissolving 
1 mg of BWA725C in 1 ml of methanol and diluting to 500 ml with ethyl acetate. The 
calibration and internal standard solutions were stored at -20°C for up to seven days. 
Sample preparation: A 10 µl aliquot of the internal standard solution and 50 µl of 2M 
sodium hydroxide were added to 100 µl of calibration standard solutions (1,2.5,5,7.5 
and 10 mg/I LTG), quality control solution (1 mg/1) and patient plasma samples alike. 
The calibration standards were used to construct a linear calibration plot that was then 
employed to estimate LTG concentrations in the patient samples. Three of quality 
control standards were included in each batch analysis to determine and monitor intra- 
and inter-assay reproducibility. 
LTG extraction: LTG was extracted from standards and patient samples into ethyl 
acetate under alkalinised conditions. A total of 1 ml of ethyl acetate was added to both 
standards and samples before vortex-mixing for 10 seconds. The organic layer was 
separated from the aqueous layer by centrifugation at 12 100 xg for 30 seconds. The 
organic layer was removed into a conical centrifuge tube, and the ethyl acetate 
evaporated using vacuum centrifuge (Heto Maxi Dry Plus). The residue was 
reconstituted with 300 µl of flow solvent. The flow solvent consisted of hexane, ethanol 
and 35% ammonia solution in a ratio of 79.75/20/0.25 by volume. Reconstituted 
standards and samples were transferred to autosampler microvials before 
chromatography. 
High-performance liquid chromatography: Chromatography was carried out at room 
temperature (20°C) on a Zorbax sil normal-phase column (250 x 4.6 mm). The 
chromatographic system consisted of a Shimadzu LC-IOAT pump, a Shimadzu SIL-9A 
autoinjector and a Shimadzu SPDF-6A ultraviolet spectrophotometer. The injection 
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volume was set at 100 µl. Flow rate was 1.75 ml/min throughout. The detector was set 
at wavelength 306 nm with aI second rise time. The lower limit of detection was 0.25 
mg/1 LTG. The intra-assay and inter-assay coefficients of variation were <4% and <6% 
at 1 mg/I LTG, respectively. 
Calculations: Chromatograms were recorded and integrated on a- Jones 
Chromatography JCL6000 chromatography data system (Crawford Scientific, 
Strathaven, UK). LTG concentrations were determined by comparison of peak height 
ratios of analyte to internal standard, quantified in relation to volume, and expressed in 
mg/l. 
5.3.3.5 Database construction 
Details of the LTG dosage regimen, the time of last dose and the time of blood sampling 
were recorded in a specific database that could be read by NONMEM® (Beal & Sheiner, 
1992). All patients received a twice-daily LTG regimen, which is believed to 
be 
associated with optimal compliance. Where the time of the previous evening dose was 
not available, a standardised dosing interval of 12 hours was assumed. The time at 
which the morning and evening doses were taken is required because daily LTG 
doses 
may not be divided equivalently. A scoring system was employed to 
incorporate 
categorical data into the database, such as, gender (1 = female; 0= male), and genotypes 
of the ABCB 1 c. 1236C>T and c. 3435C? T polymorphisms (0 = C/C; 1= 
C/T; 2= T/T). 
5.3.3.6 Population pharmacokinetic analysis 
The population pharmacokinetic analysis of LTG was performed 
by the NONMEM°D 
software package, version V, level 1.1 (GloboMax L. L. C., Hanover, 
USA). NONMEM 
subroutines ADVAN2 and TRANS2 were specified to fit a model with 
first-order 
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absorption and first-order elimination to the LTG concentration data. The first-order 
conditional estimation (FOCE) algorithm was used throughout the modelling procedure. 
FOCE uses conditional estimates of the random interindividual variability while 
estimating the population parameters. The choice of a structural pharmacokinetic model 
was based on prior knowledge of LTG disposition and preliminary data from the present 
study. 
The base model (without any covariates) was initially used to describe LTG plasma 
concentration-time data and to obtain initial estimates of CL/F, Vd/F and K,. Covariate 
modelling in NONMEM® was undertaken using the following general model structures: 
Base model: TVCL = OCL 
Linear model: TVCL = OCL* WT 
Linear model with intercept: TVCL = OCL*(1 + OWT *(WT-median WT)) 
O 
Nonlinear model: TVCL = OCL*(WT/median WT) "fww 
where: TVCL is the typical population estimate of CUF; 0 is the population parameter 
estimate; WT is the body weight. 
Typical values (TVCL, TWd and TVKa) represent the population estimates of CL/F, 
Vd/F and Ka, respectively. For each patient, the magnitude of interindividual variability 
in parameters, such as CL/F, was modelled as follows: 
CLL = TVCL*exp'b'c` 
where: CLj is the value of CL/F for the j`h patient; TVCL is the typical population 
estimate of CL/F; and rl;, cL was assumed to be a random 
Gaussian variable with zero 
mean and variance 0CL2 that distinguished the j`h patient's parameter from the population 
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estimate as predicted by the model. A similar model was used to estimate VIF. 
Individual estimates of CL/F and Vd/F were obtained from individual Tlj estimates which 
were obtained as part of the FOCE analysis. 
The magnitude of the residual variability in plasma concentrations was modelled using 
3 error models: 
Additive error model: Cobs, ij = Cprcd, ij + error, 
Proportional error model: Cobs, ij = Cprcd, ij (1 + error2) 
Combined error model: Cobs, ij = Cpred, ij (1 + error2) + error, 
where: Cobs, y is the ith observed LTG concentration in the j`h patient; CPrca, ;j is the 
predicted LTG concentration corresponding to the ih observed LTG concentration for 
the j`h patient; error, is the additive error; error2 is the proportional error and the 
magnitude of error was assumed to be a random Gaussian variable with mean of zero 
and variance a2. Additive, proportional and combined error models were tested in this 
study. 
The potential influence of clinical factors on the population parameter estimates was 
first examined subjectively using scatterplots of individual estimates of CL/F against the 
available clinical factors. Generalised Additive Modelling (GAM) was then used as an 
additional screening tool to objectively evaluate the effect of univariate and multivariate 
factors on the base model. The Akaike Information Criterion (AIC) value produced by 
the GAM analysis was compared between the model that included clinical factors and 
the base model. A lower AIC value indicates a better goodness-of-fit of the statistical 
model to the data. 
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Various structural and covariate models were analysed using NONMEMS. Covariate 
models included body weight and ABCB 1 c. 3435C>T and ABCBI c. 1236C>T 
polymorphisms. Hierarchical models were compared by a likelihood ratio test. A 
decrease in the value of objective function (OBJF) as a result of structural 
pharmacokinetic remodeling or the inclusion of a parameter indicates a better fit. A 
change in OBJF of more than 6.63 and 9.21 are required to reach statistical significance 
(p = 0.01) for the addition of 1-fixed or 2-fixed effects, respectively. In addition to the 
above statistical condition, the following two criteria were also required to be met: good 
fit in the diagnostic plots (predicted versus measured concentration and weighted 
residuals versus predicted concentration), and low relative standard errors of the 
parameter estimates. The coefficient of variation (cv) which represents a measure of 
dispersion of a probability distribution was calculated for each parameter estimated. 
5.3.4 Results 
5.3.4.1 Patient demographics 
The study population consisted of 50 newly diagnosed epilepsy patients of whom 52% 
were male. The mean age and weight of the participants was 39 years (range 13.5 to 
80.5 years) and 75.4 kg (range 48.3 to 129 kg), respectively. There was no association 
between weight and age (r = 0.139, p=0.334), or weight and genotypes of ABCB 1 
c. 1236C>T (p = 0.279) and c. 3435C>T (p = 0.340). Female patients had a slightly 
lower body weight than male patients (70.8 kg vs 79.0 kg; p=0.057). The duration of 
treatment from initiation of LTG to time of final blood sample, was between I and 131 
weeks (mean 62 weeks). The daily doses of LTG ranged between 50 mg and 550 mg 
(median 150 mg). 
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5.3.4.2 Genotype distribution of ABCBI c. 1236C>T and c. 3435C>T 
polymorphisms 
The genotype frequencies of the ABCB I c. 1236C>T polymorphism was 14% C/C, 52% 
C/T, and 34% T/T.. The genotype frequencies of the c. 3435C>T polymorphism was 
28% C/C, 46% C/T, and 26% T/T. The genotype distributions of ABCB 1 c. 1236C>T 
and c. 3435C>T polymorphisms were consistent with HWE (p = 0.853 and p=0.841, 
respectively). 
5.3.4.3 Lamotrigine population pharmacokinetics 
The OBJF values for selected pharmacokinetic models fitted using NONMEM® are 
presented in TABLE 5.12. The first pharmacokinetic model incorporating a combined 
error model had an OBJF value of 257.7 with an aborted covariance step. The OBJF 
value did not significantly change when the interindividual variability in K. was fixed to 
zero, however, the covariance step managed to achieve completion. This simpler model 
was chosen as the base model (Model 2) and provided the following initial estimates of 
population values (mean value with relative standard error expressed as a percentage): 
OCL = 2.46 Uh (7.5%) cvn, = 45.3% (22.4%) 
Ov = 51.51(41.0%) cv = 132% (62%) 
OKa = 1.57 /h (73.0%) 
Plots of individual estimates of CL/F versus clinical factors are presented in FIGURE 
5.5. There was no significant correlation between the individual estimates of CIJF and 
the clinical factors, except for body weight (r = 0.490, p<0.001). Plots of individual 
estimates of CL/F versus genotypes of the ABCB 1 c. 1236C>T and c. 3435C>T 
polymorphisms are presented in FIGURE 5.6. There was no significant difference in 
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individual estimates of CL/F between genotypes of either ABCB 1 c. 1236C>T (p = 
0.690) or c. 3435C>T (p = 0.384). 
The GAM analysis produced similar results to those obtained with the scatterplots 
(FIGURE 5.7). None of the factors tested improved the AIC value of the base model 
(Model 2), except body weight. Addition of other factors into the model did not improve 
the AIC value in the presence of weight. These analyses indicated that weight was the 
only factor that was likely to improve the population model fit. 
A linear effect of weight on the population value of CL/F improved the pharmacokinetic 
model fit (Model 3) and reduced the interindividual coefficient of variation in clearance 
from 45% to 37%. There was no advantage in using a non-linear model to describe the 
influence of weight. Although no influence of weight could be detected on Vd/F, this 
was deemed to be physiologically appropriate and therefore included (Model 4; TABLE 
5.12). The residual error was adequately described using a proportional error model. 
Model 4 was therefore used to evaluate the effects of ABCB 1 gene polymorphisms on 
LTG pharmacokinetics. Addition of ABCBI e. 1236C>T and c. 3435C>T genotype 
scores into model 4, either individually or in combination, did not significantly improve 
the OBJF value (Models 5&6; TABLE 5.12). The model fitting was consistent with 
the results of GAM analysis and visual examination of the scatterplots. 
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The optimal pharmacokinetic model for LTG provided the following estimates of 
population values (mean value with relative standard error expressed as a percentage; 
TABLE 5.13): 
OcL = 0.0334 1/h/kg (6.4%) cvCý = 37.8% (22.4%) 
Ov = 0.5151/kg (37.0%) cv = 136% (46.4%) 
OKa = 0.681 /h (37.0%) 
0 
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Both the estimates of Vd/F and K$ were poorly characterised with relative standard 
errors of 37% and the interindividual variability in Vd/F had an estimated cv of 136%, 
which again indicates wide interindividual variability. 
The measured versus population predicted and individual predicted LTG concentration 
plots of the base and optimal models are presented in FIGURE 5.8. The plots indicate a 
slightly better fit with the optimal model for measured, compared to population 
predicted, concentrations, with less scatter around the line of identity. There was no 
difference between the models when the individual predictions were used. This is 
expected since the structural model was identical. 
5.3.5 Discussion 
Given the wide variability in interindividual pharmacokinetics, these findings may 
improve current understanding of the clinical pharmacology of LTG. This investigation 
complements previous traditional-type studies that have been performed in standardised 
populations receiving monotherapy or polytherapy regimens (Cohen et al., 1987; 
Ramsay et al., 1991; Bartoli et al., 1997; Hussein & Posner, 1997; Armijo et al., 1999), 
but, in addition, has uniquely examined the effects of ABCB I gene polymorphisms on 
LTG pharmacokinetics. 
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TABLE 5.13. Lamotrigine pharmacokinetic parameter estimates and their relative 
standard errors (RSE) using various models. 
Model 
Parameter 23456 
Base model Optimal model 
OcL 2.46 0.033 0.0334 0.0324 0.0329 
RSE OCL 7.5% 6.3% 6.4% 8.5% 7.4% 
Ovd 51.5 42.1 0.515 0.529 0.508 
RSE OW 41.0% 38.0% 37.0% 37.0% 37.0% 
OKa 1.57 0.709 0.681 0.657 0.691 
RSE OKa 73.0% 35.0% 37.0% 40.0% 38.0% 
OAdd NG 0.0974 --- 
RSE OAdd - 428% --- 
OPro 0.276 0.262 0.265 0.267 0.264 
RSE OPro 8.5% 10.0% 7.7% 7.7% 7.7% 
OPo11 ---0.132 
RSE OPo11 --- 
136% - 
OPo12 ---0.0552 
0.0319 
RSE OPo12 --- 
237% 398% 
cva 45.3% 37.3% 37.8% 
36.9% 37.8% 
RSE CVCL 22.4% 22.9% 22.4% 
22.2% 21.9% 
cvvd 132% 141% 136% 
138% 134% 
RSE cv. 62% 24.5% 46.4% 49.6% 
47.7% 
0, population value; CL, oral clearance; Vd, volume of 
distribution; Ka, rate 
constant of absorption; cv, coefficient of variation; 
Poll, polymorphism of 
ABCB1 c. 3435C>T; Po12, polymorphism of ABCBI c. 1236C>T; 
Add, additive 
error; Pro, proportional error; NG, negligible. 
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Population pharmacokinetic analysis methods, such as NONMEM®, were originally 
designed for the analysis of the type of sparse data that is routinely collected in a 
clinical setting. However, these approaches have also been shown to be useful in 
analyzing rich data sets collected in an experimental setting. The advantages of using 
NONMEM® include the ability to estimate pharmacokinetic parameters for individuals, 
to correctly handle differing numbers of data points per patient, to investigate the 
influence of clinical factors on pharmacokinetic parameters, and to separate random 
effects into interindividual variability in pharmacokinetic parameters and residual error 
in concentration measurements. 
When compared with published data, only the population estimates of CUF were 
consistent with previous results. The estimate of Vd/F was half that of previous reports 
and K. was one third of the value that has been reported elsewhere (Cohen et al., 1987; 
Ramsay et al., 1991; Hussein & Posner, 1997; Wooton et al., 1997). Both of these latter 
parameters were poorly characterised (relative standard error 37%) and interindividual 
variability in Vd/F was high. Poor quality data obtained during the absorption phase up 
to the time of peak concentration might have contributed to the inadequate estimation. 
The time to peak concentration for individual LTG doses in a chronic treatment regimen 
has been reported to range between 0.5 and 4.0 hours (Cohen et al., 1987). In this study, 
the majority of samples (67.3%) were collected within 4 hours of the last dose and 
would thus have been influenced by variability in CUF, Vd/F and K. To estimate all 
parameters effectively with sparse data collection in the absorption and distribution 
phases is difficult. In addition to the high interindividual variability and narrow range of 
time to peak concentration, any small inaccuracy in recording the time of last dose and 
the time of blood sampling could, in theory, have influenced the estimates of Vd/F and 
Ka. 
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In this study, the optimal population estimate for CL/F was 0.033 1/h/kg or 2.5 1/h based 
on a mean population body weight of 75 kg. This is in agreement with previously 
published values (Cohen et al., 1987; Hussein & Posner, 1997; Wooton et a!., 1997). 
The magnitude of interpatient variability in CL/F was 38%, which indicates significant 
unexplained interindividual variation. 
Although the estimate of CL/F was consistent with a previous report (Hussein & Posner, 
1997), it failed to demonstrate any association with the duration of therapy. This is 
probably because most of the blood samples (73%) were taken after at least 8 weeks on 
therapy, which is beyond the expected time of completion of the autoinduction process 
with LTG. It is believed that the autoinduction process is complete within 2 weeks after 
LTG initiation (Hussein and Posner, 1997), and that the short duration of autoinduction 
with LTG is unlikely to be clinically significant (Rambeck & Wolf, 1993). 
The interindividual variability in CL/F was reduced slightly when body weight was 
included in the model. This finding is consistent with a previous study by Hussein & 
Posner, (1997) who found that a higher body weight was associated with a higher CUF. 
This may be explained by the proposed correlation between body weight and liver size. 
Some studies have demonstrated a significant correlation between body weight and liver 
size (Andersen et al., 2000) and for drugs that are principally metabolised in the liver, 
there is a clear association between systemic clearance and lean body mass (Morgan & 
Bray, 1994). Studies exploring the relationship between liver size and AED clearance 
are limited. A single study in children and adolescents receiving CBZ demonstrated that 
clearance was correlated with liver volume (Reith et al., 2000). The present study lends 
further weight to the proposed association between body weight and the clearance of 
AEDs which undergo hepatic metabolism. 
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The wide tissue distribution and disparate list of compounds that are transported by P- 
gp indicate its potentially important role in drug absorption, distribution, and 
elimination. Genetic polymorphisms that alter the drug transport capacity of P-gp 
therefore have the potential to affect the pharmacokinetics of many therapeutic agents. 
The most commonly studied ABCB 1 polymorphisms are c. 123 6C>T, c. 2677G>T/A and 
c. 3435C>T substitutions. Significant linkage disequilibrium between these 
polymorphisms has been reported in both Oriental and Caucasian populations (Kim et 
al., 2001; Tang et al., 2002). Although the functional significance of ABCB 1 variants 
remains controversial, genotypes and haplotypes of ABCB 1 polymorphisms have been 
associated with alterations in the pharmacokinetics of drugs such as digoxin (11offineyer 
et al., 2000), fexofenadine (Kim et al., 2001) and cyclosporin (Yates et al., 2003). 
The current study suggests that ABCB 1 c. 1236C>T and c. 3435C>T polymorphisms do 
not significantly influence the clearance of LTG. The most obvious explanations for this 
observation include the possibility that LTG may be not a substrate for P-gp, or that the 
polymorphisms investigated do not significantly influence the expression or activity of 
P-gp. However, it is reasonable to speculate that the level of expression of P-gp in the 
intestine and any genetic variability therein may not be sufficient to influence the 
pharmacokinetics of a drug with high oral bioavailability such as LTG (Patsalos, 1999). 
Equally, P-gp efflux transport capacity may be saturable, leading to substrate overload, 
and absorption of LTG by passive diffusion or active influx transport (Cascorbi, 2006). 
Either of these alternative mechanisms could potentially mask any deficiency in P-gp 
transport capacity resulting from genetic polymorphisms. A study with cyclosporin has 
shown that the effect of the ABCB1 3435C>T polymorphism on CL/F can be largely 
attributed to altered absorption rather than hepatic clearance (Yates et al., 2003). In 
addition, a study with digoxin has also highlighted the important effect of the ABCB I 
3435C>T polymorphism on the extent of absorption rather than the rate of renal 
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clearance (Johne et al., 2002). Accordingly, the current study may indirectly indicate 
that the effect of ABCB1 c. 1236C>T and c. 3435C>T polymorphisms on the absorption 
of LTG is negligible. 
There was a large variation in. LTG CL/F within each ABCB I genotypic group. This 
might indicate the presence of other confounding factors, including as yet undetected 
SNPs or dietary and environmental contributors. It is also possible that the overall rate 
of LTG clearance is predominantly influenced by physiological factors, rather than 
genetic polymorphisms. Other than the sample size issue, the variability in estimated 
pharmacokinetic parameters can be attributed collectively to model mis-specification, 
assay variability, intraindividual variability and non-compliance with medication. Some 
of this variability may also be related to the assumption of a 12-hour dosing interval in 
subjects with incomplete dosing records. 
5.3.6 Conclusion 
The population pharmacokinetic parameter estimate of CL/F during LTG monotherapy 
was in good agreement with the findings of previous studies. Steady-state plasma LTG 
concentrations can be affected by the influence of body weight on clearance. There was 
no clear evidence to support the functional involvement of ABCB i c. 1236C>T and 
c. 3435C>T polymorphisms in the CL/F of LTG. The current study findings need to be 
verified in a large, prospective, purposely-designed pharmacokinetic study. 
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6.1 General Discussion 
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The objective of this programme of work was to examine the influence of genetic 
variability in DME, DTP and voltage-gated sodium channel genes on the clinical 
pharmacology of CBZ and LTG. The individual projects which comprise this thesis are 
to a certain extent diverse, although not unrelated. While the general introduction 
endeavours to summarise present understanding of epilepsy, its clinical treatment, 
variation in human genetics, the pharmacogenetics of AEDs, the clinical pharmacology 
of CBZ and LTG, and the genes and SNPs of interest, the individual results chapters 
developed particular aspects of the pharmacogenetics of CBZ and LTG in more detail. 
Chapter 3 addressed the prevalence of common polymorphisms in the genes of interest 
and the validity of the methods used to identify these genetic variants. Next, in chapter 
4, an attempt to study the influence of common polymorphisms in DME and sodium 
channel genes on the optimal dose and adverse effect profile of CBZ (sections 4.1 and 
4.2). Finally, in chapter 5, a series of studies was conducted to investigate the influence 
of common polymorphisms in ABCB 1 and sodium channel genes on the treatment 
response, optimal dose and pharmacokinetic parameters of LTG (sections 5.1 - 5.3). 
Individual results are discussed in detail in the relevant sections, both in relation to their 
particular limitations and in their consistency with previously published work. This 
general discussion attempts to summarise individual aspects of this project and to 
highlight those of particular interest. 
Interindividual variability in the response to drug treatment is the fundamental basis of 
pharmacogenetic studies. Pharmacogenetics offers a systematic approach to the 
evaluation of genetic influences on the response to individual drug treatments. With this 
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in mind, this project has attempted to improve the current understanding of the clinical 
pharmacology of AEDs. Previous studies in this regard have tended to focus on the 
association between genetic variation and pharmacokinetic mechanisms influencing 
AED disposition. Less emphasis has been given to the potential influence of variation in 
genes encoding AED targets (Ferraro & Buono, 2005). Although this project has 
principally concentrated on pharmacokinetic factors, efforts were also made to examine 
pharmacodynamic influences. 
The ability of the body to eliminate AEDs and their metabolites affects the magnitude 
and duration of efficacy (Perucca, 1999). Responsiveness to AEDs can be influenced by 
drug metabolism in several ways. Under normal circumstances, when the parent drug is 
the principle active compound, DME variants that have relatively low activity may be 
associated with higher plasma drug concentrations than might otherwise be expected 
under standard dosing regimens. This may result in the occurrence of adverse effects. 
On the other hand, DME variants with relatively high enzymatic activity may be 
associated with lower plasma drug concentrations than might otherwise be expected 
under standard dosing regimens. This may result in a lack of efficacy. In the case of 
AEDs that are metabolically activated, such as oxcarbazepine (Perucca, 2001), 
relatively lower biotransformation capacity may result in treatment failure due to 
inadequate plasma concentrations of the active compound, whereas, relatively higher 
bioactivation may result in the elevation of plasma concentrations and the risk of 
adverse effects. For AEDs that are active as both parent and metabolite, 
for example 
CBZ, the influences of variable DME activity are more complex and dependent upon 
the specific nature of the metabolic pathway and the relative contribution of 
individual 
compounds to the efficacy and tolerability profiles. Thus, there are a variety of potential 
mechanisms by which polymorphisms in DME genes can 
influence AED 
responsiveness. 
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In addition to the above, the extent by which AEDs are absorbed and distributed to 
various regions of the brain influences their potency and adverse effect profile (Browne, 
1998; Kim, 2002b; Ramachandran & Shorvon, 2003). The absorption of AEDs and their 
distribution to organs and tissues is determined not only by the physicochemical 
properties of the drugs themselves, but also by endogenous molecules such as DTPs and 
plasma proteins (Kim, 2002b; Patsalos & Perucca, 2003). Several DTP systems have 
been described that are responsible for moving substrates both in and out of cells, which 
would suggest that DTPs can be involved in drug pharmacokinetics from multiple 
mechanistic standpoints (Kim, 2002a; Kim, 2002b). The most extensively studied DTP 
in the epilepsy field is P-gp, which has been proposed to transport several AEDs 
(Potschka et al., 2002). Like DMEs, the expression and activity of P-gp may also be 
affected by polymorphisms in the encoding gene (Hoffineyer et al., 2000). 
Most AEDs have multiple mechanisms of action (Kwan et al., 2001), and definitive 
evidence linking specific molecular targets to individual drugs is lacking. It is likely that 
the effects of any given AED are a composite of its entire spectrum of cellular actions. 
The most common AED target is the voltage-gated sodium channel (Kwan et al., 2001), 
an observation which may be consistent with the premise that epilepsy can be viewed as 
arising from group of diverse ion channelopathies. There is increasing evidence to 
support the notion that several forms of epilepsy are associated with common allelic 
variants in SCN genes (Ceulemans et al., 2004; Kamiya, 2004). Thus, it is possible that 
disease susceptibility variants may influence therapeutic activity of AEDs and 
potentially contribute to the phenomenon of pharmacoresistant epilepsy. This should 
be 
considered in the design and analysis of drug target pharmacogenetic studies. 
In section 3.1, there were significant differences in the prevalences of common 
polymorphisms in DME, DTP and sodium channel genes when these were compared 
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between the 400-strong study population and those observed in previously published 
non-Caucasian populations. The genotype distributions of these polymorphisms were 
consistent with those predicted by HWE. Deviation from IIWE is often associated with 
systematic error in the genotyping methodology (Xu et al., 2002; Ilosking et al., 2004; 
Salanti et al., 2005; Wittke-Thompson et al., 2005). Thus, HWE can be useful as an 
initial test to evaluate assay reliability. In section 3.1, the PCR-RFLP assay designed for 
the identification of EPHX1 c. 337T>C polymorphisms produced a genotype 
distribution that was inconsistent with HWE. Re-analysis was conducted for this 
polymorphism using direct sequencing. The genotype distribution identified by direct 
sequencing was consistent with HWE. If one assumes that this discrepancy was a 
reflection of the genotyping methodology and not a characteristic of the population 
itself, then it is reasonable to suggest that direct sequencing is a more reliable technique 
than PCR-RFLP for the identification of the EPHXI c. 337T>C polymorphism. Indeed, 
several studies employing a PCR-RFLP assay to identify this polymorphism have 
reported a similar problem (Takeyabu et al., 2000; Gsur et al., 2003; Godderis et al., 
2004). 
Given that two of the study subjects were not European, population stratification can be 
useful to eliminate the diversity in drug response between ethnics. Population 
stratification refers to differences in allele frequencies between cases and controls due to 
systematic differences in ancestry rather than association of genes and disease. It has 
been proposed that false positive associations due to stratification can 
be controlled by 
genotyping a few dozen unlinked genetic markers. This available method 
is also known 
as genomic control. Further studies should utilise this approach to address the 
population stratification issue. 
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Response to AED treatment can be defined in terms of efficacy (abolition of seizures or 
reduction in their frequency) or in terms of tolerability (prevalence and/or severity of 
adverse effects). However, it is a challenge to establish a definite association between 
genotype and treatment response phenotype because non-genetic confounders, such as 
drug-drug interactions, treatment compliance and patient lifestyle, are difficult to 
control. The AED response phenotype is highly complex and represents a classic 
example of the interaction between genetic and environmental factors. As a result, 
understanding genetic variation may not fully explain the outcome of pharmacological 
treatment. When faced with such difficulties in defining responsiveness, it may be more 
prudent to employ pharmacokinetic parameters as the principal phenotypic definition in 
AED pharmacogenetic studies. These are more quantifiable and more reliable than 
measures of efficacy and/or tolerability and a more easily extrapolated from patient to 
patient, investigator to investigator and from research centre to research centre. Even 
then, a multitude of events and protein interactions occur from the moment that an AED 
is ingested. The fundamental issues of absorption, distribution, metabolism and 
excretion all involve interaction with multiple endogenous and exogenous factors, 
binding of drug to target proteins, and interactions of those proteins with both other 
proteins and DNA (Spear, 2001; Clancy & Kass, 2003; Ramachandran & Shorvon, 
2003). Despite this enormous complexity, it is possible that identifying the relative 
contribution of genetic variation to the phenotype of AED response will permit 
preliminary progress in the field of pharmacogenetics. 
Using a comprehensive drug response phenotype definition and a well-defined study 
population can improve the quality of pharmacogenetic findings, and result in a better 
understanding of the association between genotypes and phenotypes. In the current 
project, for studies involving drug responsiveness and clinical outcome, inter- 
investigator variability in clinical practice and in the assessment of individual patients 
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was largely eliminated by the selection of subjects from research projects within a 
single centre and which employed a similar procedure for the initiation of treatment and 
clinical follow-up. This ensured that all patients were treated equally. The potentially 
confounding effects of drug-drug interactions on drug response phenotypes were 
similarly eliminated by employing only those patients who were treated with AED 
monotherapy. Drug-drug interactions can affect the dose and concentration of each 
individual compound in the therapy regimen (Patsalos & Perucca, 2003), with a 
consequent influence on treatment response. CBZ and LTG were evaluated individually 
as each drug has different pharmacokinetic and pharmacodynamic characteristics. 
Categorising patients according to the severity of their seizures may have helped to 
optimise the phenotype definition. However, given the limited number of patients and 
the retrospective nature of this project, no sub-analysis was performed in terms of 
seizure severity. 
To identify a pure association between genotype and drug response phenotype, one 
should also consider the clinical relevance of each phenotypic definition. Drug response 
phenotypic definitions that are clinically relevant have more practical application and 
thus, increase the value of pharmacogenetic findings. With this in mind, in Chapters 4 
and 5, OD was employed as a composite measure of both efficacy and tolerability of 
CBZ and LTG, respectively. The OD is equivalent to the maintenance dose and is more 
advantageous than maximal tolerated dose. Previously, association between genetic 
markers and maximal tolerated doses of PHT and CBZ has been reported by Tate et a!. 
(2005). The maximal tolerated dose phenotype has clinical implications with regard to 
safety but does not provide any measure of efficacy that might have added to the 
clinical applicability of the findings. Many patients, even in a tertiary referral setting, 
become seizure free on a modest dose and may never reach their personal limit of 
tolerability (Kwan & Brodie, 2001). In these individuals, estimating maximal tolerated 
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dose on the basis of genotype is of limited and non-existent value. In the current study, 
clinical response phenotypes focused on two relevant outcomes, namely seizure 
freedom and intolerable adverse effects. These outcome measures demonstrate the 
efficacy and safety of AEDs, respectively. The probability of achieving seizure freedom 
varies greatly depending on the effectiveness of treatment and also on seizure severity, 
pre-treatment seizure frequency and the duration of the assessment period (Pcrucca, 
1997; Kwan & Brodie, 2000). Intolerable adverse effects of AEDs arc the most 
common reason for early treatment withdrawal. In many patients, the health-related 
quality of life is affected more by adverse effects than by seizures themself (Perucca, 
1997). As such, evaluation of seizure freedom and adverse effects represents an 
important component in the assessment of overall clinical outcome. 
In section 4.1, the influence of genetic variability on CBZ dose requirement was 
evaluated. Like most AEDs, CBZ doses are predominantly determined by the level of 
response and the occurrence of adverse effects. Inadequate seizure control necessitates 
an increase in CBZ dose, whereas the emergence of adverse effects limits the amount of 
drug that can be prescribed. Dosage adjustment of CBZ is complicated due to the 
potential for drug-drug interactions and the phenomenon of autoinduction. As a result of 
autoinduction and the onset of adverse effects, the maintenance dose of CBZ will be 
higher than the initial dose, but often lower than maximum dose. Typical CBZ 
maintenance doses have been reported between 200 to 1600 mg/day (Kwan & Brodie, 
2001), similar to the range of doses observed in the current project. 
This project identified polymorphisms in the EPHX1 gene as potential predictors of the 
OD of CBZ. The influence of DME variants on the pharmacokinetics of CBZ is 
important because CBZ is predominantly metabolised through hepatic enzyme 
biotransformation (Pelkonen et al., 2001). There is limited genetic variability in the 
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CYP3A4 and CYP3A5 genes (Gracia-Martin et al., 2002) and the most common of 
these had no influence on CBZ dose. This might suggest that any genetically determined 
variability in CBZ metabolism occurs at other stages of the pathway. It is possible that 
the rate of CBZ-E hydrolysis could determine the variability in CBZ metabolism. This 
hydrolysis process is predominantly mediated by mEH (Pelkonen et al., 2001). 
Polymorphisms in the EPHX1 gene are known to affect the activity of mEll (Nakajima 
et al., 2005) and therefore have the potential to influence plasma concentrations of CBZ 
and its dose requirement. Other common DME polymorphisms examined did not 
predict the OD of CBZ. This might suggest that these polymorphisms have limited 
functional consequences or that the enzymes in question are not fundamental 
contributors to CBZ metabolism. On the basis of this study, it would appear that genetic 
variants of the EPHX1 gene are the strongest candidate markers of inter-individual 
variability in CBZ dosing. 
In section 4.2, the association between polymorphisms in DME genes and a unique 
phenotype that may be exquisitely sensitive to CBZ adverse effects was evaluated. This 
study failed to reveal any association between common genetic polymorphisms and the 
proposed phenotype in question. Previous studies examining the EPIIXI gene have also 
failed to associate multiple polymorphisms with the incidence of CBZ hypersensitivity 
reaction (Gaedigk et al., 1994; Green et al., 1995). Two common polymorphisms 
(c. 337T>C and c. 416A>G) in the EPHX1 gene have, however, been associated with 
variation in the plasma concentrations of CBZ-E (Nakajima cl al., 
2005). If the 
functional effect of these polymorphisms is genuine and if they are associated with 
CBZ 
dose (as reported in section 4.1), the the current study might question the popular notion 
that CBZ-E is responsible for precipitating many of the adverse effects associated with 
CBZ treatment (Ramsay & Wilder, 2002). Although it is dangerous to make such 
sweeping generalisation on the basis of studies with such low numbers of participants, 
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several previous investigations have indeed failed to demonstrate any correlation 
between CBZ-E concentrations and the toxicity of CBZ in epilepsy patients (Theodore 
et al., 1989; Semah et al., 1994). The current study also suggested that, with the 
exception of EPHXI, the contribution of other DME polymorphisms to the risk of 
developing CBZ adverse effects is modest or non-existent. This would support the 
suggestion that common polymorphisms in these genes do not significantly influence 
the activity of their respective enzymes. 
As with other AEDs, response to LTG treatment is likely to be significantly influenced 
by the activity of DMEs, DTPs and sodium channels. LTG is predominantly 
metabolised by UGT1A4 (Magdalou et al., 1992; Vashishtha et al., 2001) and is 
believed to be transported by P-gp (Potschka et al., 2002). As such, the major 
determinants of LTG pharmacokinetics are likely to be UGTIA4 and P-gp. The 
mechanism of action of LTG is similar to that of many other AEDs, such as CBZ and 
PHT, and is mediated by inhibition of voltage-gated sodium channels. Thus, any 
alteration in the expression or activity of UGTIA4, P-gp and voltage-gated sodium 
channels has the potential to impact on LTG pharmacokinetics and pharmacodynamics. 
Such alterations include polymorphisms in the respective encoding genes. The influence 
of UGTIA4 variants was not examined in this project because polymorphisms in this 
gene are rare and no functional variants had been reported in the Caucasian population 
at the time this project was planned. As a result, only polymorphisms in the ABCB 1 and 
SCN2A genes were evaluated in relation to the LTG treatment response phenotype. 
The findings reported in section 5.1 suggest that ABCB 1 and SCN2A variants do not 
significantly influence the response to LTG monotherapy. There are several potential 
explanations for this observation. Firstly, LTG may not be a strong substrate for P-gp, in 
which case LTG distribution in the brain might not be significantly influenced by P-gp- 
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mediated efflux transport. This is plausible because LTG is known to be highly 
lipophilic (Mashru et al., 2005). Secondly, common polymorphisms in ABC131 and 
SCN2A genes may not be functional, and thus may not affect the expression or activity 
of P-gp or Na,, 1.2 proteins, respectively. Even if they were functional, the modification 
in protein structure or function may not be of sufficient magnitude to influence the 
response to LTG treatment. Finally, it is important to remember that LTG may act on 
other subtypes of voltage-gated sodium channel and may be transported by other DTPs. 
One should also be aware that the response to AED therapy in terms of efficacy is easily 
influenced by other clinical and environmental factors, including seizure severity and 
pathological causes (Stephen et al., 2001; Brodie, 2005). 
In section 5.1, it was reported that patients who are seizure free on LTG monothcrapy 
have a wide distribution of optimal doses. Since the efficacy of LTG treatment does not 
significantly associate with its plasma concentration (Kilpatrick et al., 1996; Mahmood 
et al., 1998), it is possible that the diversity in dose requirement might be influenced by 
inter-individual variability in P-gp function and the resulting ability of LTG to cross the 
BBB. Polymorphisms in the ABCB 1 gene that have the potential to alter the expression 
and activity of P-gp were postulated to be responsible for the spread of individual LTG 
dose requirements. This hypothesis was confirmed (section 5.2) with the association 
between common polymorphisms in the ABCBI gene and the OD of LTG. This is an 
interesting finding and one which may help to dismiss concerns about whether LTG is a 
substrate for P-gp mediated transport. 
The influence of ABCB 1 variants on LTG pharmacokinetics was further examined 
in an 
effort to understand the relationship between polymorphisms 
in this gene and LTG 
dose, as reported in section 5.2. This additional investigation 
failed to identify any 
association with the clearance of LTG, suggesting that the influence of 
dose is most 
Chapter 6: Discussion & Conclusion 245 
likely related to some other as-yet unidentified pharmacokinetic or pharmacodynamic 
factors. P-gp is believed to be expressed in a tissue-specific or disease-specific manner 
(Croop et al., 1989). For example, epileptic brain tissue has been shown to have a 
higher expression of P-gp than normal brain (Marchi et al., 2004; Volk et al., 2004). It 
is possible that, in epilepsy patients, the expression of P-gp in the gastrointestinal tract, 
kidney and liver is relatively lower than that observed at the BBB. The effect of ABCB I 
variants may be enhanced in conditions where P-gp is over-expressed whereas genetic 
variability would have less impact in conditions or in tissues where P-gp expression is 
low or normal. This would explain how ABCB 1, polymorphisms can associate with 
LTG dose (by influencing BBB transfer) but not LTG clearance, which is a more 
peripheral phenomenon and not necessarily subject to disease mediated augmentation. 
The studies presented in this thesis have revealed some previously unrecognised factors 
that may influence individual AED dose requirement. The predominant application of 
these pharmacogenetic findings is in AED dosing strategies. Polymorphisms in the 
SCN1A gene have previously been identified as useful predictors for CBZ and PUT 
dose (van der Weide et al., 2001; Tate et al., 2005; Tate et al., 2006). This observation, 
together with the intriguing findings presented in this thesis, provide a theoretical 
direction for future clinical investigations to assess whether pharmacogenetic profiling 
can improve dosing decisions. There is clear clinical benefit in determining the optimal 
titration rate and target dose for an individual patient. Those who require a lower dose 
and a slower titration rate can be identified before the initiation of treatment, and any 
unnecessary exposure to high doses of AEDs can be prevented, thereby minimizing the 
risk for adverse effects. Similarly, patients with a high dosing requirement can be 
titrated faster in order to avoid prolonged periods of under-exposure and a consequent 
lack of efficacy. Pharmacogenetic profiling may also be more useful than therapeutic 
drug monitoring in determining the dose of AEDs, particularly for those AEDs that have 
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a poor plasma concentration-response relationship (Patsalos, 2001). Finally, 
pharmacogenetic testing can be utilised prospectively, before the AED is started and 
only a small amount of blood sample or a cheek-swab sample is required for genotypic 
analysis. 
These findings represent another step in the ongoing effort to improve understanding of 
the role of pharmacogenetics in epilepsy management. Knowledge of AED mechanisms 
of action and awareness of genetic factors that determine treatment response should not 
only improve the use of AEDs but may also allow AEDs to be designed for specific 
targets in particular populations or that avoid any detrimental genetic variability in 
therapeutic response. The preponderance of genetic polymorphisms in the human 
genome suggests that pharmacogenetic variability will likely be an issue for 
consideration in almost all drug treatments. 
Pharmacogenetic research has developed rapidly, with recent advances in molecular 
genetics and genome sequencing. This is largely due to the emergence of new 
technologies that allow rapid screening for specific polymorphisms, as well as recently 
gained knowledge of genetic sequence derived from the Human Genome project. 
Epilepsy-related pharmacogenetic research is beginning to take advantage of this new 
information in order to enhance current understanding of epilepsy therapeutics. This 
new found knowledge can be employed effectively in two main areas: identification of 
specific genes and gene products associated with various forms of epilepsy and which 
may act as targets for new AEDs and identification of genes and allelic variants of 
genes that can influence the response to current AEDs. 
We are still a long way from having a pharmacogenetic test that clinicians can routinely 
use to identify the most appropriate AED for any particular patient, however there is 
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increasing evidence that pharmacogenetics will be important in clinical practice. In the 
future it may be considered unethical not to perform such tests routinely to avoid 
exposing individuals to doses of AEDs that could be harmful. The ability to identify 
sensitive or insensitive individuals before commencing AED treatment would also be of 
economic importance. AED treatment based on genetic profile might avoid the current 
empiricism associated with matching the most appropriate AED, at its optimal dose, to 
each patient. The development of pharmacogenetics as a scientific discipline should 
offer a departure from current empirical prescribing and a move towards more 
individualised AED treatment. 
6.2 Future Research Directions 
The recent advances in genetic technology encourage a rapid development of 
pharmacogenetic research. The relatively high prevalence of seizure disorders, limited 
number of drugs, relatively poor success rate and the broad range of interindividual 
responses make epilepsy an ideal target for pharmacogenetic research and its 
application in clinical practice. To date, pharmacogenetie studies in epilepsy have 
predominantly explored the association between genetic polymorphisms and either the 
pharmacokinetics of specific AEDs (i. e. PHT) or the efficacy of AEDs in general 
(irrespective of individual treatments). Other established drugs such as CBZ, VPA, PB 
and ethoxusimide, and newer AEDs such as LTG, topiramate and levetiracetam have 
not yet been investigated in any significant detail. Drugs with single mechanisms of 
action (i. e. levetiracetam) or single metabolic pathways may be the best place to start. 
Levetiracetam does not appear to act via conventional AED mechanisms such as, 
GABAergic facilitation, inhibition of voltage-gated sodium channels or modulation of 
voltage-gated calcium channels. In contrast, it would appear to bind to synaptic vesicle 
protein SV2A, which is ubiquitously found in the mammalian CNS (Lynch et al., 2004). 
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As such, genetic polymorphisms in the SV2A gene are potential contributors to 
variability in the response to levetiracetam treatment. This is a single example of the 
enormous potential which exists for the exploration of pharmacogenetics in epilepsy in 
an effort to better understand the clinical pharmacology of both established and modern 
AEDs. 
The OD predictive models that were developed for CBZ and LTG in this project 
explained less than 20% of the dose variation between individuals. More genetic and 
non-genetic variables are clearly required to improve the predictability of this approach. 
Polymorphisms in genes which encode voltage-gated sodium channels, other DMEs and 
other DTPs that are related to the pharmacokinetics and pharmacodynamics of CBZ and 
LTG may be the most appropriate place to start. Polymorphisms of the SCNIA gene 
that have been reported to be associated with the maximum dose of CBZ (Tate et al., 
2005) should almost certainly be included in any such predictive model of CBZ OD or 
LTG OD, as both drugs act by blockade of voltage-gated sodium channels. However, 
other less obvious genes should not be excluded and DME and DTP genes should be 
subject to further investigation particularly with regard to those SNPs which occur less 
commonly than those reported here. Haplotype studies may be more appropriate than 
those based on genotype and whole-genome scans may become available in the near 
future. However, the genotype-based approach, as presented in this project, has some 
advantages over the haplotype strategy. Genotyping may permit the identification of 
causal variants, especially for rare SNPs, which can dramatically alter the expression 
and/or the activity of their respective proteins. This approach is typically directed by the 
notion that functional variants are highly associated with SNPs located 
in the promoter 
and coding regions. As such, the number of SNPs which need to be typed 
is limited and 
this reduces the cost of genotyping. In fact, these are the variants to which random 
SNPs 
searches are most likely to lead and such polymorphisms are more likely to be in 
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linkage disequilibrium with the causal allele (Risch, 2000). Employing a haplotypc 
strategy, on the other hand, is useful for SNPs that have a relatively high allele 
frequency (>10%; Becquemont, 2003) and is entirely dependent on linkage 
disequilibrium (Roses, 2000). Linkage disequilibrium occurs when combinations of 
alleles at different loci present more frequently than would be expected from random 
association. Variations of several ordered SNPs that are close to, or within, a particular 
chromosomal region are likely to be inherited together when they are in linkage 
disequilibrium. As such, SNPs associated with a drug response phenotype can `mark' 
the position on the chromosome where a susceptibility gene is located. The whole- 
genome scan technique may enable the identification of several multiple small 
susceptibility regions, within which the search for genetic markers can be focused 
(Roses, 2000). However, the haplotype strategy is not the best choice for low frequency 
SNPs because it misses rare haplotypes, which might otherwise be clinically relevant. 
To generate stronger research data, prospectively designed studies is preferred than 
retrospectively designed studies, largely because avoidance of confounding variables. A 
prospective study is designed before the data is collected, which allows the 
researchers 
several advantages over the retrospective study. Researchers can design a 
pharmacogenetic study with a control group, design internal devices to eliminate bias, 
and follow subject throughout the length of the study to observe development of the 
outcome in question. The down-sides of prospective studies are that they are more 
expensive and time-consuming to design and execute, and are difficult to use to study 
rare polymorphisms as the number of subjects is often too low. Although studies 
presented in this thesis have produced several intriguing findings, these 
have to be 
further explored in prospectively designed studies with formal power calculations 
included and followed by replication studies. 
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In conclusion, this series of pharmacogenetic studies examined the clinical 
pharmacology of CBZ and LTG and served to identify polymorphisms in genes 
encoding mEH and P-gp as potential predictors of CBZ and LTG OD, respectively. 
Common genetic polymorphisms of other DMEs that are responsible for CBZ 
metabolism, namely CYP3A4 g. -392A>G, CYP3A5 g. 6986A>G, CYPIA2 g. 5734C>A, 
and UGT2B7 c. 802C>T, did not significantly associate with the OD of CBZ and none 
were associated with CBZ adverse effects. Polymorphisms in the ABCB I gene 
encoding P-gp did not prove useful in predicting the response to LTG treatment and did 
not appear to influence the oral clearance of LTG. 
The experimental work contained in this thesis advances current knowledge of the 
association between genetic variability and the clinical pharmacology of AEDs. Positive 
findings require confirmation in a prospectively-designed study employing a larger 
cohort of newly diagnosed epilepsy patients. Characterisation of polymorphisms in 
genes that encode proteins related to AED pharmacokinetics and pharmacodynamics 
may enable us to predict efficacy and tolerability of AEDs and to make informed 
decisions with regard to titration rates and target doses for individual patients. Fostering 
a closer relationship between clinical pharmacology and genetics has the potential to 
make significant progress in the treatment of epilepsy. 
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